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Guidelines strongly recommend patients with Heart Failure (HF) be treated with multiple 
medications proven to improve clinical outcomes, as tolerated. Guideline-led prescribing of 
HF evidence-based medicines is strongly associated with improved survival, prognosis, and 
quality of life in HF. The guidelines strongly recommend, and the optimal patient outcomes 
are achieved with an appropriate prescription of target doses of all HF therapies. The degree to 




To assess guideline-led prescribing of the evidence-based HF medications in routine clinical 
practice in Ireland and Egypt and to assess the prevalence of HF-specific potentially 




Firstly, a narrative literature review was undertaken to determine and compare the available 
data and gaps in knowledge regarding HF management in Ireland as a developed European 
country, and Egypt as a developing Middle-Eastern country, with a particular focus on the 
guideline-directed medical therapies. Secondly, a systematic review was undertaken to identify 
the objective quantitative tools to assess the quality of HF prescribing practice. Next, a 
prospective cohort study was conducted on an Irish outpatient population to evaluate the extent 
of use and dosing of the guideline-directed medical therapies. Then, a multicentre retrospective 
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study was carried out in 14 Long-Term Care (LTC) facilities in Cork County to assess the 
prevalence of appropriate and potentially inappropriate prescribing practices. In Egypt, a 
longitudinal observational study was conducted in order to evaluate the prescribing quality and 
patterns in HF patients in an Egyptian critical care setting at discharge. Finally, a descriptive 





The literature review identified many gaps in knowledge in the Egyptian and Irish literature on 
HF. For instance, the studies included in the review did not discuss the target dose prescribing. 
The systematic review identified the widespread use of the Guideline Adherence Index (GAI-
3) in 13 studies worldwide in the quantitative assessment of HF prescribing. The Irish HF 
outpatient study showed room for optimising the prescription of the guideline-directed medical 
therapies in 34% of ambulatory patients. No patient achieved the 100% target dose of all three 
evidence-based medications. The prevalence of potentially inappropriate prescribing was 20%. 
The Irish LTC study showed that patients with HF were older than those without HF (84.8 ± 
7.4 vs 83.4 ± 7.9 years, p-value = 0.024). Loop diuretic was the most frequently prescribed HF 
medication up to 88% of the total population and renin-angiotensin system inhibitors to 24.2% 
only. The prevalence of potentially inappropriate prescribing in LTC was 24%. On the other 
hand, the Egyptian longitudinal study showed the moderate adherence level at discharge from 
the critical care unit but the potential role of clinical pharmacy service in HF drug therapy 
optimisation via improving beta-blocker prescription rates by from 24% to 38% and reducing 
digoxin rates from 34% to 23%. However, the service did not improve the overall guideline 
adherence levels or the prevalence of inappropriate prescribing. The survey explored some new 
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aspects in HF practice, such as the urgent need for locally-drafted guidelines and the more 
significant implementation of clinical pharmacy service to optimise the implementation of 




This thesis has made a significant contribution to the knowledge and generated a much needed 
conceptual understanding of the complexity of HF guideline-led prescribing. This work reflects 
the moderate adherence levels to guidelines and high prevalence of potentially inappropriate 
prescribing in the two countries. None of the prescribers either in Ireland or Egypt prescribed 








This chapter provides a background to the thesis through an overview of the clinical 
presentation of Heart Failure syndrome, its aetiology, clinical epidemiology, management and 




1.1 Heart Failure  
 
Heart Failure (HF) syndrome is often the final and most severe manifestation of almost any 
form of cardiac diseases. (1, 2) According to the European Society of Cardiology (ESC), it is 
clinically defined as “a syndrome in which patients have typical symptoms such as 
breathlessness, ankle swelling, and fatigue, and signs such as elevated jugular venous pressure, 
pulmonary crackles, and displaced apex beat, resulting from an abnormality of cardiac 
structure or function”. (1) 
 
Pathologically, HF is the inadequate pumping function of the myocardium such that the cardiac 
output is reduced relative to the metabolic demands of the body. (2, 3) Then, multiple 
hemodynamic and neurohormonal compensatory mechanisms occur in an attempt to 
compensate for the cardiac insufficiency. (2, 3) Once activated, these mechanisms lead to 
progressive deleterious consequences. (2, 3) 
 
1.2 Left ventricular ejection fraction 
 
Left ventricular ejection fraction (EF) is a parameter of ventricular remodelling and a reliable 
indicator of the myocardial pumping function. (4, 5) Ejection fraction is defined as the stroke 
volume, which is the end-diastolic volume minus the end-systolic volume, divided by the end-
diastolic volume. (4, 5) Left ventricular EF is an essential marker of the progression of the 
myocardial disease as well as prognosis in HF patients. (4, 5) The lower the EF the patient has, 
the poorer the survival outlook for the patient. (4, 5) Most HF clinical trials select patients based 
upon their EF value. (6-8) According to the ESC Guidelines for the Diagnosis and Treatment of 
Acute and Chronic Heart Failure 2012, HF is of two phenotypes: (i) HF with reduced ejection 
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fraction (HFrEF), also known as systolic HF; and (ii) HF with preserved ejection fraction 
(HFpEF), also known as diastolic HF. (9) In HFrEF, the ventricle contracts poorly and empties 
inadequately; and EF is < 50%. (9) In HFpEF, the ventricular filling is impaired, resulting in 
increased end-diastolic pressure at rest and/or during exercise; and EF is ≥ 50%. (9) 
 
1.3 New York Heart Association classification 
 
The New York Heart Association (NYHA) is a functional classification of HF severity that is 
widely used and accepted based on the patient’s exercise capacity and severity of the disease 
symptoms. (1, 2) NYHA classifies HF patients into four grades as follows: (1) 
(i) NYHA class I: No limitation on physical activity; 
(ii) NYHA class II: Slight limitation on physical activities but comfortable at rest;  
(iii) NYHA class III: Marked limitation on physical activities but comfortable at rest; 
(iv) NYHA class IV: Inability to carry on any activity without symptoms, even at rest.  
 
1.4 Main causes of Heart Failure  
 
Heart Failure is a clinical syndrome rather than a complete diagnosis, and the underlying cause 
of the cardiac dysfunction should always be determined. (10) Internationally, the aetiology of 
HF is diverse. There is no agreed single classification system for the causes of HF, with much 
overlap between potential causes. (1, 10) Many patients will have several different pathologies - 
cardiovascular and non-cardiovascular - that lead to HF. (1, 10)  
 
The major aetiologies are detailed in Table 1.1. Heart Failure is mainly a result of a diseased 
myocardium such as ischemic heart disease or abnormal loading conditions caused by 
hypertension or arrhythmias. (1, 2, 10) In the developed world, ischaemic heart disease and 
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hypertension remain the leading causes of HF. (11) There are little data for developing countries, 
but rheumatic heart disease continues to be a major health problem, particularly in Africa and 
Asia. (12-15) In African and African-American populations, hypertension remains the aetiology 





Table 1.1 Aetiology of Heart Failure. 
 
I. Coronary artery disease  
II. Intrinsic myocardial disease  
a. Dilated cardiomyopathy 
b. Hypertrophic cardiomyopathy  
c. Restrictive cardiomyopathy  
III. Valvular heart disease  
a. Age-related/calcific 
b. Infective endocarditis  
c. Immunological (e.g. rheumatic fever) 
IV. Congenital heart disease  
V. Hypertension  
a. Systemic hypertension 
b. Pulmonary hypertension 
VI. Arrhythmias and cardiac conduction disturbances 
a. Tachyarrhythmias  
b. Bradyarrhythmias 
c. Intraventricular conduction disturbance 
VII. High-output cardiac failure  
a. Anaemia  
b. Thyrotoxicosis  
c. Pregnancy  
d. Liver cirrhosis  
e. Paget’s disease 
VIII. Pericardial disease  
a. Constrictive pericarditis 
b. Pericardial effusion with cardiac tamponade 
 
Source: Cowie MR, Poole-Wilson PA. Pathophysiology of Heart Failure (10) and the European Society 
of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2016. (1)  
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1.5 Clinical epidemiology of Heart Failure  
 
1.5.1 Heart Failure epidemiology 
 
The prevalence of HF is estimated to be 2% of the total adult population in the developed 
countries, rising to ≥ 10% among people of ≥ 70 years. (17) In total, there are 21 million adult 
patients estimated to be living with HF in Europe and the United States of America (USA). (17) 
Despite great advances in therapeutics, this number is expected to rise, partly due to the 
significant improvement of post-myocardial infarction survival rates, population ageing and 
the vast prevalence of cardiovascular risk factors worldwide. (19)  
 
1.5.2 Heart Failure hospitalisation 
 
Heart Failure accounts for 3% of all USA hospital admissions. In Europe, HF exacerbation is 
the leading cause of more than 1 million hospitalisations annually. (20) Also, rehospitalisation 
is common among patients with HF following their initial discharge. (21) The Acute 
Decompensated HEart failure national REgistry (ADHERE) in the USA reported a 
rehospitalisation rate of 22% in the first 30 days post-discharge. (22) Data from Europe showed 
a rehospitalisation rate of 44% in one-year post-discharge. (21, 23) It is of note that HF mortality 
risk increases considerably with repeated hospitalisations. (24)   
 
The median length of hospitalisation for HF is typically between five and ten days. (21, 23) The 
length of stay reached a peak of 10 days in France. (21) However, the average length of stay 
tends to increase with patient age. (21) In England, the length of stay was five days for those < 
65 years old and nine days for those > 85 years. (21)  
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1.5.3 Heart Failure mortality 
 
Nearly 10% of HF patients die within 30 days of hospital discharge, 30% within the first year 
of diagnosis and 50% of HF patients die within five years. (25) The most recent European data 
demonstrates that 12-month all-cause mortality rates for hospitalised and ambulatory HF 
patients were 17% and 7%, respectively. (26) The INTERnational Congestive Heart Failure 
(INTER-CHF) registry showed that the overall one-year all-cause mortality in the Middle East 
is 9%, and in Africa, it is 34%. (27) 
 
1.5.4 Patient quality of life 
 
Heart Failure patient’s quality of life is related to the frequency of hospitalisation and mortality. 
(21, 28, 29) Quality of life is subjective and does not merely reflect an objective clinical or 
physiological status. (28) Heart Failure patients’ ability to work or to participate in social 
activities is significantly diminished. They are also more likely to suffer from other 
comorbidities such as depression, anxiety and social isolation. (21, 29) Work, travel and day-to-
day social and leisure activities are difficult for those with breathlessness and extreme fatigue. 
(30-32) Worsening of the disease impacts not only the patient but also their caregivers. (33, 34) 
Studies have identified relatively high levels of deteriorating mental health and quality of life 
among partners of people with HF. (33, 34)  
 
1.5.5 Economic burden of Heart Failure 
 
Due to the high and increasing prevalence rates, HF constitutes an enormous economic burden 
for the healthcare systems in the developed countries. (35, 36) For example, Europe and the USA 
spend 1% to 2% of their annual healthcare budget on HF. (36) In 2014, the global economic 
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burden of HF was estimated at US$108 billion per annum, with US$65 billion attributed to 
direct costs and US$43 billion to indirect costs. (36) In the time period of 2004 to 2016, Europe 
accounted for 7% of the total global HF costs. (35, 36) For instance, estimates for the annual 
prevalence-based costs for HF patients ranged from US$868 in South Korea up to US$25,532 
in Germany. (35, 36) In Europe, two-thirds of the HF budget was spent on hospital-related issues. 
(35, 36) 
 
1.6 Heart Failure pathophysiology 
 
Heart Failure represents a complex clinical syndrome in which an initial myocardial insult 
results in the over-expression of multiple peptides with different short- and long-term harmful 
effects on the cardiovascular system. (10, 37)  
 
1.6.1 Renin-angiotensin-aldosterone system 
 
Neurohormonal activation of the renin-angiotensin-aldosterone system (RAAS) is recognised 
as playing a pivotal role in the development as well as the progression of HF. (2) In the acute 
phase, the neurohormonal activation of renin, angiotensin-II and aldosterone seems to be 
beneficial in terms of maintaining adequate cardiac output and peripheral perfusion. (10) 
However, sustained neurohormonal activation eventually results in increased ventricular wall 
stress, dilation, and ventricular remodelling, as well as vasoconstriction. (10, 38) All these effects 
contribute to the disease progression in the failing myocardium, which eventually leads to 
further neurohormonal activation and fluid congestion. (10, 38) These effects will increase the 
heart rate (HR), which will further augment the metabolic demands and reduce the myocardium 
performance by increasing myocardial cell death. (2, 10, 38) Simultaneously, increased total 
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peripheral resistance results in higher afterload, impeding the left ventricle’s stroke volume and 
reducing cardiac output. (2) 
 
1.6.2 Left ventricular remodelling 
 
Chronically elevated angiotensin-II and aldosterone trigger the production of cytokines, which 
activate macrophages and stimulate fibroblasts resulting in adverse ventricular remodelling. (2) 
Left ventricular remodelling is the process by which mechanical, neurohormonal, and possibly 
genetic factors alter ventricular size, shape, and function. Its hallmarks include hypertrophy, 
loss of myocytes, and increased interstitial fibrosis. (39)  
 
1.6.3 Natriuretic peptides 
 
Natriuretic peptides are peptide hormones which regulate sodium-water balance, inducing 
natriuresis - the excretion of sodium by the kidneys. (10, 37) Several natriuretic peptides have 
been sequenced such as atrial natriuretic peptide and brain natriuretic peptide. (10, 37) The atrial 
natriuretic peptide is released from the atria in response to stretch, leading to natriuresis and 
vasodilatation. (40) Brain natriuretic peptide is also released from the heart, predominantly from 
the ventricles, and its actions are similar to those of atrial natriuretic peptide. (40) The atrial and 
brain natriuretic peptides increase in response to volume expansion and pressure overload of 
the heart and act as physiological antagonists to the effects of angiotensin-II on vascular tone, 
aldosterone secretion, and renal-tubule sodium reabsorption. (10, 37) These peptides participate 
in the long-term regulation of blood volume, arterial pressure, and sodium-water balance. (10, 
37, 40) These potent vasodilatory peptides improve heart function and performance. (10, 37, 40)  
Also, they decrease the central venous pressure and increase the glomerular filtration rate at 
the renal level. (40) These vasoactive peptides are physiologically cleared by the enzyme 
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neprilysin endopeptidase. This clearance exacerbates HF progression and manifestations. (10, 
37) 
 
1.7 Pharmacological management of Heart Failure  
  
Management of HF is complex and multifaceted. Pharmacotherapy is the cornerstone of HF 
management. (1) The medications used in HF block the adverse effects of the various 
neurologic, hormonal, and inflammatory mechanisms activated by the failing heart and relieve 
fluid congestion. (1)  
 
1.7.1 Pharmacological options of Heart Failure management 
 
Several medications have shown incremental benefits in HF syndrome. (41) These are:  
(i) Angiotensin-converting enzyme (ACE) inhibitors to lower the arterial blood 
pressure (BP) and decrease the workload of the heart;  
(ii) Beta-adrenergic blockers to stabilise and decrease the heartbeats;  
(iii) Mineralocorticoid receptor antagonists (MRA) to reduce sodium retention and 
prevent myocardium remodelling;  
(iv) Vasodilators to relax the smooth muscle lining of the veins and arteries;  
(v) Digoxin cardiac glycoside to increase the strength of the myocardial contractility;  
(vi) Ivabradine to reduce the HR;  
(vii) Angiotensin receptor-neprilysin inhibitor (ARNi) to reduce remodelling, 
vasoconstriction, and renal sodium retention;  
(viii) Diuretics to remove fluid congestion that is primarily manifested in the form of the 
ankle or pulmonary oedema. 
 
The current therapeutic strategies are used to stabilise HF symptoms and progression. The main 
goals of therapy in HF patients are outlined in Table 1.2. (1, 21) Persistence of symptoms despite 
treatment usually indicates the need for intensification of therapy. (41) Oral HF therapy should 
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be continued on admission with acute HF, during and after hospitalisation, except in the 
presence of haemodynamic instability, hyperkalaemia or severely impaired renal function. (1, 9, 
42) In these cases, the daily dosage of oral therapy may be reduced or stopped temporarily until 
the patient is stabilised. (1, 9) 
  
1.7.2  Clinical practice guidelines 
 
The ESC defines the clinical practice guidelines as “systematically developed statements to 
assist practitioner and patient decisions about appropriate health care for specific clinical 
circumstances”. (1) The National Cardiac Societies of the ESC are encouraged to endorse, 
translate and implement all ESC guidelines. (1, 9) Implementation programmes and audits are 
recommended because it has been shown that the precise application of clinical 
recommendations may favourably influence the outcome of the syndrome. (1, 43, 44) 
 
A great number of guidelines have been issued in recent years by the ESC as well as by other 
societies and organisations such as the American College of Cardiology, American Heart 
Association, Heart Failure Society of America (43), National Institute for Health and Care 
Excellence in the United Kingdom (45), and National Heart Foundation of Australia/Cardiac 
Society of Australia and New Zealand (44).  
 
Concurrently, the ESC Task Force and the working groups of American College of Cardiology, 
American Heart Association, Heart Failure Society of America separately surveyed the 
evidence, arrived at similar conclusions, and constructed similar recommendations in 2016. (1, 
43) Given the concordance, the respective organisations simultaneously issued aligned 
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recommendations on the use of these new treatments to minimise confusion and improve the 
care of patients with HF. (1, 43)  
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Table 1.2 Goals of therapy in patients with established Heart Failure diagnosis. (1, 21) 
 
Relieve symptoms and signs such as oedema and low-cardiac output 
Restore normal oxygenation 
Optimise volume status 
Identify aetiology 
Identify and manage potential precipitating factors and comorbidities 
Initiate or optimise chronic Heart Failure guideline-directed medical therapies 
Minimise side effects 
Achieve target blood pressure and target heart rate 





1.7.3  Guideline-led prescribing 
 
Guideline-led prescribing refers to the appropriate prescription of the drug treatments that 
benefit patients with HF, and it evokes the body of evidence-based literature and the 
endorsement of several professional societies. (46-48) Guideline-led prescribing, which is the 
appropriate prescription of the guideline-directed medical therapies, represent the mainstay of 
initial and chronic management of HF. (1, 49) The cornerstone of guideline-led prescribing is the 
prompt initiation of the inhibitors of the RAAS and the evidence-based beta-blockers (EBBB) 
shown to improve symptoms, cardiac function, morbidity and mortality. (41, 49) 
 
1.7.4  Guideline-recommended target dose 
 
The target dose is defined as the dose that achieves a recommended target effect of the study 
medication over placebo. (50) In HF, the ESC guidelines strongly recommend the uptitration of 
guideline-directed medical therapies to the evidence-based levels in order to achieve the full 
beneficial outcomes of medications. (1, 47, 48) 
 
1.7.5  Differences between ESC 2012 and 2016 guidelines  
 
The major changes from the 2012 guidelines relate to: (1, 9) 
(i) A new term for patients with HF and a left ventricular EF that ranges from 40 to 
49% — ‘HF with mid-range EF (HFmrEF)’ 
(ii) A new algorithm for the diagnosis of HF in the non-acute setting based on the 
evaluation of HF probability; 
(iii) Recommendations aimed at prevention or delay of the development of overt HF 
or the prevention of death before the onset of symptoms;  
(iv) Indications for the use of the new compound sacubitril/valsartan, the first in the 
class of ARNi (Figure 1.1 vs Figure 1.2);  
18 
 
(v) The concept of early initiation of appropriate therapy along with relevant 
investigations in acute HF that follows the ‘time to therapy’ approach already well 
established in acute settings. 
 
1.7.6  Management of Heart Failure with reduced ejection fraction 
 
The ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic HF in 2012 (Figure 
1.1) and 2016 (Figure 1.2) recommend the utilisation of up to seven disease-modifying agents 
in addition to the diuretic therapy for managing HFrEF. (1, 9) The incremental use of 
combinations of disease-modifying agents has resulted in the progressive improvement in 
mortality and hospitalisation outcomes in HFrEF. (41) In the case of de-novo HFrEF 
presentation, every attempt should be made to initiate these agents after haemodynamic 
stabilisation. (1, 9) In the case of worsening chronic HFrEF, every attempt should be made to 
continue the guideline-directed disease-modifying therapies, in absence of haemodynamic 
instability or contraindications. (1, 9, 42) 
 
1.7.6.1 Pharmacological options recommended in all symptomatic patients with Heart 
Failure with reduced ejection fraction 
 
ACE inhibitors have been shown to decrease HF morbidity and mortality and should be given 
to all patients with left ventricular dysfunction, symptomatic or otherwise unless there is a 
contraindication or prior intolerance to therapy. (51-53) Several trials showed the significant 
benefits of ACE inhibitors in reducing all-cause mortality between 10% to 40% and HF 
hospitalisation by 15% over a mean follow-up period of 0.5 to 3.8 years. (51-53)  
 
Evidence-based beta-blockers have also been shown to decrease the morbidity and mortality 
associated with HF. (1, 41) The EBBBs are bisoprolol, carvedilol, metoprolol succinate, 
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nebivolol. They should be initiated at low doses and titrated upwards target doses. (1, 9) 
Although adverse drug reactions can include bradycardia, worsening of reactive obstructive 
lung diseases, and worsening HF, these can often be avoided by the careful patient selection, 
appropriate selection of the agent, gradual dose titration, and close monitoring. (1) Clinical 
improvement may be delayed and may take two to three months to become apparent. However, 
the persistent long-term treatment with EBBB lessens HF symptoms and significantly 
improves the clinical outcomes such as all-cause mortality by 35%. (54-57) A meta-analysis of 
observational studies and clinical trials demonstrated that discontinuation of EBBB in patients 
hospitalised with acute HF was associated with significantly increased in-hospital mortality, 
short-term mortality and the combined endpoint of short-term rehospitalisation or mortality. 
(42) 
 
Mineralocorticoid receptor antagonists such as spironolactone and eplerenone are 
recommended in HF patients who are in NYHA class II to IV unless contraindicated. (1) The 
Randomized Aldactone Evaluation Study (RALES) trial showed a reduction of 30% in 
mortality and 35% in rehospitalisation among the patients in the spironolactone arm versus 
those in the placebo arm. Similarly, the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF) trial showed a significant reduction in all-






1.7.6.2 Other pharmacological options recommended in selected symptomatic patients 
with heart failure with reduced ejection fraction 
 
Angiotensin-II receptor blockers (ARBs) are a reasonable alternative to ACE inhibitors in 
all patients with HFrEF or HFpEF who are intolerant of ACE inhibitors because of cough or 
angioedema. (1) Experience with this medication class in controlled clinical trials of patients 
with HF is considerably less than that with ACE inhibitors. (1) Nevertheless, valsartan and 
candesartan have demonstrated a similar reduction in hospitalisations and mortality compared 
to ACE inhibitors. (59-61) Overall, several clinical trials of ARBs have shown a significant 
decrease in combined cardiovascular mortality and HF hospitalisation by 3.2% up to 15% over 
1.9 years to 3.4 years. (59-61) 
 
Angiotensin receptor-neprilysin inhibitors are a novel class of HF medical therapy 
consisting of a combination of sacubitril, a neprilysin inhibitor, and valsartan, an ARB. (7) In 
the Prospective Comparison of ARNi with ACEi to Determine Impact on Global Mortality and 
Morbidity in Heart Failure (Paradigm-HF) trial, sacubitril/valsartan was superior to enalapril 
in reducing mortality and HF hospitalisation in HFrEF. (7) In 2015, the drug combination was 
approved in Europe and the USA for the treatment of HFrEF, and it is included in the ESC 
2016 guidelines (Figure 1.2). (1, 7) In these guidelines, ARNi is recommended as a replacement 
for an ACE inhibitor therapy to further reduce the risk of HF hospitalisation and mortality in 
ambulatory patients with HFrEF who remain symptomatic despite optimal medical therapy 
with an ACE inhibitor, an EBBB and an MRA at target dose or maximally tolerated dose. (1) 
Compared to the established therapy of ACE inhibitor, ARNi is an expensive therapy. Although 
this agent was licenced in Ireland, it was not approved for use on the Primary Care 
Reimbursement Service dispensing schemes until December 2017. (62) It must be initiated by a 
cardiologist, and the cardiologist must complete an online form to justify its use. For this 
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reason, the use of ARNi has been limited in Ireland up to this time. (62) Similarly, the use of 
this medication class is minimal in Egypt due to its cost implications since its introduction in 
the Egyptian market in October 2017.   
 
Ivabradine slows the HR through inhibition of the mixed sodium-potassium (If) channel in 
the sinus node and therefore should only be used for patients in sinus rhythm. (8) In the Systolic 
Heart failure treatment with the If inhibitor ivabradine (SHIFT) clinical trial, ivabradine 
reduced the combined endpoint of mortality and hospitalisation by 18% for symptomatic HF 
patients with EF ≤ 35%, who were in sinus rhythm, with a HR ≥ 70 beats per minute, who had 
been hospitalised for HF within the previous 12 months, and who were receiving optimal 
medical therapy with the target dose of EBBB (or maximally tolerated dose), ACE inhibitors 
(or ARB), and an MRA. (1, 8)  
 
Digoxin can be beneficial in patients with current or prior symptoms of HF, especially those 
with comorbid atrial fibrillation. (1, 9, 63) When added to ACE inhibitors, beta-blockers, and 
diuretics, digoxin can reduce symptoms, prevent hospitalisation, control rhythm, and enhance 
exercise tolerance. (63) In recent years, the use of digoxin has diminished as newer therapies 
demonstrated more significant survival benefits (Figure 1.1 and Figure 1.2). (1, 9, 64) 
 
Vasodilators such as hydralazine and isosorbide dinitrate combination may be a useful 
therapeutic alternative in patients intolerant to both ACE inhibitors or ARB. (65) The African 
American Heart Failure Trial (A-HeFT) showed that this therapy was of particular 




Diuretics should be used in all HF patients with symptoms or signs of congestion, irrespective 
of their EF. (1, 67) Loop diuretics have emerged as the preferred diuretic agents for use in most 
patients with HF as they produce a more intense and shorter diuresis than other classes of 
diuretics. (1) Careful monitoring of renal function and electrolytes is essential. (1) The lowest 
therapeutic dose of diuretic should be used to relieve congestion, keep the patient 
asymptomatic, and maintain a dry weight. (67, 68)  In the case of resistant congestion, the addition 
of a second diuretic of different mechanism of action is required. (69) The combinations of loop 
and thiazide diuretics act synergistically and may be used to treat resistant oedema. (1) However, 
adverse effects are more likely, and these combinations should only be used with care. Diuretic 




Figure 1.1 Management algorithm of Heart Failure with reduced ejection fraction in the 
European Society of Cardiology Heart Failure guidelines 2012. 
 
Source: European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and 
Chronic Heart Failure, 2012. (9) Abbreviations: ARB, angiotensin-II receptor blocker; CRT-D, Cardiac 
Resynchronization Therapy-Defibrillator; CRT-P, Cardiac Resynchronization Therapy-Pacemaker; H-
ISDN, hydralazine-isosorbide dinitrate; HR, heart rate; ICD, implantable cardioverter-defibrillator; 
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LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MR, mineralocorticoid 




Figure 1.2 Management algorithm of Heart Failure with reduced ejection fraction in the 
European Society of Cardiology Heart Failure guidelines 2016. 
 
Source: European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and 
Chronic Heart Failure, 2016. (1)  
 
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor 
blocker; ARNi, angiotensin receptor - neprilysin inhibitor; CRT, cardiac resynchronization therapy; 
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HFrEF, heart failure with reduced ejection fraction; H-ISDN, hydralazine-isosorbide dinitrate; HR, 
heart rate; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; LVAD, 
left ventricular assist device; MR, mineralocorticoid receptor; NYHA, New York Heart Association; 
OMT: optimal medical therapy; VT/VF, ventricular tachycardia/ventricular fibrillation..
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1.7.7  Management of Heart Failure with preserved ejection fraction 
 
There are no specific disease-modifying agents currently recommended for this cohort of HF 
patients as no treatment has been shown to reduce the disease mortality. (6, 70-72) However, in 
older patients ≥ 70 years with HFrEF or HFpEF, nebivolol reduced the combined endpoint of 
mortality or cardiovascular hospitalisation by 14% regardless of the EF level in comparison to 
placebo. (57)  
 
In clinical practice, all the aforementioned pharmacological options (section 1.7.6) are used in 
stabilising HFpEF signs and symptoms and preventing its progression, as well as the 
management of the cardiovascular comorbidities. (6, 72-74) The guidelines suggest the utilisation 
of the same medications for managing cardiovascular comorbidities and HFpEF symptoms. (1, 
9)  
 
The Candesartan cilextil in Heart Failure Assessment of Reduction in Mortality (CHARM-
PRESERVED) trial of HFpEF patients showed a significant 2.4% decrease in the HF 
hospitalisation rate in the candesartan arm versus the placebo arm over three years of follow-
up. (75) Similarly, the Treatment of Preserved Cardiac Function Heart Failure with an 
Aldosterone Antagonist (TOPCAT) clinical trial showed a significant 2.2% reduction in HF 
hospitalisations in the spironolactone arm in comparison to the placebo arm. (6) A sub-analysis 
of the TOPCAT trial found a significant reduction in all-cause mortality in the arm of the 





1.7.8 Benefits of guideline-directed medical therapies 
 
Guideline-led prescribing leads to many clinical and economic benefits, including:  
(i) Reduction of hospitalisation and rehospitalisation frequency; (46-48, 76, 77)  
(ii) Shortening of hospital length of stay; (46, 78)  
(iii) Improvement of survival; (47, 48, 76, 79)  
(iv) Reduction of adverse cardiovascular events; (46, 79, 80)  
(v) Decrease of mechanical ventilation needs; (1, 78, 80, 81)  
(vi) Improvement of patient’s quality of life. (78, 81, 82) 
 
Robust evidence demonstrates the strong association between guideline-led prescribing of the 
evidence-based medications and improved survival as well as the patient’s quality of life. (1, 21, 
48, 76) In the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) 
and QUality of Adherence to guidelines’ recommendations for LIFe‐saving treatment in heart 
failure survey (QUALIFY) registries, the optimisation of HF medications and prescription of 
≥ 50% of the guideline-recommended target doses demonstrated considerable benefits in terms 
of survival and rehospitalisation outcomes in the short and long term. (48, 76) In the QUALIFY 
registry, perfect adherence to guideline-led prescribing was significantly associated with a 50% 
reduction in all-cause mortality and a 32% reduction of HF-related rehospitalisation when 
compared to moderate or poor adherence levels. (47, 48) 
 
The majority of international registries show that HF management in routine clinical practice 
is not well aligned with the recommendations of the clinical practice guidelines (Table 1.3). 
Adherence to HF guideline-led prescribing is highest in North America, Western Europe, and 
Japan and lowest in Eastern Europe, Africa and Asia. (83) The pilot study of the European Long-
Term Registry (ESC – HF Pilot) showed significant differences in the management of HF 
across European countries, resulting in different 1-year clinical outcomes. (26) The Sub-Saharan 
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Africa Survey on Heart Failure (THESUS-HF) registry showed underutilisation of beta-
blockers in the Middle-East and Africa in comparison to populations from Western regions. (12)  
 
The guidelines strongly recommend, and the optimal clinical outcomes are achieved with the 
target dosing of guideline-directed medical therapies. (41, 84) The Assessment of Treatment with 
Lisinopril And Survival (ATLAS) and the Effects of high-dose versus low-dose losartan on 
clinical outcomes in patients with heart failure (HEAAL) clinical trials emphasised the 
significant benefits of renin-angiotensin system inhibitors (RASi) target dose prescribing in 
comparison to lower doses in terms of mortality or rehospitalisation. (53, 85) Medication dosing 
should target the evidence-based levels to improve heart function, and should not be based on 
specific BP readings or established symptom relief. (1) However, the most recent registries of 
contemporary ambulatory HF patients such as the American CHAnge the Management of 
Patients with Heart Failure (CHAMP-HF) (86), the European BIOSTAT-CHF (76) and the Dutch 
Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) 
(87) revealed a persistent gap between the guidelines’ recommendations and the actual 
utilisation rates of the guideline-recommended target doses. For instance, in CHAMP-HF 
registry, only 1% of eligible patients achieved the target dose of all three guideline-directed 



















Digoxin, % Diuretics, % 
ADHERE (22) USA 2005 107,362 89 48 N/A 28 70 
EHFS II (88) Europe 2006 3,508 82 61 48 31 90 
OPTIMIZE-HF (89) USA 2008 4,402 68 67 N/A N/A N/A 
IMPACT-RECO II (90) France 2009 1,907 98 70 35 19 85 
ESC – HF Pilot (23) Europe 2010 1,855 89 87 55 20 83 
I-PREFER (91) L-MICs 2011 699 95 71 52 39 74* 
THESUS-HF (12) Africa 2012 1,006 82 28 72 62 80* 
GET WITH THE GUIDELINE  
(92) 
USA 2013 99,930 52 52 11 16 65 
QUALIFY (93) 36 countries 2016 7,092 87 87 69 25 83 
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*Loop diuretics only.  
Abbreviations: ADHERE, Acute Decompensated Heart Failure National Registry; EHFS II, European 
Heart Failure Survey II; ESC-HF, European Society of Cardiology – Heart Failure Long-Term Registry; 
I-PREFER, Identification of Patients With Heart Failure and PREserved Systolic Function: an 
epidemiological regional study; L-MICs, Low-Middle Income Countries; N/A, not available or not 
reported; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients 
with Heart Failure; QUALIFY, QUality of Adherence to guidelines’ recommendations for LIFe‐saving 
treatment in heart failure survey; RASi, renin-angiotensin system inhibitor (ACE inhibitor/angiotensin-
II receptor blocker); THESUS-HF, The Sub-Saharan Africa Survey of Heart Failure; USA, the United 




1.7.9 Therapeutic contraindications to the guideline-directed medical 
therapies 
 
The ESC 2016 guidelines defined a list of relative and absolute contraindications as specific 
situations in which the HF recommended medication should not be used because it may be 
harmful to the particular patients. (1)  The ESC guidelines outlined the presence or the previous 
history of a drug-specific allergic reaction as a general absolute contraindication to all 
medications mentioned above. (1) 
 
1.7.9.1 Contraindications to renin-angiotensin system inhibitors (ACE inhibitor, ARB 
and ARNi) 
 
 History of angioedema. 
 Known bilateral renal artery stenosis. 
 Pregnancy/risk of pregnancy. 
 
1.7.9.2 Contraindications to evidence-based beta-blockers 
 
 Second or third-degree atrioventricular block (AV-block).  
 Critical limb ischaemia.  
 Asthma (relative contraindication). 
 
1.7.9.3 Contraindications to ivabradine 
 
 Unstable cardiovascular conditions (acute coronary syndrome, stroke/transient 
ischaemic attack, severe hypotension). 
 Severe liver dysfunction or renal dysfunction (no evidence on safety or 
pharmacokinetics for creatinine clearance < 15 mL/min). 




1.8 Potentially inappropriate prescribing in Heart Failure  
 
Medications are considered to be appropriately prescribed when they have a clear evidence-
based indication, are cost-effective and are well tolerated. (94) Potentially inappropriate 
prescribing is defined by the American Institute of Medicine as “the practice of administering 
medications in a manner that poses more risk than benefit, particularly where safer 
alternatives exist”.(94-96) Unlike contraindications, potentially inappropriate prescribing 
introduces the risk of an adverse drug event which has the potential to outweigh the 
medication’s clinical benefit, mainly when a safer or more effective alternative treatment 
option is available. (97) 
 
Comorbidities and multimorbidity frequently accompany the HF syndrome, leading to 
therapeutic complexity, treatment conflicts and high prevalence of potentially inappropriate 
prescribing. (98-101) In HF setting, potentially inappropriate prescribing refers to the medications 
or medication classes that are not recommended in symptomatic patients with HF. (102) This 
type of prescribing is believed to cause harm or contradict the effects of the HF guideline-
directed medical therapies. (1, 102) Well described examples of this harmful interaction are non-
steroidal anti-inflammatory drugs (NSAIDs), non-dihydropyridine calcium channel blockers 
(CCB) and thiazolidinediones. (1, 102) 
 
In a Danish nationwide population of 36,354 ambulatory HF patients prescribed NSAIDs, 
Gislason et al. found that NSAIDs significantly increased the mortality rate by 70% regardless 
of the dose. (103) They also found a dose-dependent increase in the risk of mortality and 
cardiovascular hospitalisation. (103) Elsewhere, a meta-analysis of observational studies and 
randomised controlled trials showed the harmful effects of NSAIDs on HF patients in terms of 




Non-dihydropyridine CCBs are not indicated for the treatment of patients with HF. Diltiazem 
and verapamil are unsafe in patients with HF due to their potent negative inotropic effects. (1) 
In a study of 2,466 patients with recent myocardial infarction randomised to diltiazem or 
placebo, diltiazem significantly increased the risk of adverse cardiac events (hazard ratio [HR], 
1.41; 95% confidence intervals [CI], 1.01–1.96). The risk of adverse cardiac events in patients 
receiving diltiazem was directly related to the severity of baseline HF in the subgroup of 490 
patients with baseline pulmonary congestion. (105)  
 
Furthermore, the Diabetes Reduction Assessment with ramipril and rosiglitazone Medication 
(DREAM) trial, which evaluated rosiglitazone versus placebo in patients at risk for type 2 
diabetes mellitus, demonstrated the higher frequency of HF onset in those patients treated with 
rosiglitazone (n = 2,635) compared with placebo (HR, 7.03; 95% CI, 1.60 – 30.9; p-value = 
0.01). (106) Another example of an HF potentially inappropriate medicine is the antifungal agent 
itraconazole which has been associated with occasional reports of cardiotoxicity, and new-
onset and worsening HF due to its negative inotropic effect. (107, 108) 
 
The ESC 2016 guidelines address the point of potentially inappropriate prescribing in the form 
of potential drug interactions that may result in lower efficacy, poorer safety, the occurrence of 
unfavourable side effects, or worsening HF. (1) The guidelines mentioned NSAIDs, 
thiazolidinediones, non-dihydropyridine CCBs, and beta-2 agonists as therapeutic conflicts 
with the guideline-directed medical therapies in HF patients. (1)  
 
However, the literature about potentially inappropriate prescribing towards HF patients in 
routine clinical practice is very scarce. (98, 99, 101) Heart Failure-specific potentially inappropriate 
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prescribing was marginally part of many explicit prescribing review tools of potentially 
inappropriate medications in older individuals such as the Screening Tool of Older Person’s 
Prescriptions / Screening Tool to Alert doctors to Right Treatment (STOPP/START) or Beer’s 
criteria. (94, 96, 97, 109-111)  
 
The first HF-specific potentially inappropriate prescribing review tool was designed by the St. 
Vincent’s University Hospital, Dublin, using the Delphi technique. (112) The St. Vincent’s 
Potentially Inappropriate Medicines in Heart Failure (PIMHF) tool included 11 medications or 
medications’ classes that are deemed harmful to HF prognosis or clinical outcomes (Appendix 
1). (112) In 2016, Page et al. published the first scientific statement for potentially inappropriate 
medications in HF patients. (102) The purpose of the scientific statement was to assist prescribers 
in improving the quality of care for patients with HF, potentially reducing hospital admissions, 
improving quality of life for patients with HF, and reducing healthcare costs. (102) The statement 
is a comprehensive list included medications or medications classes that may cause, exacerbate 
HF prognosis or limit the beneficial effects of the guideline-directed medical therapies. (102) 
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1.9 Rationale of work 
 
Heart Failure is a major cause of mortality, morbidity and impairment of patient’s quality of 
life and places a substantial financial burden on healthcare systems worldwide. (17) International 
guidelines make clear recommendations as to which evidence-based medications should be 
prescribed for patients with HF. (1) However, observational studies from national and 
international registries have repeatedly shown that patients are missing out on guideline-
directed medical therapies. (47, 76, 86, 87, 113) Even when prescription rates are high, patients 
frequently fail to reach the target doses. The guidelines strongly recommend, and the optimal 
patient outcomes are achieved, with the prescription of the recommended target doses of HF 
therapies. (41, 84) 
 
The HF syndrome is accompanied by a broad spectrum of both cardiovascular and non-
cardiovascular comorbidities. (100, 114) Thus, patients with HF often have a high medication 
burden consisting of complex dosing regimens and problematic polypharmacy. (115, 116) On 
average, HF patients take 6.8 prescription medications per day, resulting in 10.1 doses per day. 
(102) Drugs may cause or exacerbate HF by causing direct myocardial toxicity; by negative 
inotropic, lusitropic, or chronotropic effects; by exacerbating hypertension; by altering serum 
electrolyte levels; or by drug-drug interactions that limit the beneficial effects of HF 
medications. (1, 112) 
 
To our knowledge, the current literature lacks a combined assessment of HF-specific 
appropriate and potentially inappropriate prescribing in the same clinical settings to establish 
all possible opportunities for improving prescribing practice.  
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1.10 Aims and Objectives 
 
1.10.1 The aims of this thesis: 
 
This thesis has a twofold aim:  
 
Firstly, to assess guideline-led prescribing of the evidence-based HF medications and to 
identify the potential barriers to guideline-led prescribing in routine clinical practice in Ireland 
and Egypt; 
 
Secondly, to assess the prevalence of HF-specific potentially inappropriate prescribing and the 
relationship between potentially inappropriate prescribing and guideline-led prescribing, if 
any, in Irish and Egyptian settings. 
  
 
1.10.2 Study objectives 
 
Specifically, the objectives are to:  
 
Review the published literature in Ireland and Egypt regarding HF prescribing practices and 
utilisation of HF pharmacotherapy. This objective will be covered in Chapter 2.  
   
Identify the objective tools for assessing adherence to guideline-led prescribing in HF and to 
assess the clinical outcomes associated with guideline adherence measured by such tools. This 
objective will be addressed in Chapter 3.   
 
Evaluate the guideline-led prescribing and potentially inappropriate prescribing to 
contemporary HF patients in an Irish ambulatory setting. This objective will be addressed in 




Measure guideline-led prescribing and potentially inappropriate prescribing in the Irish Long-
Term Care facilities and identify the clinical factors associated with guideline-led prescribing 
in this vulnerable HF population. This objective will be covered in Chapter 5.  
 
Assess guideline-led prescribing towards HF patients at discharge from a critical care setting 
and assess the effect, if any, of the introduction of clinical pharmacy service in this setting. 
This objective will be addressed in Chapter 6. 
 
Explore the behaviours and perspective of physicians towards prescribing to HF patients at 
discharge from a critical care unit and investigate the potential barriers and solutions to HF 





1.11 Thesis outline  
 
Each of the six objectives outlined above is aligned to a specific study chapter (Chapter 2 – 7), 
and each of these chapters is either published in an international peer-reviewed journal or 
drafted for submission. The six study chapters are then followed by an overall discussion 
chapter (Chapter 8). The methods used in this thesis and the resultant findings are discussed 
separately in each of the six study chapters (Figure 1.3). In brief, the outline for the remainder 
of this thesis is as follows: 
 
Chapter 2: A narrative literature review of HF prescribing in Ireland and Egypt to identify the 
gaps in knowledge in each country.   
 
Chapter 3: A systematic review and meta-analysis of the objective tools for assessing the 
quality of HF guideline-led prescribing and the outcomes of guideline-led prescribing.  
 
Chapter 4: A prospective observational study of guideline-led prescribing in a cohort of HF 
ambulatory patients, in the Mercy University Hospital, Cork City, Ireland. 
Chapter 5: A retrospective multicentre observational study of the level of HF appropriate and 
potentially inappropriate prescribing among the older patients residing in Long-Term Care 
facilities in Cork City and County, Ireland.  
 
Chapter 6: A quantitative analysis of guideline-led prescribing in hospitalised HF patients and 
assessment of the quality of care before and after the implementation of clinical pharmacy 




Chapter 7: A descriptive survey exploring the perspective of prescribers towards HF patients 
in a critical care setting and identifying the barriers to the guideline-led prescribing in the 
Critical Care Medicine Department, Cairo University Hospitals, Egypt.  
 
Chapter 8: An overall discussion of the research, including the strengths and limitations with 




Figure 1.3 Thesis Chapters and Recommendations. 
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2 Chapter 2 
A Comparative Study of Heart Failure Management in 
Ireland and Egypt: A Narrative Review 
 
 
This chapter provides a narrative literature review on Heart Failure management in Ireland 
as a developed European country and Egypt as a developing Middle-Eastern country. This 
literature review aims to identify the gaps in knowledge about Heart Failure management in 
either country. Based on this literature review, the rationale of the future work, and the thesis 






2.1 Introduction to the healthcare system in Ireland and Egypt  
 
Ireland is a Western European country with a population of 4.85 million people in 2018. (117, 
118) The Irish Gross National Income per capita is USD 59,360, and 0.2% of the population are 
below the poverty line of USD 1.9 per day. The average life expectancy in Ireland is 82 years 
old. (117, 118) In 2010, Ireland spent €2,862 per capita on health, compared to a European Union 
average of €2,172 per capita. Of this spending, approximately 79% was governmental 
expenditure. (117, 118) According to the Irish Central Statistics Office, health expenditure in 2015 
was €19.9 billion, representing 7.8% of the country’s Gross Domestic Product. In 2013, the 
ratio of hospital beds to the population was estimated to be 28: 10,000. (117, 118) 
 
Ireland has a comprehensive, government-funded public healthcare system. (119) The Irish 
healthcare system is two-tier: public and private sectors. The public health care system is 
governed by the Health Act 2004, which established a new body to be responsible for providing 
health and personal social services to everyone living in Ireland – the Health Service Executive. 
(119) The new national health service came into being officially on 1 January 2005; however, 
the new structures are currently in the process of being established as the reform programme 
continues. In addition to the public sector, there is also a large private healthcare market. (119) 
 
According to a national report about HF costs in Ireland published in 2015 by the Irish Heart 
Foundation, 90,000 Irish people are living with HF, and there are another 160,000 
asymptomatic HF cases in Ireland. (120) The report mentioned that in 2013, the rehospitalisation 
rates ranged from 24% to 44%, where 50% of patients are readmitted within six months of 
discharge, and the estimated length of stay is 11 days. The mortality rates are estimated to be 
8% in the first-month post-discharge and 60% to 70% within the first five years post-diagnosis. 
44 
 
(120) According to this national report, the total annual cost of HF in Ireland is estimated to be 
€660 million per annum. This cost is mainly driven by hospitalisation that consumes 47% of 
the total annual cost of HF care in Ireland while 16% of the cost is spent on HF medications. 
The total cost of inpatients hospitalisations for the year 2012 was estimated at €43 million. The 
cost of community-based pharmacological management of HF patients was estimated to be €26 
million, and the annual drug cost per patient was estimated to be between €194 and €290 per 
annum based on 2012 figures. (120) 
 
On the other hand, Egypt is a Middle-Eastern North African (MENA) country with a population 
of 98.42 million.  (117, 118) In 2018 the Egyptian Gross National Income per capita was USD 
275.41 billion, in and (117, 118) 1.2% of the population were below the poverty line of USD 1.9 
per day. The average life expectancy in Egypt is 72 years old. In 2014, the total expenditure of 
Egypt on health per capita was $594. (117, 118) and total expenditure on health represented 5.6% 
of the country Gross Domestic Product (GDP). In 2015, the ratio of hospital beds to the 
population was estimated to be 16: 10,000.  (117, 118)  
 
The healthcare system in Egypt consists of both public and private sector. Public health 
coverage is offered through the Ministry of Health and Population, which operates a series of 
medical facilities providing free health services. (121-124) The parastatal sector is composed of 
quasi-governmental organizations in which government ministries have a controlling share of 
decision making, including the Health Insurance Organization, the Curative Care Organization, 
and the Teaching Hospitals and Institutes Organization as well as the teaching hospitals of the 
state universities. (121-125)  The former two organisations are the largest healthcare organizations 
in Egypt. The Health Insurance Organization covers employed persons, students, and widows 
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through premiums deducted from employee salaries and employer payrolls. It operates its own 
network of medical facilities and at times contracts with private healthcare providers. The 
Curative Care Organization operates in specific governorates, and contracts with other entities 
for the provision of care. There are also private insurance options and a network of private 
healthcare providers and medical facilities. In addition, many Islamic mosques also operate 
their own clinics, especially in the large cities and also, some Christian churches offer 
subsidised or free clinics. (121-125) 
 
The exact prevalence of HF in Egypt is unknown; however, the disease emerges a decade 
younger in MENA regions than in Europe and the USA. (13, 16) The available MENA data 
suggest that HF patients are more likely to be in NYHA class IV due to the delayed diagnosis 
or the late presentation to the healthcare settings in comparison to patients from the Western 
countries. (12, 27) Data from the Egyptian National Hypertension Project were collected between 
1990 and 1993 and estimated the national incidence rate of HF as 300 cases per 100,000 
persons. (121) This rate was significantly higher than that of breast cancer and cervical cancer 
that had incidence rates of 54 cases per 100,000 and 24 cases per 100,000, respectively, at that 
time in Egypt. The project estimated the national prevalence of HF up to 11% of the Egyptian 
population according to Framingham diagnostic criteria. (121, 126) The project results also 
showed that 50% of Egyptian HF patients die within four years of the diagnosis, while 50% of 




The aim of conducting a detailed narrative literature review for this thesis is to explore and 
evaluate the existing evidence base for studies investigating HF pharmacotherapy in Ireland 
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and Egypt as a comparative study between a European country of high-income and a Middle 




A search was performed in Medline, Scopus, EMBASE, and Google Scholars databases 
without a restriction to date or language. The following search terms were used: ‘heart failure’, 
‘guidelines’, ‘guideline adherence’, ‘guideline compliance’, ‘physician prescribing pattern’, 
‘Ireland’, and ‘Egypt’ used either single or combined terms as Boolean logic and MeSH terms. 
The search was supplemented by searching databases of grey literature (associations, 
organizations and government reports) and reference lists and was not limited by dates of 
publication. For building a comprehensive and complete coverage about HF in Egypt, relevant 
researchers from the Egyptian Society of Cardiology (EgSC) and Novartis Medical Information 
Office were contacted by email. (127) The online research network www.researchgate.net was 
also searched.  
 
Inclusion criteria for this literature review were data from Egypt or Ireland for patients aged 18 
years and over with HF concerning the following: (i) clinical characteristics of HF patients, (ii) 
physician practice (iii) HF management patterns and their impact, and (iv) HF 
pharmacotherapy. The review included all quantitative studies that directly or incidentally 
focused on HF pharmacotherapy in either country. The following types of studies were 
excluded: clinical, or interventional cardiology, right-sided heart failure, pharmacology 
studies, clinical trials and mechanical device based studies. 
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2.4 Heart Failure care in Irish literature 
 
Twelve studies on clinical care in HF, conducted in Ireland, were identified. The published 
Irish literature reflects a widespread acceptance of the value and importance of the 
implementation of a disease-management programme (DMP) for HF management. All twelve 
studies were conducted in DMP settings. The studies investigated HF clinical care in DMP 
from different angles and levels. Eleven of the twelve studies discussed drug utilisation in HF 
management. The characteristics of these studies are highlighted in Table 2.1. The prescription 
rates of HF medications prescribed to patients in these studies are presented in Table 2.2. 
 
2.4.1 Implementation of a Heart Failure disease-management programme 
as an intervention in Heart Failure clinical care in Ireland 
 
The clinical research group in the Heart Failure Unit, St. Vincent’s University Hospital defined 
the DMP service as a comprehensive approach to care of HF encompassing prevention, 
treatment and follow-up care, including implementation of guidelines. (120, 128-130) The clinical 
research group designed the DMP service intervention to include a physician with an interest 
in HF and an HF-specialist nurse. (130) This structured design of HF care had a threefold aim 
which was: (i) rational and better utilisation of medications; (ii) identification of potential drug-
drug interactions; and (iii) extra-intensive patient counselling and education programme. (130) 
 
In a randomised controlled trial, designed to assess the impact of an inpatient and outpatient 
DMP service on HF-related clinical outcomes in one month and three months after discharge, 
HF patients with NYHA class IV admitted to the St. Vincent’s DMP service were assigned to 
multidisciplinary care or routine care. (128, 130, 131) Both arms were managed in a cardiology 
department, received similar guideline-directed medical therapies, including, if indicated the 
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maximum dose of ACE inhibitors before discharge. The only difference between the two arms 
was the in-hospital education received by the patients in the multidisciplinary care arm. (129, 130) 
In the first month post-discharge, no patient died or was rehospitalised within both arms of the 
study population in which 20% had been admitted to the hospital in the month before enrolment 
to the study DMP service. (130) At three-month post-discharge, 8% of the multidisciplinary arm 
of patients had at least one HF-related event, compared to 26% in the routine care arm of 
patients, p-value < 0.05. (129) The drug utilisation rates of the HF medications are presented in 
Table 2.2. 
 
In 2015, the same clinical research group examined the five-year survival rate of ambulatory 
Irish HF patients enrolled in the DMP service from 2002 to 2012. (132) Compared to the non-
HF patients, HF diagnosis significantly increased the mortality risk twofold within five years 
regardless of the patients’ EF level. The study reported that the mean age at HF diagnosis was 
80 years and that 65% of the HF population was alive five-years post-diagnosis. The study 
found that a six-month delay in the diagnosis of HF has been associated with a 23% increase 
in the risk of subsequent HF-related hospitalisation. (132) The study concluded that the accurate 
early diagnosis of HF in DMP reduces the patients’ exposure to inaccurate therapy, thereby 
improving survival. However, the study did not find a statistically significant difference in the 
mortality rates or cause of death between HFrEF and HFpEF patients. (132) This finding may 
reflect the survival benefit of the early initiation of the guideline-directed medical therapies in 
HF regardless of the EF.  
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Setting Population studied Intervention Main Aim Prescribing 
data 
published* 





98 hospitalised HF 
patients 
Multidisciplinary 
care in a DMP 
To assess the effects of this 
intervention on previously high 1-
month readmission 
Yes 





98 hospitalised HF 
patients 
Multidisciplinary 
care in a DMP 
To assess the effects of this 
intervention on 3-month readmission 
Yes 





98 hospitalised HF 
patients 
Multidisciplinary 
care in a DMP 
To evaluate the cost-benefits of 
multidisciplinary care in DMP 
No 





91 hospitalised HF 
patients 
None 
To determines the impact of an in-
hospital, DMP on appropriate 
pharmacotherapy, polypharmacy and 
drug interactions. 
Yes 





39 hospitalised HF 
patients 
None 
To determine the proportion of 
preventable readmissions in DMP 
Yes 








To determine the extent, causes, and 
clinical impact of non-persistence over 



















and hospitalised HF 
patients 
None 
To examine the relationship between 
Beta-2 agonists use and mortality in 
HF in DMP 
Yes 
Bermingham et 




350 ambulatory HF 
patients 
None 
To develop a consensus Potentially 











To evaluate the association of low- 
dose aspirin with mortality and 
morbidity risk in HF in DMP 
Yes 
Moran et al. 




549 ambulatory HF 
patients 
None 
To assess the achievement of the target 
heart rate 
Yes 





733 ambulatory HF 
patients 
None 
To assess the 5-year survival of HF 
patients in DMP 
Yes 








To assess HFrEF vs HFpEF clinical 
workload and cost in the first year 




† refers to the Heart Failure Unit, St. Vincent’s University Hospital, Dublin, Ireland. * prescription rates 
of the medications from these studies are presented in Table 2.2. Abbreviations: DMP, disease-
management programme; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
heart failure with reduced ejection fraction; RCT, randomised clinical trial. 
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Table 2.2 Prescription rates of Heart Failure medications in the Irish literature, N = 11. 
Study Renin-angiotensin system 
inhibitor (%) 
Beta-blocker (%) Mineralocorticoid receptor 
antagonist (%) 
Digoxin (%) Diuretics 
(%) 
McDonald et al. (130) 2001 71 N/A N/A 59 100 
McDonald et al. (129) 2002 67 N/A N/A 49 65 
Ledwidge et al. (131) 2004 95 N/A N/A 74 100 
Phelan et al. (133) 2009 74 69 28 N/A 69 
Mockler et al. (134) 2009 97 72 15 N/A 90 
Bermingham et al. (135) 2011 90 63 13 32 85 
Bermingham et al. (112) 2014 92 87 17 22 78 
Bermingham et al. (136) 2014 84 84 27 44 93 
Moran et al. (137)  2014 96 89 45 3 76 
James et al. (132) 2015 79 65 8 N/A 89 
Murphy et al. (138) 2017 74 68 9 N/A 92 
 
Data presented as a percentage. Abbreviations:  N/A, not applicable or not reported.
53 
 
2.4.2 Reasons for rehospitalisation in Heart Failure 
 
In 2007, Phelan and colleagues investigated the reasons causing rehospitalisation in the St. 
Vincent’s DMP within one-year post-discharge. (133) Despite the structured care of the DMP, 
the study showed that nearly one-third of hospital admissions could have been prevented. Of 
these preventable admissions, 20% were caused by drug therapy problems. As the study 
investigated 39 hospitalisations only, its small sample size impeded the generalisability of its 
results. (133) 
 
In the same DMP, Mockler et al. studied the relationship between HF patient’s non-persistence 
to the HF guideline-directed medical therapies and the clinical outcomes. (134) The medication 
non-persistence was defined as the discontinuation of an HF guideline-directed medical therapy 
for any period within a mean follow-up of three years. The study included 183 HF patients, 
where 30% of patients were categorised as non-persistent. (134) The study found that 50% of 
non-persistence occurrences did not have a clear documented explanation despite enrolment in 
DMP. (134) Mockler found that patient’s non-persistence to the medications represented a 
significant predictor of all-cause readmission (Hazard Ratio 3.2, 95% CI 1.74 – 11.34). 
Compared to the persistent patients, the study found a higher rate of unscheduled clinic visits 
among the non-persistent patients (1.5 ± 2.7 versus 4.3 ± 5.8 per patient, p-value < 0.01). The 
author added that the DMP structured care explains the delay of the first occurrence of non-
persistence for more than one-year post-discharge. (134) In this study, the clinical factors 
associated with non-persistence were previous HF-related hospitalisation (odds ratio [OR] 
0.314, 95% CI 0.138 – 0.718), chronic kidney disease (OR 1.019, 95% CI 1.0008 – 1.030), and 





2.4.3 Achievement of the guideline-recommended therapeutic goals 
 
Moran et al. assessed the achievement of the target HR, defined as ≤ 70 bpm, in 549 patients 
attending 12 HF DMPs throughout Ireland. (137) The study showed that nationally, two-thirds 
of patients achieved the target HR. Compared to patients within the guideline-recommended 
target of HR, patients above the target were more likely to be diabetic and in NYHA class III 
but less likely to be prescribed a beta-blocker. (137) The study investigated the frequency of 
prescribing the guideline-recommended target dose of the HF medications that affect HR, such 
as beta-blockers or ivabradine. Beta-blockers were prescribed to 89% of patients and 
ivabradine to 11% whereas the achievement of the recommended target dose of either 
medication was moderate as beta-blockers (25%) and ivabradine (10%) only received the target 
dose. (137) The study found that respiratory disorders were the main barriers to the utilisation 
and uptitration of the beta-blockers. (137) 
 
2.4.4 Therapeutic complexity in Heart Failure management 
 
The Irish literature investigated two prescribing issues in HF practice in DMP, which were the 
safety of beta-2 agonists and aspirin use in HF patients. Bermingham and colleagues 
longitudinally discussed these two issues over twelve-year (1998 – 2010) data of prescribing 
towards the Irish HF patients in the St. Vincent’s DMP. (135, 136) 
 
Bermingham et al. did not find any harmful association between beta-2 agonists and the long-
term mortality among a study population of 1,294 HF patients. (135) In 2014, Bermingham et 
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al. showed the long-term survival benefit of using low dose aspirin in HF patients in a study 
population of 1,476 ambulatory HF patients. (136) 
 
Over the twelve years, loop diuretic was the most frequently prescribed medications as to 95% 
of St. Vincent’s DMP patients. (136) ACE inhibitors were prescribed to 85%, beta-blockers to 
85% and MRA to 27%. (136) Digoxin was prescribed to 44%. (136) However, it is crucial to 
consider the time factor and the significant changes in HF prescribing perspectives over this 
time interval prior to judge the quality of prescription. (1, 139)  
 
2.4.5 Potentially inappropriate prescribing in Heart Failure 
 
In 2004, Ledwidge et al. published the effect of the St. Vincent’s DMP service on HF 
prescribing quality on admission and at discharge from an emergency HF admission. (131) In 
this paper, potentially inappropriate prescribing was defined as (i) a prescription of medications 
that were contraindicated to the HF guideline-directed medical therapies; (ii) an omission of 
any of the guideline-directed medical therapies; or (iii) inappropriate dosing of any of the 
guideline-directed medical therapies as defined according to the ESC guidelines at that time. 
(131) Pre-admission, patients were prescribed were 66 contraindicated medications, 107 
medications’ omissions, and 37 inappropriate dose regimens. At discharge from the DMP, 
these numbers significantly decreased to 31, 33, and 19, respectively, all p-value < 0.05 for the 
comparison between admission and discharge medicines. However, polypharmacy and 
potential drug-drug interactions had significantly increased by 33% and 62% upon discharge 
in comparison to the admission results. The study authors explained these results by the fact 
that the patients were selected following an emergency HF admission implying the disease 
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severity and the greater need of polypharmacy, in comparison to a more stable ambulatory HF 
population. (131) 
 
In 2014, the same clinical research group described a different approach to address 
inappropriate prescribing in HF patients. (112) The study developed the first HF-specific criteria 
for the potentially inappropriate prescribing, the St. Vincent’s PIMHF tool (Appendix 1). This 
tool consisted of 11 medications or medication classes that are harmful or contraindicated in 
HF. The application of this tool on ambulatory HF patients enrolled in a DMP found that 15% 
were prescribed at least one PIMHF agent. Of the list, the non-dihydropyridine CCB were the 
most frequently prescribed PIMHF item among the DMP patients. (112) Compared to patients 
who have not been prescribed a PIMHF item, the total number of medications and the 
comorbidity index were significantly higher, and the prescription of beta-blockers was 
significantly lower in the patients prescribed a PIMHF. Patients who were prescribed at least 
one PIMHF agent were at 88% higher risk of combined hospitalisation or mortality over a 
mean follow-up period of two years. (112) 
 
2.4.6 Economic evaluation of the Heart Failure disease management 
programme 
 
The implementation of DMP service might raise questions about its economic viability because 
it may involve employing extra staff members, potentially require higher workload and 
lengthen the hospital stay.  
 
Data from the St. Vincent’s University Hospital have shown the cost-effectiveness of the DMP-
based multidisciplinary care, demonstrating significant cost savings from the perspective of the 
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healthcare provider. (140) The results found a net saving of €37,216 in the arm of the 
multidisciplinary care over a follow-up period of three months. The costs of hospitalisations in 
the multidisciplinary care and the routine care arms of DMP in St. Vincent’s University 
Hospital were as follows: €4,114 versus €47,190, p-value < 0.05. The medications represented 
3.5% of all-direct hospitalisation costs. (140) 
 
In a study published in 2017, Murphy et al. performed a microeconomic comparison between 
HFrEF and HFpEF patients enrolled in St. Vincent’s DMP in terms of the workload and cost. 
(138) This retrospective analysis included 1,292 patients who were followed up for one year after 
their admission with HF and enrolment in the DMP. The analysis found the higher costs of 
HFpEF at the end of the follow-up period due to the non-cardiovascular hospitalisations. (138) 
The total annual costs of HFrEF and HFpEF were €13,011 and €12,206 per patient in the first 
year post-discharge. The study found that medication dose optimisation was the major 
contributor to the workload within the initial months post-discharge regardless of the HF type. 
Among discharges, diuretics were prescribed to 92% of patients, RASi to 73.7%, beta-blockers 
to 67.7% and MRA to 8.8%. (138) Compared to HFpEF, adjustment of RASi and beta-blockers 
doses was more common in the HFrEF cohort within the first three months post-discharge. In 
HFrEF, the medications related issues represented 4.5% of the total costs of patient care per 









2.5 Heart Failure care in Egyptian literature 
 
The study of HF clinical care in Egypt is very scarce, as only six studies addressed HF care in 
the Egyptian context. The characteristics of the six studies are outlined in Table 2.3. Of the six 
studies, only four studies were concerned with HF pharmacotherapy and medications’ 
prescription rates. The prescription rates of HF recommended medications in Egyptian settings 
are presented in Table 2.4. 
 
2.5.1 Heart Failure care in Egypt 
 
The first original Egyptian HF research was published in 2002 by Bassem Ibrahim over 155 
patients in the Cardiology Outpatient Clinic of the National Heart Institute of Egypt in Cairo. 
(15) This study aimed to estimate the clinical profile and outcomes of HFrEF and HFpEF among 
Egyptian ambulatory HF patients. Two-thirds of patients had HFrEF.  Over a follow-up period 
of 1.5 years, the rehospitalisation rate per patient was significantly higher in the HFrEF than in 
the HFpEF (1.01 vs 0.58 rehospitalisation per patient, p-value < 0.05). However, the difference 
in the mortality rates was not significant between the two types of HF patients. Diuretics were 
prescribed to 99% of HFrEF patients, ACE inhibitors to 93%, digoxin to 52% and beta-blockers 
to 37%. (15) 
 
The second Egyptian HF study was conducted in a single private hospital in the governorate of 
‘6th October’ and published in 2009. (141) It focused on the clinical presentation and outcomes 
of acute decompensated HF in 107 hospitalised HFrEF patients. The rehospitalisation rate was 
20% in a two-year follow-up. The study found that 83% of patients were NYHA class IV at 
59 
 
admission, but only 12% were prescribed a combination of RASi and beta-blocker at 
admission. This study did not provide the prescribing data at discharge. (141)  
 
HF prescribing in Egypt was included in a systematic review by Callender et al. of “Heart 
Failure Care in Low- and Middle-Income Countries”. (18) The review illustrated a comparison 
of HF clinical care in non-acute settings between three Middle-Eastern nations, which were 
Egypt, Tunisia and Lebanon. The review showed that diuretics were prescribed to 82.3% of 
the Egyptian HF patients while in Lebanon and Tunisia, diuretics were prescribed to 98.3% 
and 88.7%, respectively. In comparison to Egypt’s neighbouring countries, the review showed 
considerable underutilisation of ACE inhibitors (44%) in Egypt whereas ACE inhibitors were 
prescribed to 58% of patients in Lebanon and 57% in Tunisia. The review found comparable 
utilisation rates of beta-blocker (63%) in Egypt, Lebanon (72%) and Tunisia (42%) as well as 
comparable use of MRAs in Egypt (24.3%), Lebanon (36%) and Tunisia (24%).  (18) 
60 
 



















155 ambulatory HF 
patients 
None 
To study the relative contribution of HFrEF and 
HFpEF in Egyptians 
Yes 
Hozayen et 





107 hospitalised HF 
patients 
None 
Characteristics and outcome of acute HF 
patients in Egypt. 
No 







120 ambulatory HF 
patients 
None 









To review both published and unpublished 
information on the presentation, causes, 
management, and outcomes of HF in LMICs. 
Yes 
Hassanein et 




2,145 ambulatory and 
hospitalised HF patients 
None 
To describe the clinical characteristics and 
management of HF patients 
Yes 
Hassanein et 




1,634 hospitalised HF 
patients 
None 
To evaluate gender differences in the Egyptian 




*prescription rates of the medications are presented in Table 2.4. Abbreviations: HF, heart failure; 
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; LMIC, low – medium income countries; N/A, not applicable or not reported; SR - MA, 









Beta-blocker (%) Mineralocorticoid receptor 
antagonist (%) 
Digoxin (%) Diuretics 
(%) 
Ibrahim et al. (15) 2002 89 41 N/A 38 97 
Callender et al. (18) 2014 * 44 62 24 N/A 82 
Hassanein et al. (16) 2015 87 66 74 41 89 
Hassanein et al. (143) 2018 83 61 67 37 78 
 
Data presented as a percentage. Abbreviations: N/A, not applicable or not reported. 
 
*The source of Egyptian data used in the Callender et al. systematic review was I-PREFER study, a multiregional, cross-sectional, observational 
study conducted in Latin America, the Middle East, and North Africa.  (18, 91) The source and site of the Egyptian data collected  for the I-PREFER study 
were not provided in the study supplementary material. 
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2.5.2 The Long-Term Heart Failure Registry of Egypt  
 
As part of the ESC-HF Long-Term Registry, the Egyptian registry included 20 cardiology 
centres covering the different Egyptian governorates except for the Sinai Peninsula. (16) 
 
The first published study of the registry included an HF population of 2,145 patients. (16) This 
study is the largest study of HF profile in Egypt in terms of sample size and multicentre design. 
The study had a different aim than the above three studies as it aimed to highlight the 
differences of the clinical profiles of hospitalised HF and chronic HF in Egypt and to compare 
the Egyptian data to the international data in the ESC-HF Long-Term Registry. (16) 
 
The study found that the onset of HF in Egypt occurs 12 years earlier than in Europe (61 years 
in Egypt versus 73 years in Europe). (16) Also, the prescription rates of HF guideline-directed 
therapies were significantly lower than the ones of the ESC-HF Long-Term Registry. Among 
the hospitalised HF patients, diuretics were prescribed to 93%, RASi to 86%, beta-blocker to 
66% and MRA to 36%. In ambulatory care, beta-blockers were prescribed to 67% and digoxin 
to 47% of the HF outpatients. However, the study did not provide an explanation for the low 
rate of beta-blockers prescription or the high rate of digoxin prescription in this outpatient 
population. (16) 
 
In 2018, the Long-Term Registry research group published the second output of the registry 
with a focus on hospitalised HF patients only. (143) The study aimed to examine the effect of 
gender on the provision of the guideline-directed diagnostic and therapeutic recommendations 
in Egypt. The results demonstrated a significant difference in the baseline characteristics and 
the provision of diagnostic and therapeutic interventions to female and male HF patients. For 
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instance, diuretics prescription rates were significantly higher in the male gender as 81% of 
males versus 69% of females, p-value < 0.001. (143) An MRA was prescribed to 73% of male 
HF patients and 61% of female patients, p-value < 0.05. However, the authors did not 
investigate the reasons for these gender differences. Also, the authors confirmed that there is a 
considerable underutilisation of beta-blockers at discharge regardless of the patient’s gender. 
(143) Finally, the registry results showed that the 1-year mortality of HF in Egypt ranges from 
26% to 28% post-discharge. (16, 143)  
 
2.5.3 Egyptian Heart Failure patient behaviour 
 
Another aspect of the Egyptian HF literature is the study of patient’s behaviour. A survey of 
120 patients was carried out by Samir et al. (142) in a governmental hospital in Alexandria. The 
study used an HF self-management survey initially developed in 2000 by Riegel et al. (144) to 
investigate the patient understanding of HF disease progression, treatment evaluation and self-
confidence in coping with HF disease complications. (142) The results showed that 66% of this 
HF population was living a sedentary lifestyle, and 58% were suffering from comorbidities, 
and 33% had a family history of HF. Although 87% of patient respondents recognised the 
shortness of breath as a sign for disease progression, only 16% associated ankle oedema with 
HF and 50% did not consider sudden weight gain as a meaningful HF sign. Only 52% of 
patients sought medical advice in the case of any new sign or symptoms. (142) 
 
On the level of patients’ compliance, 73% only took their HF medications, and 80% took their 
diuretic therapy, regularly. Regarding patients’ compliance to the non-pharmacological 
measures, 25% only reduced the salt intake, and five per cent decreased their fluid intake. 
Overall, the survey results identified two crucial factors in relation to patient’s medication-
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taking behaviour. (142) Firstly, there was a significant positive association between the level of 
patients’ education and treatment administration. Secondly, the study found a significant 
positive association between the patient’s recognition of the sudden changes in symptoms and 
the administration of treatment. (142) 
 
The Long-Term Registry of Egypt marginally considered a few aspects of the patient’s 
behaviours. For instance, the registry found that patient non-compliance to the medications was 
the cause of 10% of HF hospitalisation in Egypt. (143) Also, Egyptian HF patients had a higher 
rate of obesity than HF patients in Europe (47% vs 28%, p-value < 0.001). (143)  
 
2.6 Chronological comparison of Heart Failure management in 
Ireland and Egypt 
 
Despite the single centred design in the majority of studies, HF literature in Ireland is diverse 
and covers HF clinical care from different angles. The Irish literature represents a 
comprehensive study of DMP implementation in terms of clinical and economic aspects as well 
as the patient’s quality of life. In contrast, HF literature in Egypt is still sporadic despite the 
significant contributions of the Long-Term Registry. Ibrahim’s study, published in 2002, was 
the only reference source for HF information in Egypt for three different international studies 
published between 2013 and 2015. (13, 18, 145) This may reflect the striking lack of HF data in 
Egypt before the contribution of the registry. Overall, both countries studied the two types of 
HF patients that are HFrEF and HFpEF.  
 
Some studies shared factors from which the HF profile and management in Ireland and Egypt 
can be compared. For a better and accurate study of HF care in the Irish and Egyptian context, 
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the comparison should be carried out in two timeframes; early and late 2000s. An Egyptian 
study published in 2002 and an Irish study published in 2004 can lead to a brief comparison 
about HF profile in Ireland and Egypt at that time (Table 2.5). (15, 131) Interestingly, the largest 
two HF reports were published more recently in Ireland in 2014 and Egypt in 2015. (16, 137)  This 
allowed conducting an updated comparison of HF management in both countries (Table 2.6). 
(16, 137)   
 
In the early 2000s, the comparison between Ledwidge et al. (131) and Ibrahim et al. (15) shows 
that there was no sizeable difference in the prescription rates of HF medications between the 
Irish and Egyptian practice except in digoxin prescription (Table 2.5). At that time, digoxin was 
deemed the first-line therapy for HF management according to the recommendations of the then 
ESC guidelines. Also, it was considered counter-intuitive to use a negative inotropic agent such 
as a beta-blocker in patients with impaired systolic function. That is why prescribing of beta-
blockers was not reported by Ledwidge et al. (131) while it was prescribed to just 37% of the 
HFrEF study population of Ibrahim et al. (15) Notably, both studies mentioned the drug 
utilisation rates incidentally to the main objectives of the studies. Also, both studies shared a 
common limitation, which was a small sample size of HF patients recruited from a single centre. 
This limited the generalisability of the results of the studies. 
  
According to studies published in 2014 and 2015, HF clinical care has not significantly changed 
(Table 2.6). According to the results of Moran et al. (137) and Hassanein et al. (16), the utilisation 
rates of medications in both Ireland and Egypt were comparable. The key differences between 
the two studies are the high rate of digoxin prescribing and the relatively low rate of beta-
blocker prescribing in Egypt. However, both of these studies overlooked some essential ESC 
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guideline-recommended practices. Firstly, Moran et al. included atenolol as an EBBB in HF 
management despite the existence of DMP structured and specialist care. (137) Secondly, 
Hassanein et al. did not define the type of beta-blockers or diuretics included in the analysis 
despite being part of the ESC-HF Long-Term Registry. (16)  
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Table 2.5 Heart Failure management in Ireland and Egypt in the early 2000s. 
 
1st Author Ledwidge et al.  (131) Ibrahim et al.  (15) 
Publication date 2004 2002 
Study design Prospective chart review  Retrospective chart review 
Study aim 
To determine the impact of an in-hospital, specialist HF 
care programme on appropriate pharmacotherapy, 
polypharmacy and drug interactions. 
To study the prevalence of HFrEF and HFpEF in an 
Egyptian population 
Clinical setting 
DMP Service, St. Vincent’s University Hospital, Dublin, 
Ireland 
Cardiology outpatient clinic, National Heart Institute, Cairo, 
Egypt 
Population 91 hospitalised HF patients 155 ambulatory HF patients 
HFrEF 68% 66% 
Gender (male) 66% 76% 
Mean age ± SD 
(years) 
71 ± 10 years 60 ± 10 years 
Commonest cause 
of HF 
Ischaemic heart disease (50%) Ischaemic heart disease (72%) 
Valvular diseases 20% 23% 
Diabetes 21% > 33% 
Smoking prevalence 37% 23% 
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Table 2.5 Heart Failure management in Ireland and Egypt in the early 2000s, Cont’d. 
1st Author 
Ledwidge et al.  (131) Ibrahim et al.  (15) 
Heart Failure medications’ prescription rates among patients having Heart Failure with reduced ejection fraction (HFrEF) 
Number of patients 62 102 
RASi 95% 93% 
Beta-Blocker N/A 37% 
Digoxin 74% 52% 
Diuretics 100% 99% 
 
Abbreviations: HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; N/A, not applicable 
or not reported in the study; RASi, renin-angiotensin system inhibitor (ACE inhibitor/angiotensin-II receptor blocker); SD, standard deviation.
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Table 2.6 Heart Failure management in Ireland and Egypt in 2014 - 2015. 
1st Author 
Moran et al. (137) Hassanein et al. (16) 
Study type Prospective observational study Prospective observational study 
Clinical Setting Multi-centre (n =12 hospitals) Multi-centre (n =20 hospitals) 
Setting type Disease management programmes Cardiology wards 
Study aim To identify the prevalence of patients with heart rate >70 
To identify the proportion of patients achieved the target 
doses of heart rate-controlling medications 
To describe HF profile, characteristics and management 
in Egypt 
Population size 549 607 
Population type Chronic stable HF Chronic stable HF 
HFrEF 51% 75% 
Gender (male) 71% 64% 
Mean age (years) N/A 57 
Commonest 
aetiological cause of HF 




Diabetes 23% 32% 
Smoking prevalence 33% 52% 
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Table 2.6 Heart Failure management in Ireland and Egypt in 2014 – 2015, Cont’d. 
1st Author 
Moran et al. (137) Hassanein et al. (16) 
Heart Failure medications’ prescription rates 
RASi 97% 90% 
Beta-Blockers 90% 67% 
MRA 45% 87% 
Ivabradine 11% 20% 
Digoxin 3% 47% 
Diuretics 76% 85% 
Achievement of target dose 
Beta-Blockers Target 






CRT/ICD 28% 2% 
 
Abbreviations: CRT, cardiac resynchronisation therapy; DMP, disease management programmes; HF, heart failure; ICD, implantable cardiac 
defibrillator; MRA, mineralocorticoid receptor antagonists; N/A, not available or not reported in the study; RASi, renin-angiotensin system 
inhibitor (ACE inhibitor/ angiotensin-II receptor blocker).
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2.7 Gaps in knowledge 
 
The present literature review identified two levels of gaps in knowledge: (i) common gaps in 
knowledge in both countries; and (ii) country-specific gaps in knowledge.  
 
2.7.1 Gaps in knowledge in both Ireland and Egypt 
 
There is considerable research on HF in Ireland and Egypt; however, very little of it is solely 
concerned with drug utilisation, and none is concerned with guideline-led prescribing. In most 
cases, prescribing data were presented incidentally to the other research aims. Overall, the data 
from 2000 to 2018 showed that in Ireland, the range of RASi prescription was 67% - 97% of 
patients, beta-blockers (63% – 89%) and MRA (8% - 45%) while in Egypt, their ranges were 
RASi (44% - 89%), beta-blockers (41% - 66%) and MRA (24% - 74%). 
 
All the aforementioned studies overlooked some important prescribing-related factors. Firstly, 
the appropriate choice of the beta-blockers is crucial in HF care as only the four EBBB are 
proven to be beneficial in HF management. (1) Secondly, the achievement of the recommended 
target dose is one of the most important ESC guidelines’ recommendations to get full benefits 
of the prescribed medications. (1, 84) This point was discussed only once in the Irish HF literature 
(137) but was not studied in the Egyptian literature. Thirdly, the identification and consideration 
of the evidence-based relative or absolute contraindications are essential for assessing the 
quality of HF prescribing. (1, 146) Hence, contraindications represent a potential explanation for 
the omission of the evidence-based medications in many circumstances. Consequently, the 
exact causes of non-adherence to the guidelines are unknown. 
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2.7.2 Gaps identified in the Irish Heart Failure literature 
 
Almost all research was performed in Dublin and mainly, in a single tertiary academic care 
setting. Also, routine clinical practice of HF is not assessed in any of the HF studies. Heart 
failure DMPs offer structured care; however, this type of care may not be available to all 
patients nationally. Furthermore, no study focussed on vulnerable populations such as the 
residents of nursing homes. Finally, the majority of the Irish studies were selective in the patient 
recruitment process as some studies excluded patients having diseases that adversely affect the 
survival (128-131) while others excluded patients in whom HF was not the primary reason for 
hospitalisation. (128-131, 133, 137) 
 
2.7.3 Gaps identified in the Egyptian Heart Failure literature 
 
The review of the Egyptian literature points to many gaps in knowledge. Firstly, all the 
Egyptian literature covered cardiology departments only and did not include other types of 
healthcare settings that have the ability to discharge patients to home, such as the critical care 
medicine departments. Secondly, the prevalence of potentially inappropriate medicines was not 
addressed in the literature. Thirdly, the Egyptian studies did not discuss any quality measure 
or intervention in order to improve the prescribing outcomes and particularly, the prescription 
of beta-blockers and digoxin. Finally, the guideline-recommended target goals of therapy, such 
as target HR or target BP, were not considered in any of the studies.   
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3 Chapter 3 
A Tool for Assessment of Heart Failure Prescribing 
Quality: A Systematic Review and Meta-Analysis 
 
 
The previous two chapters discussed HF pharmacological management worldwide and 
particularly, in Ireland and Egypt. This chapter aims to identify the potential quantitative tools 
assessing HF guideline-led prescribing objectively and overcoming the problems of sole use 
of prescription rates. Evidence from this chapter will be used in the following chapters to assess 
guideline-led prescribing in various settings.  
 
The work of this chapter has been published as: El Hadidi S, Darweesh E, Byrne S, 
Bermingham M. A tool for assessment of heart failure prescribing quality: A systematic review 












Heart Failure guidelines aim to standardise patient care. Internationally, prescribing practice in 





A systematic review and meta-analysis were performed to identify a quantitative tool for 




Twelve electronic databases were searched to include studies reporting a comprehensive tool 
for measuring adherence to prescribing guidelines in HF patients aged ≥ 18 years. Qualitative 
studies or studies measuring prescription rates alone were excluded. Study quality was assessed 
using the Good ReseArch for Comparative Effectiveness (GRACE) Checklist for rating the 




In total, 2,455 studies were identified. Sixteen eligible full-text articles were included (n 
=14,354 patients, mean ± standard deviation (SD) age 69 ± 8 years). The Guideline Adherence 
Index (GAI-3), and its modified versions were the most frequently cited tool (n = 13). Other 
tools identified were: the Individualised Reconciled Evidence Recommendations, the 
Composite Heart Failure Performance, and the Heart Failure Scale. The meta-analysis included 
the GAI studies of good-high quality. The average GAI-3 was 62%. Compared to Low-GAI, 
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High-GAI patients had a lower mortality rate (7.6% vs 33.9%) and lower rehospitalisation rates 
(23.5% vs 24.5%); both p-value < 0.05. High-GAI was associated with reduced risk of 
mortality (Hazard Ratio 0.29, 95% CI 0.06 - 0.51) and rehospitalisation (Hazard Ratio 0.64, 




The GAI is the most frequently used tool to assess guideline adherence in HF. High-GAI is 
associated with improved HF outcomes.  
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3.2 Introduction  
 
Landmark clinical trials demonstrated the significant benefits of guideline-directed medical 
therapies on mortality, hospitalisation and patient’s quality of life in HF. (55, 148, 149) However, 
international reports suggest that prescribers do not optimally adhere to the recommendations 
of HF practice guidelines. (150-152) It has been shown that under-prescribing of guideline-
directed medical therapies is associated with worsening HF and higher rates of HF hospital 
admissions and mortality. (79, 134, 153) Furthermore, where these agents are prescribed, but at 
lower than the target dose, patients may not obtain the full beneficial effect of the agents. (151, 
154) Thus, HF clinical care could be vastly improved with the optimal use of guideline-directed 
medical therapies. (1, 154) 
 
Guideline adherence refers to the adoption of clinical practice guidelines by clinicians in their 
routine clinical practice, rather than to the patients’ adherence. There remains a wide variation 
in HF prescribing patterns, and quality internationally (13, 151, 155) and several barriers to 
guideline adherence have been described. Prescribing for patients with multiple comorbidities 
(151), polypharmacy (156), or advanced age (156) can affect prescriber’s adherence to guidelines. 
Furthermore, the lack of resources in the healthcare setting or lack of knowledge on behalf of 
the prescriber may also play a role in poor guideline adherence. (157) 
 
Given the complexity of HF management, the simple prescription rates alone are not sufficient 
to evaluate prescribing quality as they do not consider factors such as a patient’s eligibility for 
or contraindication to therapy or achievement of the target dose. Some health systems have 
developed HF performance measures, which include prescribing indicators. However, these 
measures often involve a simple assessment of a single prescription item and are not 
comprehensive regarding the complex HF practice guidelines. (158, 159) The Guideline 
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Adherence Index (GAI) addresses many of these shortcomings and has been widely cited since 





This systematic review and meta-analysis were performed in order to identify and characterise 
the objective tools for quantifying adherence to guideline-led prescribing in HF practice and to 
assess the clinical outcomes associated with physician’s guideline adherence measured by such 
tools.  
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3.3 Methods  
 
3.3.1 Review protocol 
 
Prior to the start of the review process, a protocol for the work was submitted as part completion 
of PG7016 Systematic Reviews for the Health Sciences, a postgraduate training module in 
University College Cork. The protocol was reviewed by Professor John Browne, School of 
Epidemiology and Public Health, University College Cork. This systematic review and meta-
analysis were performed in line with Preferred Reporting Items for Systematic Review and 
Meta-Analyses (PRISMA) guidelines. (162)  
 
3.3.2 Study eligibility criteria 
 
The inclusion criteria for the systematic review were studies: (i) specific to chronic or acute 
HF patients aged ≥ 18 years; (ii) measuring adherence to a national or international chronic or 
acute HF guideline; and (iii) using a quantitative review tool to assess adherence to practice 
guidelines. The exclusion criteria for the systematic review were: (i) studies reporting 
prescription rates in absence of a quantitative or comprehensive prescribing review tool; and 
(ii) qualitative studies.  
 
3.3.3 Search methods  
 
3.3.3.1 Information sources  
 
The following electronic databases were searched in April 2016: Medline PubMed, Scopus, 
Web of Knowledge, Science Direct, EBSCO (Academic search complete, CINAHL, and 
PsycINFO), EMBASE, Cochrane Library, Campbell Collaboration, Open Grey and Grey Lit. 
No restriction was placed on publication date or language.  
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3.3.3.2 Search terms 
 
The following search terms were combined as appropriate across each database: heart failure, 
care indicator, global prescribing score, guideline adherence indicator, guideline adherence 
index, GAI, guideline compliance, guideline implementation, implementation of guidelines, 
process indicator, quality circle, and strategies for guideline implementation, (Appendix 2). 
The search terms were used as single terms or combined via Boolean logic (AND, OR) in 
each database. 
 
3.3.4 Study selection 
 
A database search was performed, and duplicate results were removed. Two reviewers (SE, 
MB) independently reviewed the titles and abstracts of studies identified in the search. Studies 
that were eligible for full-text review were identified and reviewed by the two reviewers for 
final determination of study inclusion in the systematic review and meta-analysis. 
 
3.3.5 Assessment of risk of bias in included studies  
 
Risk of bias assessment was performed using the Good ReseArch for Comparative 
Effectiveness (GRACE) Checklist for observational studies. (163) 
 
3.3.6 Outcomes  
 
A meta-analysis was performed on studies identified in the systematic review that used the 
Guideline Adherence Index (GAI) tool. Studies of good to high quality according to the 
GRACE Checklist were included in the meta-analysis. Overall GAI is a mean score of the 
guideline adherence levels (range from 0% - 100%) of all the eligible patients prescribed HF 
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medications as recommended by the relevant guidelines. The GAI-3 is the proportion of the 
three principle HF guideline-directed medical therapies: RASi, beta-blocker and MRA that is 
actually prescribed to each patient according to the indications of the relevant guidelines. In 
this study, GAI scores are categorised into (i) High-GAI that is prescription of ≥ 2 
recommended HF agents and (ii) Low-GAI that is prescription of < 2 recommended HF agents. 
The GAI can also be calculated for each pharmacological class individually as the proportion 
of eligible patients prescribed the pharmacological class. This is compared to the percentage of 
patients prescribed a medication out of the total population regardless of the patient’s 
eligibility. 
 
3.3.7 Statistical analysis 
 
Data were extracted from the studies identified using a structured form in Microsoft Office 
Excel® 2016. Pooled odds ratios (OR) and respective 95% confidence intervals (CI) were 
displayed using the forest plot generator of DistillerSR®. Hazard ratios and 95% CIs were 
pooled using NCSS® Statistical Software for Data Analysis v.11 for meta-analysis of Hazard 
Ratios, computed by random-effects regression for combining study data. Cochran’s Q test was 
used to estimate heterogeneity. Random effects were applied to compensate for the potential 
for between-study heterogeneity in observational studies. Means were rarely reported with an 
estimate of variability and consequently, are presented as pooled mean with its appropriate SD 
or the range of means. 
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3.4 Results 
 
3.4.1 Search results  
 
A total of 2,454 titles were identified through the database search and one manuscript via hand 
search (Appendix 2). Of these, 1,529 were duplicates. Following title and abstract review, 66 
studies were identified as eligible for full-text review. Finally, 16 studies were considered 
relevant to this systematic review, as shown in the PRISMA flowchart (Figure 3.1).  
 
3.4.2 Profile of included studies 
 
The characteristics of each included study are shown in Table 3.1. All included studies were 
non-interventional. Study populations ranged from 58 – 3,292 HF patients. The combined study 
population included in the review was 14,354 HF patients, and the mean ± SD age was 69.0 ± 
8.0 years. Patients having HFrEF were included in all 16 studies (46, 161, 164-177) and patients 
having HFpEF in 11 studies. (46, 161, 164, 167, 169-171, 175, 176, 178, 179)  
 
The studies reported the use of prescribing review tools in several different healthcare settings 
including eight studies performed in ambulatory care (46, 166-169, 172, 176, 178), six studies in primary 
care (164, 168, 170, 173, 175, 180) and seven studies in hospital inpatient settings (161, 166, 171-173, 176, 179). 
Seven studies (46, 166-168, 172, 178, 179) included a follow-up period of 6-12 months, while two studies 
(161, 176) reported a follow-up period of almost two years.  
 
Twelve studies were performed in Europe, six of which were performed in Germany (46, 164, 172, 
176, 178, 180). All studies assessed guideline adherence by reference to ESC guidelines except 
Popescu et al. (161), which used an American quality measure. Fifteen studies were adjudged to 
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be of good - high quality (Table 3.1). One study was judged to be of poor quality and was not 
included in the meta-analysis. (166) 
 
3.4.3 Tools identified in the systematic review 
 
Four objective tools were identified in this review: i) the GAI (46); ii) the Composite Heart 
Failure Performance (161); iii) the Heart Failure Scale (170) and iv) the Individualized 
Recommended Evidence-based Reconciliation (IRER) (169). 
 
The GAI was initially defined by Komajda and colleagues as the proportion of the indicated 
guideline-directed medical therapies prescribed for every patient by their physicians according 
to the recommendations outlined in the ESC 2001 guidelines. (46)  Thirteen of the 16 studies 
identified used the GAI. (46, 164, 166-168, 171-173, 175, 176, 178-180) This tool has been modified in several 
ways since its publication, and only two studies used the original tool. (168, 175) Modifications to 
the GAI include the consideration of contraindications to therapy (167, 171-173, 175, 176, 180), 
recommended target doses (167, 180), general practitioner rationale (164, 173) and patients’ 
socioeconomic level (171, 173) as eligibility criteria for guideline adherence. While 11 studies 
reported GAI for both HFrEF and HFpEF patients, only one study reported the GAI results for 
each HF type (176). 
 
Each of the other guideline adherence tools identified has been reported in a single study. The 
Composite Heart Failure Performance is calculated as a ratio of the number of HF patients in a 
given hospital who received guideline-directed medical therapy divided by the number of HF 
patients in that hospital who should have received the indicated treatment. (161) Therefore, this 
tool was developed for application at a hospital population level rather than at a direct patient 
level.  
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The third tool identified is the Heart Failure Scale. (170) It is calculated as the percentage of HF 
patients appropriately receiving the following elements of care: laboratory tests, lipid profile, 
prescription of a RASi and prescription of a beta-blocker. (170) The fourth tool is the IRER. (169) 
This tool consists of software that merges the guidelines of several chronic diseases and 
includes recommendations on vaccination, lifestyle measures and therapy goals as well as 
pharmacological therapy. The software generates a list of evidence-based recommendations 
personalised to each HF patient. (169) This is the most recently published tool and is characterised 
by its multi-disciplinary approach; however, it does not take contraindications to therapy into 
consideration. (169) All non-GAI studies took into account some clinical aspects of prescribing, 
such as availability of echocardiography results or serum creatinine level as a pre-requisite to 
RASi prescription. The components of clinical care considered by each tool are described in 
Table 3.2.  
 
No tool identified here has been utilised as a tool to improve or optimise the quality of 
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Figure 3.1 Flow diagram of the systematic review search strategy.  
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3.4.4 Measured guideline adherence and changes in guideline adherence 
indices over time  
 
The studies reporting the IRER and the Composite Heart Failure Performance both reported 
guideline adherence of > 90% whereas the Heart Failure Scale reported a relatively low 
guideline adherence score of 1.6 / 4. Among studies reporting GAI, the mean GAI-3 was 62.9% 
± 20.4% (range 14% - 95%) in the period from 2005 to 2016. These changes reflect the on-
going modifications to the GAI-3 and guidelines updates. Also, the small sample size may 
adversely affect overall GAI-3 score in certain studies such as Oliveira et al. (171)   
 
 
3.4.5 Guideline adherence tools compared to the prescription rates  
 
Four GAI based studies reported a comparison between the simple prescription rates and the 
GAI scores for RASi, beta-blocker and MRA (Table 3.3). In each pharmacological class, the 
GAI is calculated as the proportion of eligible patients whose physicians prescribed according 
to the guidelines. Two studies (46, 171) showed that GAI scores of pharmacological classes were 
higher than the prescription rates as GAI considered the patient’s eligibility to therapy as the 
denominator. However, the other two studies (175, 180) showed the opposite result. This paradox 
was explained by Klimm et al. (180), that the GAI score should take into account both 
contraindications and achievement of target dose in order to reflect the guideline’s 
recommendations comprehensively. However, in Bosch et al. (175), the higher prescription rates 
were justified as HF medications were prescribed to patients in absence of their guideline-
outlined indications. 
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3.4.6 Daily target dose prescription 
 
Six studies (164, 167, 173, 175, 179, 180) reported the frequency of HF patients receiving ≥ 50% of the 
daily target dose of the guideline-directed medical therapies (Figure 3.2). Overall, 57% of 
patients were prescribed ≥ 50% of the target dose of RASi and 33.2% of patients were 
prescribed ≥ 50% of the target dose of beta-blocker. The daily dose of MRAs was studied in 
two populations (173, 179), where ≥ 50% daily target dose was prescribed to 95.6% and 100% of 
patients respectively.   
 
3.4.7 Guideline adherence achieved by cardiologists and general 
practitioners 
 
Three studies compared the general practitioner (GP) and cardiologist prescribing patterns. 
Stork et al. calculated the GAI-3 as 67% for cardiologists and 60% for GPs (p-value = 0.01). 
(176) Luttick et al. calculated the GAI-3 for each type of prescriber at baseline and one-year 
follow-up. (168) The GAI-3 rates for GP prescribers were 95% at baseline, and 92% at follow-
up and the GAI-3 rates for cardiologists were 94.5% at baseline and 91% at follow-up. 
However, the difference at both time points was non-significant. (168) Elsewhere, Bosch et al. 
(175) found that the percentage of patients receiving the guideline-directed target dose of ACE 
inhibitors was significantly higher when prescribed by a cardiologist than when prescribed by 
a GP (29.5% vs 14.3%, p-value < 0.05). Elsewhere, Visca and colleagues found that single or 
team-based GP practice has no relationship with the HF composite score. (170) 
 
3.4.8 Achievement of High Guideline Adherence Index  
 
High-GAI achievement was calculated in eight GAI studies (46, 164, 167, 172, 176, 178-180). The mean 
number of patients achieving High-GAI was 53.8 ± 12.2% (range 38% (176) to 71% (172, 179)). 
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Before 2010, the mean proportion of HF patients achieving High-GAI was 42.5% while in the 
period since 2010, a mean of 63% of patients have achieved High-GAI. Clinical factors 
associated with High-GAI achievement are illustrated in Figure 3.3. 
 
3.4.9 Barriers to achieving guideline adherence  
 
Twelve studies identified barriers to guideline adherence in their study population. Seven 
studies cited increasing patient age of HF patients  (165, 168, 172, 174-177) and five studies cited patient 
comorbidity burden. (164, 165, 167, 175, 176) Other barriers to guideline adherence identified were: 
increasing NYHA class (172, 175) and the presence of obstructive lung disease (177), chronic kidney 
disease (165, 173, 177), hypotension (164, 165, 171) and bradycardia (164, 171, 177). However, two studies 
reported that there was no explanation available for guideline non-adherence in up to 15% of 
patients in their populations (165, 173).  
 
3.4.10 Clinical outcomes associated with Guideline Adherence Index 
 
The clinical impact of guideline adherence was studied in seven study populations. (46, 167, 168, 
172, 176, 178, 179) Two studies reported Cox proportional hazards models estimating the relationship 
between the GAI score and one-year mortality. (172, 178) Mortality risk associated with High-GAI 
ranged from 5% to 13% while mortality risk associated with Low-GAI ranged from 10% to 
21.5% (p-value < 0.005 each). On the other hand, six studies (46, 167, 171, 176, 178, 179) reported 
mortality rates as mortality percentage in the whole population sample, High-GAI and Low-
GAI cohorts separately as 16.0 ± 8.1%, 7.6 ± 3.0% and 33.9 ± 18.8%, respectively. Both 
approaches of mortality outcome measurement showed a significant mortality benefit of High-
GAI levels over Low-GAI levels. Adjusted for age and sex, High-GAI score was a significant 
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independent predictor of mortality risk reduction in five studies (overall Hazard Ratio 0.289, 
95% CI 0.061 - 0.516, Figure 3.4).  
 
All-cause hospital admission was studied in three populations (46, 167, 168), where the overall mean 
± SD rehospitalisation rate was 9.1 ± 6.1%. Also, the variation of rehospitalisation rates among 
the different GAI cohorts was studied in two study populations (46, 172), where the overall mean 
± SD rehospitalisation rate per 100 patients in the High-GAI cohorts was 23.5 ± 20.2% but in 
the Low-GAI cohorts was 24.23 ± 10.6%. Paradoxically, Zugck et al. reported that HF 
hospitalisation rate was significantly higher in the High-GAI cohort than in the Low-GAI cohort 
(50% vs 36%, p-value = 0.026) although a clear explanation for this effect was not offered. (172) 
Finally, in the MAHLER study over a 12-month follow-up period, the risk of rehospitalisation 
was significantly reduced in patients with High-GAI compared to those with Low-GAI (Hazard 
Ratio 0.64, 95% CI 0.41 - 1.00). (46) 
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Figure 3.2 Heart Failure patients prescribed ≥ 50% of the recommended target dose of (i) renin-








































Renin-angiotensin system inhibitors Beta-blockers
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Figure 3.3 Clinical factors associated with High Guideline Adherence Index based on data from two study populations (Bosch (175) and Frankenstein 
(178)) using multivariable Cox regression analysis model.   
 
Abbreviations: HF, heart failure; LCL, lower confidence level; MDRD, modified diet for renal disease; NYHA, New York Heart Association functional 
classification; OR, odds ratio; UCL, upper confidence level. Model I2 static = 73.1%, p-value < 0.001. 
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Figure 3.4 A meta-analysis of the association between Guideline Adherence Index and mortality.  
The following Guideline Adherence Index (GAI) parameters were seen to be associated with mortality 
risk reduction: (a) GAI-3 Medium compared to GAI-3 poor; (b) GAI-3 High compared to GAI-3 low; 
(c) GAI-5 Medium compared to GAI-5 poor; (d) GAI-5 High compared to GAI-5 low; (e) high dose of 
ACE inhibitor/angiotensin-II receptor blocker; (f) GAI per 10% increase; (g) GAI-3; (h) improvement 
in GAI over one year; (i) improvement in target dose GAI over one year; (j) GAI-123 compared to GAI-
0. Results (a) – (e) based on HFrEF cohort, n = 641. Definitions: GAI-0, No heart failure recommended 
medication prescribed; GAI-123, prescription of any one of the top three heart failure recommended 
agents; GAI-3, prescription of all the top three recommended heart failure medications; GAI-5, 
prescription of all five heart failure recommended medications. Cochran’s Q = 3.8; p-value = 0.924. 
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Table 3.1 Profile and characteristics of the studies included in the systematic review, N = 16.  
Study author, 
country, year 
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Table 3.1 Profile and characteristics of the studies included in the systematic review, N = 16, Cont’d. 
Study author, 
country, year 
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Table 3.1 Profile and characteristics of the studies included in the systematic review, N = 16, Cont’d. 
Study author, 
country, year 
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Table 3.1 Profile and characteristics of the studies included in the systematic review, N = 16, Cont’d. 
Study author, 
country, year 
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Abbreviations: GAI, Guideline Adherence Index; GAI-5, prescription of RASi ± beta-blocker ± MRA ± cardiac glycoside (digoxin) ± loop diuretic; GAI 
tertiles, (a) Perfect GAI is prescription of the three principle HF medications; (b) Medium GAI is prescription of two out of the three HF medications; (c) Poor 
GAI is prescription of one or zero HF medications; mGAI, modified Guideline Adherence Index; MRA, mineralocorticoid receptor antagonist; RASi, renin-
angiotensin system inhibitor; USA, the United States of America; 
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Guideline Adherence Index studies   ● ● ● ● ● ● ● ● ● ● ● 
1 Komajda 2005   ● ● ● ● ● ●      
2 Klimm 2008   ● ● ● ●   ● ●    
3 Stork 2008   ● ● ● ● ● ● ●     
4 Bosch 2010   ● ● ● ●   ●     
5 Frankenstein 2010   ● ● ● ●        
6 Oertle 2010   ● ● ● ●   ●   ● ● 
7 Zugck 2012   ● ● ● ●   ●     
8 Oliveira 2013   ● ● ● ● ● ● ●    ● 
9 Luttick 2014   ● ● ● ● ● ●      
10 Poelzl 2014   ● ● ● ●   ● ●    
11 Yoo 2014   ● ● ● ●        
12 Deticek 2016    ● ● ● ● ●   ●   
13 Hirt 2016   ● ● ● ●      ●  
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Non Guideline Adherence Index studies ● ● ● ● ● ● ● ● ● ● ● ●  
14 Popescu 2008 ●  ● ●          
15 Visca 2013  ● ● ● ●    ●     
16 Ho 2014 ●   ● ● ● ● ●  ● ● ●  
 
Abbreviations: GP, general practitioner; RASi, renin-angiotensin system inhibitor (ACE inhibitor/angiotensin-II receptor blocker). 
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Table 3.3 Prescription rates compared to Guideline Adherence Index for principle Heart Failure 
medications, N = 4. 
 
Prescription rate defined as the percentage of the total study population prescribed the medication 
regardless of eligibility; Abbreviations: GAI, guideline-adherence index defined as the proportion of 




systems inhibitors (%) 
Beta-blockers (%) 
Mineralocorticoid 










Komajda 2005 69.0 85.4 53.0 58.0 28.0 36.0 
Klimm 2008 80.0 49.0 75.0 46.0 57.0 - 
Bosch 2010 61.3 58.3 54.6 47.0 24.9 31.0 
Oliveira 2013 68.8 73.5 54.1 60.4 49.2 57.1 
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3.5 Discussion  
 
The current review is the first to assess the evidence regarding standardised quantitative tools 
for assessment of guideline-led prescribing in HF. Four quantitative tools were identified from 
16 studies, each a comprehensive approach for assessment of prescription of HF guideline-
directed medical therapies. The reviewed studies encompassed different healthcare settings and 
different prescriber types. Furthermore, several studies reported the effect of guideline 
adherence on clinical outcomes.  
 
Of the four tools identified for assessing guideline adherence, the GAI was the most frequently 
cited and was used predominately in Europe. The GAI only accounts for patients who are 
eligible for particular therapy, according to the guidelines’ indications. This is a more accurate 
assessment of prescribing than the simple prescription rates. Moreover, the GAI has been 
modified to keep pace with on-going guideline changes. The Heart Failure Composite Score 
and the Heart Failure Scale, each considered just two HF medications – RASi and beta-blockers 
- as these are the therapies with the most robust evidence in HF. However, both of these tools 
included aspects of laboratory or diagnostic medical tests that are not taken into account by the 
GAI, such as examining echocardiographic evidence or serum creatinine levels before 
prescribing an ACE inhibitor. The IRER is the most recently described tool and is the only tool 
reviewed here that was developed for electronic use. (169) This tool merges the guidelines’ 
recommendations for HF and common HF comorbidities such as chronic obstructive pulmonary 
disease, dyslipidaemia and atrial fibrillation, in a single list for each patient. However, it does 
not take into account the patient’s eligibility or any contraindication to HF drug therapy. (169)  
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The GAI was initially developed by Komajda and colleagues in 2005 as a means to quantify 
prescribing quality for HF patients in Europe. (46) However, this original GAI has some 
limitations. That is why Stork et al. and Klimm et al. modified the GAI to include target dose 
and contraindications to therapy. (176, 180) Bosch et al. (175) and Deticek et al. (179)  considered the 
issue of HF licenced medications as part of guideline adherence. Each of these modifications 
has increased the complexity of the GAI and enhanced its ability to differentiate from standard 
drug utilisation rates.   
 
Most recently, Hirt et al. (164) and Oertle et al. (173) included a qualitative aspect in their GAI 
studies and showed that GAI is significantly higher when quantitative as well as qualitative 
patient data are considered. This supports previous data showing that patient and prescriber 
factors may be important barriers to guideline adherence. (157) These barriers included the 
complexity of treatment in the elderly, patient’s multiple comorbidities or low socio-economic 
status. However, these barriers were different from those barriers identified in the SHAPE 
study. (155) The latter emphasised the prescriber lack of knowledge and education as significant 
contributors to guideline non-adherence.  
 
Although the mean overall GAI score was moderate, fluctuation in GAI scores might be 
influenced by the changing definitions of GAI (46, 173, 179) or due to the wide variation in clinical 
practice between countries. (46, 173) This moderate GAI score demonstrates that there is an 
excellent scope for optimising HF prescribing internationally. In two studies reported here, 
guideline adherence by cardiologists was better to that of GPs. The rates reported for both types 
of prescriber in this review are considerably higher than those reported in the 2008 New 
England Healthcare Institute report (181), that showed guidelines adherence of 70% for 
cardiologists and 47% for GPs in cardiac disease management in the USA. The higher guideline 
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adherence rates reported in this review may indicate greater dissemination and acceptability of 
HF guidelines and diminishing barriers to guideline adherence in Europe in the intervening 
period. The increasing proportion of High-GAI rates reported from 2005 to 2016 supports this. 
However, there is still room for optimising target dose prescribing as the combined levels of 
target dose achievement in this review were lower than those reported recently by Barywani et 
al. (154) 
 
There are limitations to the GAI approach. The method has typically been applied at a 
population level to examine prescribing patterns. No study reported here examined the role of 
the GAI in near-patient assessment; initiatives to improve guideline adherence or how 
pharmacists or other members of the healthcare team may implement the GAI to improve the 
care of complex HF patients. Also, while it is clear that optimal use of guideline-directed 
medical therapies improves HF care, the data presented in this meta-analysis of observational 
data are not unanimous in demonstrating a robust association between GAI and clinical 
outcomes. The GAI is a flexible measure, and it seems possible that there is scope to improve 
GAI scores further. Deticek et al. (179) and Oertle et al. (173) have shown that there is potential 
for a 10-15% improvement by identifying patients where no barriers to prescribing exist. 
However, an electronic tool such as the IRER may be better placed to review patients in the 




Several tools have been developed to measure guideline adherence in HF. The GAI and its 
respective modifications represent a comprehensive and practical approach for assessment of 
guideline-led prescribing in HF. The GAI offers a reliable quantitative tool when compared to 
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the simple prescription rates. Future work may focus on overcoming the barriers to guideline 
adherence in order to improve prescribing quality for HF patients. 
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3.8 Addendum 
 




A systematic review entitled ‘‘A tool for assessment of heart failure prescribing quality: a 
systematic review and meta-analysis’’ was conducted in April 2016 and published in 2018 




The search was conducted in April 2019 using the same search strategy as was used in April 
2016. The same search terms were used as the first search of April 2016. The same databases 
searched, with one exception, EBSCO, which was no longer available in the research 
institution. Any full-text studies that were suitable for inclusion were quality appraised using 




The updated search results are outlined in Figure 3.5. A total of 1,701 titles were identified 
through the updated search, of which 931 were duplicates. Following title and abstract review, 
86 studies were identified for full-text review. Of these, four studies met the inclusion criteria 
as outlined in the original review (Appendix 3). (47, 48, 93, 182) The reason for excluding the other 
studies was the absence of a prescribing review tool. The four studies included were of high 
quality according to GRACE criteria. (163)  
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All four included studies used a new tool developed by Komajda and colleagues. (93) The 
QUALIFY adherence score included all HF medications that are recommended by the ESC 
2016 guidelines. The full list of QUALIFY medications and the circumstances in which they 
are used is described in Table 3.4. The QUALIFY tool differs from the GAI in that it 
incorporates newer HF medications such as ivabradine and ARNi and outlines the exact 
circumstances in which these agents should be prescribed in line with the ESC 2016 guidelines. 
(93) This tool was used in all four reports of the QUALIFY international registry published in 
the period 2016 to 2019. (47, 48, 93, 182) 
 
The QUALIFY score was defined as the ratio of the treatment actually prescribed to the 
treatment that should have been theoretically prescribed. The tool took into account the 
patient’s eligibility, guideline-based contraindications to the indicated guideline-directed 
medical therapies and the use of ≥ 50% of the recommended target dosage for each medication. 
The score quantified the physician’s prescribing and not the patient’s adherence behaviour. For 
each of the indicated medicines, a score was allocated as follows: 0 points for non-prescription 
of an indicated medicine in the absence of contraindications, 0.5 points for the prescription of 
a medication at ˂ 50% of the recommended target dose, or 1 point for the prescription of a 
medication at ≥ 50% of the recommended target dosage. Physician’s QUALIFY scores ranged 
from 0% (very poor), to 100% (excellent) and were defined at three tertiles: good adherence 
(QUALIFY score = 100%); moderate adherence (QUALIFY score from > 50% to < 100%); 




This update of the systematic review search identified the QUALIFY score, a new tool for 
assessing the implementation of the guidelines’ prescribing recommendations.  






















 Figure 3.5 Updated PRISMA flowchart of the updated search. 
Records after duplicates removed 
(n = 770) 
Titles and Abstracts screened 
(n =770) 
Records excluded as 
irrelevant to review  
(n = 684) 
Full-text articles assessed for 
eligibility after update 
(n = 86) 
Full-text articles excluded, 
due to absence of a 
measurement tool 
(n = 82) 
Studies included in the updated 
quantitative synthesis  
(n = 4) 
Duplicates  
(n = 931) 
Total studies in the final 
review  
(n = 20) 
Studies from the original 
systematic review  
(n = 16) 
Records identified through the updated database searching (n = 1,697) 
Additional records identified through hand search (n = 4) 
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Table 3.4 Algorithm of computing QUALIFY score.  
Medication class QUALIFY criteria 
Renin-angiotensin system inhibitor   
(ACE inhibitor, angiotensin-II receptor 
blocker or angiotensin receptor-
neprilysin inhibitor) 
The guidelines are met if: 
(i) the patient is prescribed RASi or  
(ii) the patient is not prescribed RASi but has a documented contraindication to RASi or 
(iii) the patient is prescribed ARNi in case of ACE inhibitors’ intolerance besides the baseline 
guideline-directed medical therapies of HF as outlined in the ESC 2016 guidelines 
Evidence-based beta-blocker 
The guidelines are met if: 
(i) the patient is prescribed an EBBB or 
(ii) the patient is not prescribed an EBBB but has a documented contraindication to EBBB and 
then prescribed an ivabradine as an alternative in presence of sinus rhythm. 
Mineralocorticoid receptor antagonist   
The guidelines are met if: 
(i) the patient is prescribed an MRA or  
(ii) the patient is not prescribed an MRA but has a documented contraindication to MRA. 
 
Abbreviations: ARNi, angiotensin receptor-neprilysin inhibitor; EBBB, Evidence-based beta-blocker; ESC, European Society of Cardiology; MRA, 
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Guideline Adherence Index studies   ● ● ● ● ● ● ● ● ● ● ● 
1 Komajda 2005   ● ● ● ● ● ●      
2 Klimm 2008   ● ● ● ●   ● ●    
3 Stork 2008   ● ● ● ● ● ● ●     
4 Bosch 2010   ● ● ● ●   ●     
5 Frankenstein 2010   ● ● ● ●        
6 Oertle 2010   ● ● ● ●   ●   ● ● 
7 Zugck 2012   ● ● ● ●   ●     
8 Oliveira 2013   ● ● ● ● ● ● ●    ● 
9 Luttick 2014   ● ● ● ● ● ●      
10 Poelzl 2014   ● ● ● ●   ● ●    
11 Yoo 2014   ● ● ● ●        
12 Deticek 2016    ● ● ● ● ●   ●   
13 Hirt 2016   ● ● ● ●      ●  
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Non Guideline Adherence Index studies ● ● ● ● ● ● ● ● ● ● ● ●  
14 Popescu 2008 ●  ● ●          
15 Visca 2013  ● ● ● ●    ●     
16 Ho 2014 ●   ● ● ● ● ●  ● ● ●  
17 Komajda 2016   ● ● ● ● ● ● ● ● ●   
 




4 Chapter 4  
Guideline-Led Prescribing to Ambulatory Heart 




This chapter aims to study prescribing quality in Cardiology outpatient practice in Cork City. 
The study identified several important factors to improve use and uptitration of the guideline-
directed medical therapies. Evidence from this study reflects HF management in routine 










Guidelines recommend HF patients be treated with multiple medications at appropriate doses 
proven to improve clinical outcomes. In absence of DMP, the degree to which gaps in 




 To study a contemporary Irish outpatient HF cohort and explore patterns of guideline-led 




A prospective observational study of ambulatory HF patients at the Cardiology Outpatient 
Clinics of Mercy University Hospital, Cork City, Ireland between March 2016 and February 
2017. Guideline-led prescribing was assessed using the GAI-3, which takes into account 
prescribing of RASi; EBBB and MRA. The adjusted GAI-3 takes into account patient’s 
contraindications to these medications. The GAI-based target dose considered the prescription 
of ≥ 50% of the recommended target dose of each of the medication classes as adherence to the 
guidelines. High-GAI based management was achieved by prescription of ≥ 2 GAI medicines. 








During the study period, 127 HF patients (mean ± SD age 71.7  13.1 years; 65.3% male) 
attended the Cardiology Outpatient Clinics. Heart Failure with reduced ejection fraction was 
the predominant HF phenotype (59.7%). Loop diuretics were prescribed to 85 (67.0%) patients. 
Prescription rates for RASi, EBBB and MRA were 86 (67.7%), 98 (77.2%) and 33 (26.0%) 
patients, while the achievement of ≥ 50% target dose of each class was 67 (52.7%), 60 (47.2%) 
and 24 (18.9%), respectively. Twelve HF patients had at least one contraindication to EBBB 
therapy; however, nine of these were prescribed an EBBB. Population mean GAI-3 was 56.6%. 
When contraindications to therapy are taken into account, the adjusted GAI-3 increased to 
57.3%. The GAI-based on prescribing ≥ 50% of the recommended target-dose was equal to 
39.6%. High-GAI based management was prescribed to 80 patients (63.0%). High-GAI 
patients were more likely to have HFrEF (67.5% vs 36.2%, p-value < 0.001) and to achieve 
the target BP (89.4% vs. 73.7%, p-value < 0.05) than patients with Low-GAI based 
management. A PIMHF item was prescribed to 25 (19.7%) patients. The most frequently used 




Most HF patients in this setting receive optimal guideline-directed medical therapies; however, 
the proportion of patients reaching the target doses was suboptimal. There is an opportunity to 
improve outcomes for ambulatory patients with HF through a focus on optimising target dose 





The clinical practice guidelines recommend the prescription of HF guideline-directed medical 
therapies at target doses as the most effective way to ensure the delivery of optimal HF care. (1, 
48) Physician’s adherence to guideline-led prescribing is consistently associated with improved 
clinical outcomes. In the QUALIFY survey, high adoption of guideline-led prescribing was 
associated with a 50% reduction in all-cause mortality and a 32% reduction of HF-related 
rehospitalisation when compared to moderate or poor adoption. (48) In the BIOSTAT-CHF 
registry, patients with under-dosing of RASi and beta-blockers experienced increased mortality 
risk compared to patients who achieved the target dose of these agents. (76) 
 
Nevertheless, several studies demonstrated suboptimal adherence to HF guideline-led 
prescribing in routine clinical practice. (48, 76, 86) The CHAMP-HF study showed that guideline-
directed medical therapies were not prescribed to over one-third of ambulatory HF patients 
despite their eligibility and the absence of contraindications. (86) Also, when patients do receive 
the recommended medications, they often receive the medications at a dose lower than the 
guideline-recommended one. (84) In one study, just 1% of the ambulatory HF patient population 
received the target dose of all three guideline-directed medical therapies that RASi, EBBB and 
MRA. (86) Elsewhere, just 50% of HF patients reached the recommended target dose three 
months post-discharge. (76)  
 
Guideline-led prescribing in HF may be challenging due to patients’ age (183), gender (143), low 
BP (146), renal dysfunction (146), the presence of pulmonary disorders (184) or the complexity of 
the medication regimens. (185) A national study in the United Kingdom showed that poor 
pulmonary functions limited beta-blockers prescription in 11% of otherwise eligible HF 
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patients. (184) Elsewhere, 40% of HF patients were not prescribed the indicated RASi at 
discharge due to reduced renal functions. (146)  
 
Furthermore, the presence of multimorbidity increases the complexity of medication regimens 
and the likelihood of potentially inappropriate medications prescription. (99, 100, 183) There is 
clear evidence of the harmful effects of certain medications such as non-steroidal anti-
inflammatory drugs (NSAIDs) and non-dihydropyridine CCB on HF prognosis and outcomes. 
(102, 112) Prescription of these medications reduces patient’s quality of life, contradicts the effects 
of the guideline-directed medical therapies and consequently increases the risk of 
hospitalisation and mortality. (99, 102, 112) In one study, NSAIDs and non-dihydropyridine CCBs 
were prescribed to 11% and 21% of HF patients, respectively. (186) In another ambulatory HF 
population, 14.5% were prescribed at least one potentially inappropriate medication despite 




This study will evaluate guideline-led prescribing to HF patients in a contemporary Irish 
ambulatory setting based on recommendations of the ESC 2012 guidelines (9) and study the gap 
to achieve the ESC 2016 guidelines application. (1) Also, the study will determine the 






Ethics approval for the study was granted by the Clinical Research Ethics Committee of the 
Cork Teaching Hospitals and University College Cork (UCC), Reference number ECM4 (o) 
12/4/16, (Appendix 4). This is a prospective observational single-centred chart review reported 
according to the STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE) guidelines. (187)  
 
The study included all ambulatory HF patients aged ≥ 18 years presenting for a scheduled 
appointment in Cardiology Outpatient Clinics in the Mercy University Hospital (MUH), Cork, 
Ireland from March 2016 to February 2017.  Where patients attended the clinics on more than 
one occasion over the study period, their first visit was the only visit recorded in the study. The 
diagnosis and type of HF were based on data recorded in the patient’s medical chart. Heart 
Failure with reduced ejection fraction was defined as an EF < 50% while HFpEF was defined 
as an EF ≥ 50%. (9)  
 
Data accessed in the patient’s medical chart included age, gender, comorbidities, EF, BP, HR 
and laboratory investigations. The recent patient’s BP, EF, HR and laboratory investigations 
were recorded if they had been documented in the medical chart at any time in the six months 
before the appointment date. The following information on prescribed medications was also 
accessed in the medical chart: drug name, dose and frequency (Appendix 5).  
 
The ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 
were used in this study as they are the guidelines that were in place at the initiation of this work. 
(9) Achievement of target HR was defined as an HR ≤ 70 beats/minute. (1, 9) Target BP 
achievement was defined as BP ≤ 150/90 mmHg. (188) The 50 – 99% and 100% target dose of 
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RASi, EBBB and MRA were defined as per ESC 2012 guidelines (Table 4.1). (9) 
Hyperpolypharmacy was defined as the prescription of ≥ 10 regular medications per day. (189) 
Hyperpolypharmacy was used as a measure of medication burden as this population is 
prescribed a high number of medications, both for HF and for comorbidities. (189) 
 
The primary outcome of the study was to assess HF guideline-led prescribing using the GAI-3 
(46), the adjusted GAI-3 (176) and the GAI-based target dose according to ESC 2012 
recommendations. (179) The GAI-3 was computed as the ratio of the treatment actually 
prescribed to the treatment that should theoretically have been prescribed regarding the 
recommended evidence-based medications: RASi (ACE inhibitor or angiotensin-II receptor 
blocker), EBBB and MRA. (9, 46) The EBBBs included in the ESC guidelines were bisoprolol, 
carvedilol, metoprolol succinate, and nebivolol. The adjusted GAI-3 considered the relative 
and absolute contraindications to the aforementioned medications as outlined in the ESC 
guidelines (Table 4.1). (9, 176) The GAI-based target dose was calculated, taking into 
consideration the prescription of ≥ 50% of the guideline-recommended target dose of each of 
the three GAI medicines as adherence to the guidelines (Table 4.1). (9, 179) Finally, the study 
population was split into those with High-GAI based management; that is the prescription of ≥ 
2 GAI medicines (RASi, EBBB or MRA) and those with Low-GAI based management; that is 
the prescription of  ≤ 1 GAI medicine. (147)  
 
The secondary outcome of the study was to identify the gap between 2012 guideline-led 
prescribing and 2016 guideline-led prescribing and its effects, if any, on GAI figures. The 
major changes into the ESC 2016 guidelines are (i) the new cut points of HFrEF as EF ˂ 40%; 
HFmrEF as EF equals to 40 to 49%; and HFpEF as EF ≥ 50%; (ii) the introduction of the new 
medication class ARNi which is a combination of sacubitril, neprilysin inhibitor and valsartan, 
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ARB. According to the recent guidelines, ARNi has deemed a part of RASi as a reasonable 
alternative of ACE inhibitors for symptomatic patients despite optimal medical therapy by 
ACE inhibitor, EBBB and MRA at target or maximally tolerated doses. (1, 48) The definitions 
of target doses, target HR and target BP, have not been changed in the recent ESC guidelines. 
(1) 
 
The tertiary outcome was to determine the prevalence of potentially inappropriate prescribing 
using the disease-specific PIMHF tool. (112) This is a list of 11 medications considered to be 
potentially harmful when used in HF patients (Appendix 1). (112) Only medications prescribed 
regularly were included in the PIMHF analysis. Medications prescribed on an “as required” 
basis were not included as there was no clear indication of how often the patient took these 
medications. 
 
4.3.1 Statistical analysis 
 
Data are presented as mean ± SD or number (%), as appropriate. Continuous data were 
compared using the independent Student’s t-test. Categorical data were compared using the 
Chi-square test or Fisher-exact test. All tests are two-tailed, and a p-value of < 0.05 was 
regarded as statistically significant. The clinical factors associated with (i) High-GAI 
achievement, and (ii) PIMHF prescription were determined using a univariable and 
multivariable logistic regression. The odds ratios (OR) and 95% confidence intervals (CI) of 
the multivariable analysis adjusted to age and sex are reported here. Data were analysed using 
SPSS® version 22.0 for Microsoft® Windows 10. 
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Table 4.1 Contraindications to and the recommended daily target dose of the Heart Failure recommended medications as outlined in the ESC 
Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. (9) 
Medication class Contraindications Agents 




(ACE inhibitor, angiotensin-II 
receptor blocker)  
 
 History of angioedema 
 Known bilateral renal artery stenosis 

















 Second- or third-degree AV-block. 












Agents listed are those agents from each class that were prescribed to one or more patients in the study population. Abbreviations: ACE, angiotensin-converting 





4.4.1 Baseline profile and characteristics of Heart Failure patients 
 
Over the study period, 127 HF patients attended the Cardiology Outpatient Clinics at MUH. 
The mean ± SD age of the patients was 71.7 ± 13.1 years, and 83 (65.3%) were male (Table 
4.2). Heart Failure with reduced ejection fraction was the predominant HF type (n = 71, 59.7%). 
An echocardiogram was available for 102 patients and mean ± SD EF was 40.2% ± 14.2%. All 
patients had more than one comorbidity, and the mean number of comorbidities was 7.4 ± 2.7. 
Hypertension was the most frequently occurring comorbidity (n = 79, 66.2%), followed by 
atrial fibrillation (n = 66, 51.9%). Coronary artery disease affected 39 patients (30.7%), (Table 
4.2).  
 
4.4.2 Prescribing to Heart Failure population 
 
Eight patients (6.3%) were not prescribed any HF guideline-directed medical therapy. A single 
HF drug was prescribed to 13 patients (10.2%) of whom, seven patients (5.5%) were prescribed 
an EBBB as the single HF therapy. Loop diuretics were prescribed to 85 patients (67.0%) of 
whom, six patients (4.7%) were prescribed two different loop diuretics concurrently.  
 
Prescription rates for GAI medicines were RASi (n = 86, 67.7%), EBBB (n = 98, 77.2%), and 
MRA (n = 33, 26.0%), (Table 4.3). A combination of two GAI medicines was prescribed 
concurrently to 57 patients (44.9%), and all three medicines were prescribed to 23 patients 
(18.1%) concurrently. Prescription of 50% - 99% of the guideline-recommended target doses 
of RASi, EBBB and MRA was achieved in 27 (21.2%), 29 (22.8%), and 23 (18.1%) of patients 
(Figure 4.1). The 100% target dose was achieved in 40 (31.5%), 31 (24.4%), and one (0.7%) 
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patients, respectively. Ten patients (7.8%) achieved 50% - 99% recommended target doses of 
all three GAI medicines. No patient achieved 100% target dose of all three GAI medicines. 
  
No patient experienced a contraindication to RASi or MRA. A contraindication to EBBB 
therapy was present in 12 patients (9.4%), 11 patients (8.7%) having asthma and one patient 
(0.8%) having an AV-block. Nine of the 12 patients with the contraindication was prescribed 
an EBBB.  
 
Population mean GAI-3 was 56.6%. When contraindications to therapy are taken into account, 
the adjusted GAI-3 increased to 57.3%. Population GAI-3 based on prescribing ≥ 50% of the 
target-dose was equal to 39.6%. There was a significant difference in the achievement of GAI-
3 between HFrEF and HFpEF patients (64.9% vs 50.0%, p-value < 0.001), (Figure 4.2.A). 
Target HR was achieved in 40 patients (31.5%) only (Table 4.3). Despite EBBB use, 17 
patients (13.4%) in sinus rhythm remained off-target and then were eligible for ivabradine 
prescription; however, ivabradine was prescribed to four patients (3.1%) only. 
 
4.4.3 High-GAI and Low-GAI achievement 
 
High-GAI was prescribed to 80 patients (63.0%), (Table 4.2 and 4.3). Patients with High-GAI 
were more likely to have HFrEF (67.5% vs 36.2%, p-value < 0.001). This cohort was more 
likely to be managed by hyperpolypharmacy (37.5% vs 19.1%, p-value = 0.040). Patients with 
High-GAI were also more likely to achieve ≥ 50% of the target dose of each of the three 
guideline-directed therapies individually than those with Low-GAI, p-value < 0.05 (Figure 
4.1). Heart Failure patients having High-GAI based management were more likely to achieve 
the target BP (73.9% vs 59.5%, p-value < 0.05) and the target HR in the presence of EBBB 
prescription (31.5% vs 8.5%, p-value < 0.001) than patients with Low-GAI (Table 4.3).  
121 
 
4.4.4 Implementation of the ESC Guidelines for the Diagnosis and 
Treatment of Acute and Chronic Heart Failure 2016 
 
The implementation of the ESC 2016 guidelines has changed the breakdown of HF patients as 
49 patients (48.0%) were categorised as HFrEF (EF < 40%), 13 patients (12.7%) as HFmrEF 
(EF = 40 - 49%) and 40 patients (39.2%) as HFpEF (EF ≥ 50%) according to the available data 
of patient’s echocardiogram. In comparison to the ESC 2012 guidelines, the overall GAI-3 was 
not changed by the consideration of the ESC 2016 guidelines’ recommendations as ARNi was 
not prescribed to any patient. Also, the new breakdown of EF did not affect prescribing towards 
HFpEF patients but reduced the GAI figures in the new HFrEF, and HFmrEF in comparison to 
the old EF cut point of 50% (Figure 4.2).  
 
4.4.5 Potentially inappropriate prescribing 
 
Potentially inappropriate medications identified by the PIMHF tool were prescribed to 25 
patients (19.7%), (Table 4.3). Two patients were prescribed two different PIMHF items. The 
most frequently prescribed PIMHF item was non-dihydropyridine CCBs in 15 patients 
(11.8%). Of which, seven HFrEF patients (5.5%) were prescribed a non-dihydropyridine CCB, 
and twelve patients (9.4%) had a concurrent prescription of EBBB and non-dihydropyridine 
CCB.  There was no difference in PIMHF prescribing rates between High-GAI and Low-GAI 
patient, p-value > 0.05 (Table 4.3).  
 
4.4.6 Logistic regression analysis 
 
Adjusted to age, sex, serum potassium, asthma/chronic pulmonary disease, diabetes and 
chronic kidney disease, the multivariable analysis estimated HFrEF as the only clinical 
associate of High-GAI based management achievement (OR 4.8, 95% CI 1.27 – 18.04), (Table 
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4.4). The multivariable analysis of PIMHF, adjusted to age, sex and serum potassium, 
estimated asthma/chronic obstructive pulmonary disease (OR 3.73, 95% CI 1.00 – 13.84) and 
increased HR (OR 1.04, 95% CI 1.01 – 1.07) as the multivariable associates of PIMHF 







Table 4.2 Characteristics of the total population, patients prescribed High-GAI and patients 
prescribed Low-GAI, N = 127 patients.  
  
 Total population  
n = 127 
High-GAI 
 n = 80 
Low-GAI 
n = 47 
p-value 
Age (years) 71.7 ± 13.1 69.9 ± 13.7 73.1 ± 11.8 0.381 
Male 83 (65.3) 54 (67.5) 29 (61.7) 0.373 
Mean arterial pressure (mmHg) 92.7 ± 13.3 92.1 ± 12.3 93.7 ± 15.1 0.693 
Heart rate (beat/minute) 79.3 ± 18.3 80.1 ± 19.7 77.8 ± 15.9 0.719 
Serum potassium 4.7 ± 0.9 4.8 ± 1.1 4.7 ± 0.8  0.918 
Ejection fraction (%) ¶  40.2 ± 14.2 37.6 ± 13.2 45.0 ± 15.1 0.021 
HFrEF ⸰ †  71 (55.9) 54 (67.5)  17 (36.2) < 0.001  
Hypertension 79 (62.2) 50 (62.5) 29 (61.7) 0.767 
Atrial fibrillation 66 (51.9) 41 (51.3) 25 (53.2) 0.348 
Coronary artery diseases 39 (30.7) 23 (28.8) 16 (34.0) 0.523 
Diabetes 28 (22.0) 18 (22.5) 10 (21.3) 0.481 
Chronic kidney disease 21 (16.5) 8 (16.3) 13 (17.0) 0.888 
Asthma 11 (8.7) 7 (8.8) 4 (8.5) 0.786 
Chronic obstructive pulmonary disease 23 (18.1) 13 (16.3) 10 (21.3) 0.381 
Number of comorbidities 7.4 ± 2.7 7.4 ± 2.9 7.4 ± 2.6 0.769 
 
Comparisons were made between Heart Failure patients with High-GAI and Low-GAI. Categorical 
variables are expressed as frequencies and percentages. Continuous variables are expressed as 
mean ± standard deviation. ¶ Echocardiogram was available for 102 patients. ⸰ Data according to the 
documented diagnosis of HF type in patients’ medical charts (n =119). Abbreviations: HFrEF, heart 
failure with reduced ejection fraction. 
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Table 4.3 Medication profile and therapeutic target goals of the total population, patients 





n = 127 
High-GAI 
 n = 80 
Low-GAI 
n = 47 
p-value 
Heart Failure Medications Profile   
RASi  86 (67.7) 74 (92.5)  12 (25.5) < 0.001 
Evidence-based beta-blocker  98 (77.2) 79 (98.8) 19 (40.4) < 0.001 
Mineralocorticoid receptor antagonist  33 (26.0) 30 (37.5) 3 (6.4) < 0.001 
Digoxin 8 (6.3) 6 (7.5) 2 (4.8) 0.716 
Loop diuretic  85 (67.0) 59 (73.8) 26 (55.3) 0.028 
Thiazide diuretic  11 (8.7) 3 (3.8) 8 (17.0) 0.031 
Ivabradine 4 (3.1) 3 (3.8) 1 (2.4) 0.635 
Regular medications 8.2 ± 3.1 8.6 ± 3.0 7.5 ± 3.1 0.218 
Hyperpolypharmacy  39 (30.7) 30 (37.5) 9 (19.1) 0.040 
Device-based therapy § 18 (14.2) 12 (15.0) 6 (13.1) 0.361 
Potentially Inappropriate Medicines in Heart Failure   
Any PIMHF medication 25 (19.7) 14 (17.5) 11 (23.4) 0.736 
Non-dihydropyridine CCB 15 (11.8) 7 (8.8) 8 (17) 0.253 
Oral Corticosteroid 5 (3.9) 3 (3.8) 2 (4.3) 0.091 
Pregabalin 5 (3.9) 3 (3.8) 2 (4.3) 0.271 
NSAID 1 (0.8) 1 (1.3) 0 (0.0) 0.819 
Metformin in poor renal functions ƪ 1 (0.8) 1 (1.3)  0 (0.0) 0.989 
Target therapeutic goals  
Target heart rate (≤ 70 bpm) 40 (31.5) 25 (37.3) 15 (37.5) 0.051 
Target heart rate on EBBB  29 (22.8) 25 (35.7) 4 (9.5) < 0.001 
Target heart rate on EBBB ≥ 50 target dose 16 (12.6) 13 (16.3) 3 (8.1) 0.067 





Comparisons were made between Heart Failure patients with High-GAI and Low-GAI. Categorical 
variables are expressed as frequencies and percentages. Continuous variables are expressed as 
mean ± standard deviation. § Device-based therapy: implantable cardiac defibrillator, cardiac 
resynchronisation therapy or left ventricular assist device; ƪ Poor renal functions: creatinine clearance ˂ 
50 mg/ml. Abbreviations: CCB, calcium channel blocker; EBBB, evidence-based beta-blocker; MRA, 
mineralocorticoid receptor antagonist; NSAIDs, non-steroidal anti-inflammatory drugs; PIMHF, 
potentially inappropriate medicines in heart failure; RASi, renin-angiotensin systems inhibitor (ACE 





Figure 4.1 Prescription rates of the ≥ 50% and 100% of the recommended target doses of the guideline-directed medical therapies among heart failure 
patients prescribed a High-GAI and Low-GAI based management.   
The proportion of patients prescribed 50-99% target dose of each medication class was compared between High-GAI and Low-GAI populations. This 
comparison for each of the three GAI medicines was statistically significant (p-value < 0.001). 
The proportion of patients prescribed 100% target dose of each medication class was compared between High-GAI and Low-GAI populations. This comparison 
for each of the three GAI medicines was not statistically significant (p-value > 0.05). 
 
























Renin-angiotensin systems inhibitor 50-99% TD *
Renin-angiotensin systems inhibitor 100% TD
Evidence-based beta-blocker 50-99% TD *
Evidence-based beta-blocker  100% TD
Mineralocorticoid receptors antagonist 50-99% TD *




Comparison is between ……* indicates a P-value < 0.05.  


































































Figure 4.2.A, Guideline Adherence Indices among Heart Failure patients classified as reduced ejection 
fraction (EF < 50%, n = 62) versus preserved ejection fraction (EF ≥ 50%, n = 40) according to ESC 
2012 guidelines. (9)  
Figure 4.2.B, Guideline Adherence Indices among Heart Failure patients classified as reduced ejection 
fraction (EF < 40%, n = 49) versus mid-range ejection fraction (EF = 40 – 49, n = 13) versus preserved 
ejection fraction (EF ≥ 50%, n = 40) according to ESC 2016 guidelines. (1)  
 
Abbreviations: GAI, guideline-adherence index; HFmrEF, heart failure with mid-range ejection 




Table 4.4 Clinical factors associated with High-GAI achievement and potentially inappropriate 
prescribing towards ambulatory patients, N = 127 patients. 
Variable 
High-GAI achieved PIMHF item prescribed 
Odds Ratio (95% CI) Odds Ratio (95% CI) 
Age 1.008 (0.951 – 1.068) 1.018 (0.962 – 1.078) 
Male 2.707 (0.768 – 9.543) 1.004 (0.261 – 3.859) 
Heart rate 1.006 (0.976 – 1.038) 1.037 (1.005 – 1.069) 
Serum potassium 0.758 (0.439 – 1.311) 1.016 (0.541 – 1.906) 
Asthma/COPD 0.595 (0.165 – 2.144) 3.728 (1.004 – 13.844) 
Diabetes 0.683 (0.151 – 3.090) 2.882 (0.602 – 13.799) 
Chronic kidney disease 0.755 (0.154 – 3.698) 0.628 (0.120 – 3.29) 
HFrEF 4.804 (1.279 – 18.049) 1.131 (0.249 – 5.145) 
Hyperpolypharmacy   0.529 (0.101 – 2.734) 
 
The multivariable logistic models of (i) High-GAI achievement (Nagelkerke's R2 = 0.215; percentage 
of correct estimation = 77.3%) and (ii) PIMHF prescribing (Nagelkerke's R2 = 0.286; percentage of 
correct estimation= 82%).  
 
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; GAI, guideline 
adherence index; HFrEF, heart failure with reduced ejection fraction, OR, odds ratio; PIMHF, 






The present study is the first assessment of guideline-led prescribing using structured 
prescribing review tools, in an Irish ambulatory HF population cared for outside a DMP in an 
acute general hospital. The results showed that two-thirds of the population were prescribed the 
guideline-directed medical therapies. The mean GAI-3 was 56.6%; however, when this was 
adjusted to include target dose achievement, it decreased to 40%. One-in-five of the population 
was prescribed an HF-specific potentially inappropriate medication.  
 
The prescription rates of RASi, EBBB and MRA as individual classes are higher here than in 
studies performed in the early 2000s (180, 190) and are comparable to more recent reports from 
other Western European countries. (164, 191) At 56.6%, the GAI-3 of the current population is 
moderately lower than the international mean GAI-3 of 63%. (147) According to a recently 
published systematic review (Chapter 3), this GAI-3 is comparable to the GAI-3 figures from 
other Western European countries such as the Netherlands (52.3%) and Germany (53.5%) in 
2016. (147) 
 
In the current setting, consideration of the contraindications had a little effect on correcting the 
guideline adherence levels. Although 75% of asthmatic patients were prescribed an EBBB, it 
is of note that asthma is a relative contraindication to EBBB use according to the guidelines. (1, 
9) The ESC guidelines strongly recommend the use of EBBB in HF in order to improve patient’s 
quality of life and reduce mortality risk. (1, 9) This means that the benefits of EBBB use in the 
current HF patients might outweigh its risk of asthma exacerbation from the prescribers’ point 
of view. (192) Despite the fact that the type of beta-blockers prescribed herein was cardio-
selective, this incidence represents a compelling indication for the use of ivabradine as a 
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reasonable alternative to EBBB in these circumstances in terms of safety and target HR 
achievement according to the recommendations of the ESC guidelines. (1)  
 
In the Low-GAI patients, no reason has been appeared to affect prescribing other than the high 
EF. Among the Low-GAI patients, the prevalence of HFpEF was more likely than in the High-
GAI cohort of patients. This may suggest the critical effect of EF level on prescribing practice. 
Yet, there is no substantial evidence that influences mortality in patients with HFpEF, unlike 
the robust evidence in HFrEF patients. (1, 57) Patients having HFpEF are often older, with higher 
levels of comorbidity and are mainly monitored and managed in primary care. (175, 191) However, 
the current results demonstrated the benefit of High-GAI based management to achieve the 
guideline-recommended therapeutic goals such as target HR and target BP regardless of the 
patient’s EF. The achievement of these goals is strictly in line with the latest ESC guidelines’ 
recommendations that lead to a significant survival benefit. (1, 193-195) 
 
The utilisation of MRA remains low in this study, similar to the other European reports despite 
the absence of the guideline-outlined contraindications. (113, 196, 197) The reason for MRA 
underutilisation is not apparent, but it adds to the fact that managing MRA therapy in outpatient 
settings is more complicated than managing RASi and EBBB therapies. (113, 196) This can be 
partly interpreted by the fact that MRA therapy is often associated with worsening renal 
functions or hyperkalaemia in the presence of a RASi prescription. (113, 196, 197) Another potential 
cause might be the low prevalence of chronic artery disease in the current population as more 
MRA evidence has based its use as post-myocardial infarction. (58, 149) 
 
The achievement of the ≥ 50% target dose is suboptimal in the current population, and no patient 
achieved the 100% target dose of all three guideline-directed medical therapies. The BIOSTAT-
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CHF registry conducted in 11 European countries and including 2,500 outpatients showed that 
a minority of patients were prescribed the target dose of RASi and EBBB. (76) However, there 
is evidence from observational studies that demonstrate the benefits of target dose prescribing. 
(1, 46, 86) For instance, in the HF-ACTION study, ambulatory HF patients who achieved EBBB 
target dose had a 21% reduction in all-cause mortality. (193) Elsewhere, ATLAS and HEAAL 
clinical trials emphasised the significant benefits of RASi target dose in the reduction of the 
combined endpoint of mortality or rehospitalisation by 12%, in comparison to lower doses of 
RASi. (53, 85) Several reasons can contribute to the sub-optimal target dosing in the current 
setting. Clinical inertia and overestimation of the risk of intolerance of medications uptitration, 
particularly intolerance of EBBB uptitration are potential barriers to the achievement of the 
guideline-recommended target doses of HF medications. (185, 198, 199).  For instance, CHAMP-
HF registry found that patients did not receive medical therapy titration at any point during their 
longitudinal follow-up. (200) 
 
According to ESC 2016 guidelines, the figures of the population GAI-3 did not change. As 
prescribed the optimal guideline-directed therapy at ≥ 50% target dose, only 7.8% patients of 
the study population who are deemed eligible for ARNi conversion if they remained 
symptomatic or showed a decrease in EF over six months. All the other patients are not eligible 
as ARNi prescription requires the precedent achievement of the target doses of all three 
guideline-direct medical therapies (RASi, EBBB and MRA).  
   
The prescription rate of potentially inappropriate medications herein is higher than that reported 
in previous reports from Ireland and Australia. (99, 112) These medications may cause harm to 
HF patients or contradict the effects of guideline-directed medical therapies. (102) Prescription 
of potentially inappropriate medicines increases the risk of death, acute hospitalisation and 
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unscheduled outpatient appointment. (99) Unlike a previous Irish study that utilised the PIMHF 
tool, the present study population are not enrolled in an HF-specific DMP. A disease-specific 
DMP provides a highly structured multidisciplinary HF care and improves prescribing quality 
and outcomes. (131, 133) Therefore, exposure to potentially inappropriate medications is less likely 
in DMP settings.   
 
The rate of potentially inappropriate prescribing in the present study was driven by the 
prescription of non-dihydropyridine CCB. The multivariable analysis estimated that the 
prescription of a PIMHF item was associated with chronic respiratory disease and higher HR. 
(100) The ESC guidelines strongly recommend against the use of non-dihydropyridine CCB in 
HF, and particularly, in HFrEF. (1, 9) It is possible that prescribers are reluctant to alter any prior 
prescription as long as the patient is stable and of good quality of life. (198, 200) Alternatively, it 
may be the case that prescribers are not very familiar with such ESC cautions pointing to a need 
for ongoing medical education on potentially inappropriate prescribing. (102, 112) For instance, 
the ESC 2012 and 2016 guidelines recommend the use of ivabradine for achieving the target 
HR due to its safety profile in HF patients rather than the CCB. (1, 9) 
 
It is also possible that cardiologists are not the primary prescribers to these patients. As 
ambulatory patients, the general practitioner may be the primary prescriber. (201) Furthermore, 
given the extent of comorbidities experienced by this patient cohort, this population may also 
receive prescriptions from other medical specialities such as endocrinologists, pulmonologists, 
and nephrologists. This diversity of prescribers caring for HF patients may lead to physician’s 
encroachment, deprescribing of a guideline-directed medical therapy or unwitting prescription 
of potentially inappropriate medicines. (202, 203) For instance, among 2,516 European 
outpatients, Ouwerkerk and colleagues found that 76% of discontinued MRA occurrences was 
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not resumed in the outpatient setting. (76) In Ireland, prescribers have limited access to 
electronic health records, and this could result in prescribing amendments and medication non-
persistence. Mockler et al. reported that three years post HF diagnosis, 29% of patients are non-
persistent to HF medications and that prescriber’s decisions rather than patient’s actions drove 
50% of the non-persistence occurrences. (134)  
 
The drug therapy problems highlighted in this work point to the vital need for clinical 
pharmacists’ inclusion in the hospital outpatient clinic medical team in order to overcome 
clinical inertia. Implementation of a clinical pharmacy service was found to improve the 
transition of care and reduced rehospitalisation rates by 30%. (204) Lopez et al. showed the 
significant impact of the clinical pharmacy service to reduce the readmission rate by 35% and 
to reduce the hospital costs by €600 per patient in 12 months post-discharge. (205) Elsewhere, 
the clinical pharmacy services optimised the utilisation of the guideline-directed medical 
therapies up to 15% in a European HF outpatient population. (206) Also, Bhat and colleagues 
showed the benefits of clinical pharmacists in HF care to overcome clinical inertia in terms of 
medications uptitration by a significant average optimisation of 20% per medication class. (207)  
 
4.6 Limitations  
 
The study is limited by its small sample size and single centred design that may limit the 
generalisability of the study results. However, this design contributed to the detailed analysis 
of some prescribing details in a real-world sample of HF patients. Second, the lack of electronic 
health records may have limited the comprehensiveness of the data for identifying the 





In this setting, the majority of HF patients receive guideline-led treatment; however, the 
proportion of patients reaching the target doses was suboptimal. There is substantial 
opportunity to improve care and outcomes for ambulatory patients with HF. There is a 
compelling need for pharmacists to optimise HF prescribing and medication titration in line 
with the ESC guidelines’ recommendations in routine clinical practice. This multidisciplinary 
care has been shown to help improve the prescription and dosing of guideline-directed therapies 
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5 Chapter 5 
Guideline–Led Prescribing to the Older Heart Failure 




In Chapter 2, the narrative review discussed the existing HF literature in Ireland. The findings 
demonstrated that the vulnerable HF patient populations were not included in the published 
Irish HF literature. Therefore, this chapter aims to (i) identify HF profile in the older HF 
patients residing in Long-Term Care (LTC) facilities; (ii) examine the level of guideline-led 
prescribing, and (iii) determine the prevalence of prescribing HF-specific potentially 
inappropriate medications among LTC HF patients. Evidence from this study will help to 
identify the divergence of the LTC-based prescribing practice from the ESC guidelines’ 










Heart Failure affects up to 45% of residents in Long-Term (LTC) facilities. This type of patient 





To assess the utilisation of HF guideline-directed medical therapies and the prevalence of HF 




This is an observational study of older HF patients in 14 LTC facilities in the greater Cork 
region of Ireland. Heart failure was documented on patient medical records or identified by 
the prescription of a loop diuretic. Guideline-led prescribing was assessed using a modified 
version of the GAI-3 tool. The GAI-3 considers prescription of the loop diuretic, RASi and 
beta-blocker, and it is adjusted to consider contraindications to therapy. High-GAI was 
defined as the prescription of ≥ 2 of these agents. Potentially inappropriate prescribing was 




The total number of LTC residents was 732, mean ± SD age 83.9 ± 7.7 years; 30% male. The 
prevalence of HF was 36.2% (n = 265). Patients with HF were older than those without HF 
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(84.8 ± 7.4 vs 83.4 ± 7.9 years, p-value = 0.024), were more likely to have coronary artery 
disease (32.5% vs 16.1%, p-value < 0.001), and atrial fibrillation (31.3% vs 16.9%, p-value 
< 0.001) but were less likely to have dementia (42.3% vs 49.9%, p-value = 0.047). Loop 
diuretics were prescribed to 87.5% of HF patients (87.5%), RASi to 24.2% and beta-blockers 
to 22.6%. Mean GAI-3 was 56%. High-GAI was achieved by 54.7% of patients. Patients with 
High-GAI had a higher comorbidity index (4.8 ± 1.9 vs 3.9 ± 1.8, p-value < 0.001) and a 
greater number of prescribed medications (10.0 ± 3.2 vs 8.4 ± 3.1, p-value < 0.001) than those 
who did not achieve High-GAI. At least one PIMHF item was prescribed to 24.2% of patients. 
In multivariable analysis, the achievement of High-GAI was associated with a higher 
comorbidity index score (OR 1.25, 95% CI 1.07 - 1.57) and coronary artery disease (OR 1.78, 




Among older HF patients in this setting, loop diuretic was the primary HF therapy; and there 
was low utilisation of the other guideline-directed medical therapies. HF-specific potentially 







Heart Failure affects up to 45% of residents in Long-term Care (LTC) facilities. (208) Long-term 
Care are a variety of a special facility that provides medically necessary professional services 
to patients who are not sick enough to need intensive hospital care but are not able to remain 
at home due to their chronic irreversible or disabling disorders. (209) Heart Failure patients are 
often vulnerable, and older populations (210, 211) and residents of LTC facilities are often of a 
similar profile. (212, 213) Older HF patients who require LTC facilities after discharge from 
hospital face a higher risk of poor HF management and outcomes. (214, 215) The mortality rate 
among the older HF patients is 22% in the first month after discharge to LTC facilities. (214) 
Patients hospitalised with HF and discharged to LTC facilities are 50% more likely to be 
rehospitalised within one month of discharge than those discharged to home. (215) 
 
There are considerable benefits to guideline-led prescribing in reducing the burden of HF 
complications in older and frail patients, including benefits to patient quality of life and clinical 
outcomes. (1) Walsh et al. demonstrated that 16% of hospitalisations caused by HF exacerbation 
in the American LTC facilities could have been prevented by the optimal prescribing of the 
guideline-directed medical therapies. (216) In an octogenarian HF population, appropriate use of 
HF guideline-directed medical therapies at their recommended target doses showed a better 
survival rate over five years by 20%. (154) Elsewhere, the prescription of the target dose of HF 
medications reduced all-cause mortality and hospitalisation by 45% in older ambulatory HF 
patients in the first year post-discharge. (167) 
 
However, the appropriate prescription of the guideline-directed medical therapies in the older 
HF patients is complicated. (217) Guideline-led prescribing is frequently limited by 
multimorbidity, limited physiological reserve, altered drug metabolism and the various side 
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effects of appropriate and inappropriate multiple medications. (218, 219) Over 50% of the older 
HF patients have at least three treatment conflicts due to guideline-indicated medicines for a 
particular comorbid condition with the potential to worsen HF progression or contradict an HF 
guideline-directed therapy. (99, 220) Polypharmacy is also frequently associated with an increased 
risk of harmful drug-drug and drug-disease interactions as well as adverse drug effects. (109, 221) 
In a nationwide study in Australia, almost 60% of an older HF population were prescribed at 
least one potentially inappropriate medication associated with an increased risk of HF 
worsening. (99) In another study, non-steroidal anti-inflammatory drugs (NSAIDs) were 
prescribed to 11% of an older HF population and non-dihydropyridine calcium channel 




Pharmacotherapy optimisation in LTC represents a challenging public health concern. (218, 219) 
Literature about optimisation of HF pharmacotherapy and patterns of HF prescribing in LTC 
facilities is sparse, and there is no data about the target dose achievement of HF guideline-
directed medical therapies in this healthcare setting. (156, 215, 218, 222) Therefore, this study has a 
threefold aim: (i) to measure the level of HF guideline adherence in a sample of Irish LTC 
facilities; (ii) to determine the prevalence of potentially inappropriate prescribing to HF 
patients in this setting; and (iii) to identify the clinical factors associated with guideline-led 





This study is a secondary data analysis of anonymised data from a previous multi-centre 
prevalence study performed in 14 LTC facilities in County Cork, Ireland by the Pharmaceutical 
Care Research Group of University College Cork (UCC), Cork, Ireland. (221) Clinical Research 
Ethics Committee of the Cork Teaching Hospitals and UCC granted the ethics approval to the 
original study. The ethics approval was not required for this anonymised secondary data 
analysis. The study is reported in line with STROBE guidelines. (187) 
 
In the original study, medical records and medication prescription details of all residents in the 
participating facilities were reviewed at a single time point. (221) Data collection was performed 
between December 2009 and September 2010. Details of residents’ demographics, 
comorbidities, BP, HR, biochemistry and medications history were extracted from their 
medical and nursing records. The method of data collection and extraction have been described 
in detail elsewhere. (221)  
 
The present analysis included all HF patients aged ≥ 65 years identified in the original dataset. 
Heart Failure was identified through one of two criteria: (i) a previous history of HF diagnosis 
documented in the resident’s medical chart; (ii) the prescription of a loop diuretic to the 
resident. Due to the high prevalence of undocumented HF diagnosis in LTC facilities, loop 
diuretics prescription was used as a surrogate marker of the disease identification and severity. 
(223-225)  
 
Comorbidities were calculated using the Charlson Comorbidity Index adapted to primary care 
patients. (226) Creatinine clearance was calculated using the Cockcroft – Gault formula. (227) 
142 
 
Chronic renal failure was defined, according to the National Kidney Foundation/ Kidney 
Disease Outcomes Quality Initiative guidelines, as creatinine clearance ≤ 15 millilitres per 
minute. (228) Hyperpolypharmacy was defined as the prescription of ≥ 10 regular medications 
per day. (189) This cut-point was selected due to the high number of medications required for 
HF management solely in the absence of other comorbidities. (139)  The ESC Guidelines for the 
Diagnosis and Treatment of Acute and Chronic Heart Failure 2005 were the guidelines 
referenced throughout this work as they are the guidelines that were in place during the data 
collection period. (139) The achievement of ≥ 50% and 100% of the target doses of the RASi 
and beta-blockers was defined as per the ESC 2005 guidelines (Table 5.1). The median and 
interquartile range (IQR) of furosemide dose equivalents were reported as a measure of HF 
severity (Table 5.1). (223-225) 
 
The primary outcome of the study was the assessment of HF guideline-led prescribing using 
the GAI-3. The GAI-3 tool was initially developed by Komajda et al. in 2005. (46) The GAI-3 
tool is the ratio of the treatment actually prescribed to the treatment that should theoretically 
have been prescribed of the HF guideline-directed medical therapies: RASi, beta-blocker and 
MRA. In the current analysis, the GAI-3 was modified so as it considered the prescription of 
RASi, beta-blocker and loop diuretic owing to the robust evidence-based benefits of loop 
diuretics in older HF patients. (1, 139) The algorithm used to compute the modified GAI-3 is given 
in Table 5.1. Based on the individual GAI-3 of each patient, the population was subdivided into 
High-GAI management, that is the prescription of ≥ 2 GAI medicines or Low-GAI 
management, that is the prescription of ≤ 1 GAI medicine. (147) 
 
The secondary outcome of the study was the evaluation of potentially inappropriate prescribing 
using the disease-specific PIMHF tool (Appendix 1) and its effect, if any, on HF guideline-led 
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prescribing. (112) In this study, only the PIMHF items prescribed regularly were included in the 
analysis while the “as required” items were not included as there was no clear indication of 
how often the patient received these medications. 
  
5.3.1 Statistical analysis 
 
Quantitative data are presented as mean ± SD or number (%), as appropriate. Continuous data 
were compared using independent Student’s t-test while categorical data by Chi-square test. All 
tests are two-tailed, and a p-value of < 0.05 was regarded as statistically significant. Univariable 
and multivariable logistic regression analyses were performed using odds ratios (ORs) with 
95% confidence intervals (CI) to determine the clinical factors associated with High-GAI 
achievement and the factors associated with PIMHF prescribing in the population. Data were 
analysed using SPSS® version 22.0 for Microsoft® Windows 10.
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Table 5.1 Adapted algorithms for computation of the Guideline Adherence Index (GAI-3). (46, 139) 
Medication class Guidelines indications for therapeutic class use 
Computation of 











1) Prescribe to all Heart Failure patients. 
2) Contraindications: (i) bilateral renal artery 
stenosis; (ii)  angioedema; (iii) deteriorating renal 
functions † or renal failure (creatinine clearance < 
15 ml/min). 
The guidelines are met if: 
(i) the patient is prescribed 
RASi or 
(ii) the patient is not 
prescribed RASi but 
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Beta-blockers 
1) Prescribe to all Heart Failure patients with NYHA 
class II-IV. 
2) Beta-blockers should not be withheld due to old 
age alone. 
3) Contraindications: (i) asthma, (ii) chronic 
obstructive pulmonary disease, (iii) symptomatic 
bradycardia † or hypotension, (iv) sick sinus 
rhythm and AV-block. 
 
The guidelines are met if: 
(i) the patient is prescribed 
a beta-blocker or  
(ii)  the patient is not 
prescribed a beta-
blocker but has a 
documented 
contraindication to 


















1) Prescribe to all Heart Failure patients with any 
sign/symptoms of congestion, oedema, volume 
overload or dyspnoea. 
2) Loop diuretics should always be prescribed with 












The algorithm is adapted from Komajda et al. 2005. (46) Agents listed are those agents from each class 
that were prescribed to one or more patients in the study population. * Dose defined as post-myocardial 
infarction dose according to the summary of the product characteristics of the medication. (229) † 
Deteriorating renal functions and symptomatic bradycardia could not be calculated in this dataset as the 
data were retrospectively analysed at a one-time point. Abbreviations: AV-block, atrioventricular 
block; NYHA, New York Heart Association functional classification; RASi, renin-angiotensin system 





5.4.1 Baseline profile and characteristics of Long-Term Care residents 
 
The dataset included 732 residents from 14 LTC facilities. The mean ± SD age of the residents 
was 83.9 ± 7.7 years, and 70.2% of residents were female (Table 5.2). Chronic kidney disease 
was the most prevalent comorbidity affecting 552 residents (71.3%) followed by hypertension 
(n = 349, 47.7%) and dementia (n = 345, 47.1%). The mean ± SD comorbidity index of the 
residents was 4.0 ± 1.9, and the mean number of medications prescribed per patient was 11.2 
± 4.0 per day.  
 
5.4.2 Identification of Heart Failure patient population 
 
The previous history of HF was documented in the medical charts of 99 patients (13.6%). Loop 
diuretics were prescribed to a further 166 patients (22.6%) in the absence of a documented HF 
diagnosis. The comparison between these two cohorts shows small differences between them 
(Table 5.3). Higher doses of loop diuretics were prescribed to the patients who had no previous 
history of HF diagnosis in comparison to the doses prescribed to the patients with a documented 
history of HF, median diuretic daily dose: 220mg (IQR 40 – 420 mg/day) vs 120mg (IQR 30 - 
220 mg/day), p-value < 0.001.  
 
5.4.3 Comparison of Heart Failure and non-Heart Failure patients 
 
Heart Failure affected 265 LTC residents (36.2%). Heart Failure patients were older than those 
without HF (84.8 ± 7.4 vs 83.4 ± 7.9, p-value = 0.024), more likely to have coronary artery 
disease (32.5% vs 16.1%, p-value < 0.001) and atrial fibrillation (31.3% vs 16.9%, p-value < 
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0.001) but less likely to have dementia (42.3% vs 49.9%, p-value = 0.047) and urinary 
incontinence (32.1 vs 43.7%, p-value = 0.002). Patients with HF were prescribed more regular 
medicines than those without HF (12.7 ± 3.5 vs 10.7 ± 3.7, p-value < 0.001), (Table 5.4).  
 
5.4.4 Prescribing to Heart Failure population    
 
In the HF population, RASi was prescribed to 64 patients (24.1%) and beta-blockers to 60 
patients (22.6%). Loop diuretics were prescribed to 232 patients (87.5%). Loop diuretics were 
prescribed as HF monotherapy to 140 patients (52.8%). All three recommended GAI medicines 
were prescribed to 20 patients (7.7%) while 22 patients (8.3%) were not prescribed any HF-
related medications. Mineralocorticoid receptor antagonists were prescribed to 13 patients 
(4.9%). The different prescribing patterns of HF management are illustrated in Figure 5.1. 
Achievement of ≥ 50% of the guideline-recommended target doses of RASi occurred in 10.6% 
of HF patients and beta-blockers in 6.0% of patients. Achievement of 100% target dose 
occurred in 3.4% and 1.9%, respectively. No patient was prescribed 50% target dose or 100% 
target dose of both medications.   
 
5.4.5 High-GAI and Low-GAI achievement 
 
Population mean GAI-3 was 55.9%. High-GAI was achieved in 145 patients (54.7%), meaning 
that 120 of HF patients (45.3%) received one or no GAI medicine (Table 5.5). Patients with 
High-GAI had higher comorbidity index (4.8 ± 1.9 vs 3.9 ± 1.8, p-value < 0.001), and higher 
prevalence of atrial fibrillation (37.9% vs 23.3%, p-value < 0.001), coronary artery disease 
(41.4% vs 21.7%, p-value < 0.001) and asthma/chronic obstructive pulmonary disease (37.2 
vs 5.8%, p-value < 0.001), than those with Low-GAI. The High-GAI population were more 
likely to have chronic renal failure (22.1% vs 2.5%, p-value < 0.001) and to be prescribed a 
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greater number of regular daily medications (10.0 ± 3.2 vs 8.4 ± 3.1, p-value < 0.001). A RASi 
agent was not prescribed to any patient in the Low-GAI cohort.  
 
5.4.6 Potentially inappropriate prescribing 
 
Among residents with HF, 64 (24.2%) were prescribed a PIMHF item, of whom 11 (4.2%) 
were prescribed ≥ 2 PIMHF items. A COX-2 inhibitor, oral beta-2 agonist, itraconazole or 
decongestant was not prescribed to any resident. An NSAID was the most frequently prescribed 
PIMHF item (n = 26, 9.8%), then oral corticosteroids (n = 21, 7.9%). Oral corticosteroids, 
NSAIDs and pregabalin were the most frequently used PIMHF items among residents 
prescribed ≥ 2 PIMHF items. There was no difference in the rate of PIMHF prescriptions 
between High-GAI and Low-GAI HF patients (Table 5.5).  
 
5.4.7 Logistic regression analysis 
 
In a logistic regression analysis, the multivariable associates of High-GAI achievement were 
higher comorbidity burden (OR 1.25, 95% CI 1.07 - 1.46), coronary artery disease (OR 1.85, 
95% CI 1.01 - 3.38) and hyperpolypharmacy (OR 2.04, 95% CI 1.15 – 3.61), (Table 5.6). 
Prescription of a loop diuretic was negatively associated with PIMHF prescription (OR 0.33, 
95% CI 0.15 - 0.73), (Table 5.7). 
149 
 
Table 5.2 Baseline profile of the total population of the 14 Long-Term Care facilities, N = 732 
residents. (221) 
Variable  
Total population characteristics  
(N = 732) 
Age (years) 83.9 ± 7.7 
Male 218 (29.8) 
Mean arterial blood pressure (mmHg) 90.1 ± 13.4 
Heart rate (beats per minute) 74.5 ± 12.5 
Creatinine Clearance (millilitre/minute) 53.7 ± 27.9 
Hypertension 349 (47.7) 
Atrial fibrillation 162 (22.1) 
Coronary artery disease 161 (21.9) 
Diabetes 110 (15.0) 
Chronic renal failure 115 (15.7) 
Asthma/Chronic obstructive lung disease 113 (15.4) 
Dementia 345 (47.1) 
History of falls 349 (47.7) 
Cerebrovascular accident/Stroke 211 (28.8) 
Urinary incontinence 289 (39.5) 
Charlson Comorbidity Index  4.0 ± 1.8 
Regular medications  8.3 ± 3.3 




Table 5.3 Characteristics of Long-Term Care residents with a documented history of Heart 
Failure and those with prescription of a loop diuretic in absence of documented Heart Failure 
diagnosis, N = 265 patients.  




(n = 99) 
Prescription of loop diuretic in 
absence of documented HF diagnosis 
(n = 166) 
p-value 
Clinical profile  
Age (years)  85.5 ± 7.0 84.34 ± 7.6 0.519 
Male 33 (33.3) 47 (28.3) 0.372 
MAP (mmHg) 91.5 (12.7) 89.4 (11.8) 0.767 
Heart rate 73.0 ± 15.0 72.0 ± 18.0 0.888 
Creatinine Clearance (ml/min) 51.5  ±  25.0 51.8 ± 24.2 0.145 
Hypertension 43 (43.4) 88 (53.0) 0.791 
Atrial fibrillation 45 (45.4) 38 (22.9) < 0.001 
Coronary artery disease 43 (43.4) 43 (25.9) 0.021 
Diabetes 17 (17.2) 21 (12.6) 0.462 
Chronic renal failure 13 (13.1) 22 (13.2) 0.429 
Asthma / COPD  32 (32.3) 29 (17.5) 0.526 
Dementia 46 (46.5) 66 (39.8) 0.518 
History of falls  42 (42.4) 90 (54.2) 0.618 
CVA / Stroke 29 (29.3) 43 (25.9) 0.681 
Urinary incontinence 28 (28.3) 57 (34.3) 0.721 
Number of comorbidities  12.4  ±  4.2 10.8 ±  3.3 0.031 
Charlson Comorbidity Index  5.3 ± 1.9 3.9 ± 1.8 0.021 
Medication profile  
RASi 22 (22.2) 42 (25.3) 0.701 
Beta-blocker 26 (26.6) 34 (20.5) 0.099 
MRA 8 (8.1) 5 (3.0) 0.819 
Digoxin   25 (25.2) 12 (7.2) < 0.001 
Loop diuretic  66 (66.7) 166 (100) < 0.001  
Calcium channel blocker 8 (8.1) 15 (9.0) 0.310 
Regular medications 12.5  ±  3.6 12.7 ± 3.7 0.862 
Hyperpolypharmacy  34 (34.3) 53 (31.9) 0.761 
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Comparisons were made between patients with a previous history of Heart Failure diagnosis and 
patients having a prescription of loop diuretic in absence of documented HF diagnosis. Continuous 
variables are expressed as mean ± standard deviation. Categorical variables are expressed as frequencies 
and percentages. Abbreviations: COPD, chronic obstructive pulmonary disease; CVA, 
cerebrovascular accident; HF, heart failure; MAP, mean arterial blood pressure; ml/min., millilitre per 




Table 5.4 Characteristics of Long-Term Care residents with Heart Failure and those without 
Heart Failure, N = 732 patients.  
N = 732 patients 
Non-HF patients  
(N = 467) 
HF patients a  
(N = 265) 
p-value  
Clinical profile  
Age (years)  83.4 ± 7.9 84.8 ± 7.4 0.024 
Male 138 (29.6) 80 (30.2)  0.617 
MAP (mmHg)  90.6 ± 12.0 90.2 ± 12.2 0.419 
Heart rate (bpm)  75.4 ± 11.1 74.6 ± 12.3 0.761 
Creatinine Clearance (ml/min)  54.9 ± 29.7 51.7 ± 24.5 0.537 
Hypertension 218 (46.7)  131 (49.4)  0.666 
Atrial fibrillation  79 (16.9)  83 (31.3)  <0.001 
Coronary artery disease  75 (16.1)  86 (32.5)  <0.001 
Diabetes 72 (15.4)  38 (14.3)  0.671 
Chronic renal failure 80 (17.1)  35 (13.2)  0.761 
Asthma / COPD  52 (11.1)  61 (23.0)  0.021 
Dementia  233 (49.9)  112 (42.3)  0.047 
History of falls 217 (46.5)  132 (49.8)  0.871 
CVA / Stroke  139 (29.8)  72 (27.2 )  0.691 
Urinary incontinence  204 (43.7)  85 (32.1)  0.002 
Number of comorbidities  10.6 ± 3.4 11.6 ± 3.5 0.035 
Charlson Comorbidity Index  3.8 ± 1.6 4.4 ± 1.9 0.029 
Medications profile  
RASi  71 (15.2)  64 (24.2)  0.031 
Beta-blocker  71 (15.2)  60 (22.6)  0.041 
MRA  7 (1.5) 13 (4.9) 0.418 
Digoxin  31 (6.6)  37 (14.0)  0.024 
Loop diuretics  0 (0.0)  232 (87.5)  < 0.001  
Calcium channel blocker 42 (9.0)  23 (8.7)  0.318 
Regular medications  7.6 ± 3.2 9.27 ± 3.2 0.041 




a: Heart Failure defined as patients with Heart Failure diagnosis or patients prescribed loop diuretic, 
highlighted in grey colour. Comparisons were made between Heart Failure patients and non-Heart 
Failure patients. Continuous variables are expressed as mean ± standard deviation. Categorical variables 
are expressed as frequencies and percentages.  
Abbreviations: COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; HF, 
heart failure MAP, mean arterial blood pressure; RASi, renin-angiotensin system inhibitor (ACE 




Table 5.5 Characteristics of Heart Failure patients receiving High-GAI and Low-GAI 
management, N = 265 patients. 
                   N = 265 patients 
High-GAI 
(n = 145) 
Low-GAI 
(n = 120) 
p-value  
Clinical profile    
Age (years) 84.4 ± 7.1 85.2 ± 7.6 0.351 
Male 46 (31.7) 34 (28.3) 0.852 
MAP (mmHg) 89.5 ± 12.6 91.1 ± 11.7 0.671 
Heart rate (bpm) 73.3 ± 13.3 76.1 ± 12.8 0.787 
Hypertension 79 (54.5) 52 (43.3) 0.050 
Atrial fibrillation 55 (37.9) 28 (23.3) < 0.001 
Coronary artery disease 60 (41.4) 26 (21.7) < 0.001  
Diabetes  22 (15.2) 16 (13.3) 0.887 
Chronic renal failure 32 (22.1) 3 (2.5) < 0.001  
Asthma/COPD 54 (37.2) 7 (5.8) < 0.001 
Dementia 56 (38.6) 56 (46.7) 0.562 
History of falls 67 (46.2) 65 (54.2) 0.251 
Number of comorbidities 12 ± 3.4 11.2 ± 3.5 0.371 
Charlson comorbidity index 4.8 ± 1.9 3.9 ± 1.8 <0.001 
Medication profile  
Regular medications  10.0 ± 3.2 8.4 ± 3.1 <0.001 
Hyperpolypharmacy  59 (40.7) 28 (23.3) < 0.001  
Potentially Inappropriate Medicines in Heart Failure  
NSAID 9 (6.2) 17 (14.2) 0.06 
Oral corticosteroid 14 (9.7) 7 (5.8) 0.912 
Pregabalin 9 (6.2) 5 (4.2) 0.816 
Metformin in poor renal function † 8 (5.5) 1 (0.8) 0.819 
Non-dihydropyridine CCB 2 (1.4) 3 (2.5) 0.738 




Comparisons were made between Heart Failure patients with High-GAI and those with Low-GAI 
management. Continuous variables are expressed as mean ± standard deviation. Categorical variables 
are expressed as frequencies and percentages. * indicates a statistically significant p-value < 0.05. † poor 
renal function is defined as creatinine clearance < 50 millilitres/minute. Abbreviations: bpm, beats per 
minute; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; GAI, guideline 




Table 5.6 Univariable and multivariable logistic regression of High-GAI achievement among residents with Heart Failure, N = 265 patients. 
Variable 
Univariable analysis Multivariable analysis 
Odds ratio (95% Confidence Interval) Odds ratio (95% Confidence Interval) 
Age (years) 0.98 (0.951 – 1.010) 0.978 (0.948 - 1.023) 
Male 1.17 (0.691 – 1.990) 1.023 (0.555 - 1.888) 
Charlson comorbidity index 1.31 (1.141 – 1.515) 1.249 (1.074 - 1.457) 
Atrial fibrillation 2.00 (1.170 – 3.450) 1.737 (0 .955 - 3.006) 
Coronary artery disease 2.55 (1.479 – 4.405) 1.784 (1.059 - 3.250) 
Dementia 0.719 (0.446 – 1.17) - 
Hyperpolypharmacy 2.254 (1.317 – 3.858) 2.039 (1.150 - 3.614) 
PIMHF item prescribed 0.919 (0.523 – 1.615) - 
 
The multivariable logistic model of High-GAI achievement: Nagelkerke's R2 = 0.159; percentage of correct estimation = 66.6%. Abbreviations: PIMHF, 
potentially inappropriate medicines in heart failure. 
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Table 5.7 Univariable and multivariable logistic regression of the use of Potentially Inappropriate Medicines in Heart Failure among residents with 
Heart Failure, N = 265 patients. 
Variable 
Univariable analysis Multivariable analysis 
Odds ratio (95% Confidence Interval) Odds ratio (95% Confidence Interval) 
Age (years) 0.961 (0.923 - 1.012) 0.966 (0. 927 - 1.021) 
Male 1.29 (0.713 - 2.352) 1.155 (0.591 - 2.174) 
Dementia 0.991 (0.566 - 1.761) - 
Documented Heart Failure diagnosis 0.834 (0.469 – 1.482) - 
Hyperpolypharmacy  1.570 (0.877 - 2.812) - 
Loop diuretic 0.373 (0.179 - 0.792) 0.355 (0.165- 0. 765) 
 
The multivariable logistic model of PIMHF prescription: Nagelkerke's R2 = 0.55; percentage of correct estimation = 77.5%. Abbreviations: PIMHF, potentially 




Figure 5.1 The most frequent prescribing patterns of Heart Failure medications, N = 265 patients.  
















Prescribing of medicines is a fundamental element of HF care in all healthcare settings. (1) The 
current study represents a unique assessment of the prescribing of HF guideline-directed 
medical therapies and the patterns of appropriate and potentially inappropriate HF prescribing 
practices in LTC facilities. This study is the first application of the GAI-3 and PIMHF 
prescribing review tools in an LTC context. The results illustrate the considerable sub-optimal 
utilisation of guideline-directed medical therapies in this population of older HF patients and 
that one in four of these HF patients was prescribed at least one medicine that is potentially 
harmful in HF. 
 
Accurate HF diagnosis is challenging in older patients and particularly among LTC residents 
for many reasons including frailty, dementia, multimorbidity, immobility, and polypharmacy. 
(114, 219, 223, 224) This means that many HF cases are undiagnosed or undetected as the HF 
manifestations may be misinterpreted as ageing-related or as symptoms of other illnesses. (213, 
218, 223, 224) Hancock and colleagues found that HF diagnosis is missed in 50% of LTC residents 
with previously recorded HF diagnosis in their hospital charts. (224) A study by Heckman et al. 
of 450 HF patient residents in LTC showed that previous history of HF (OR 13.66, 95% CI 
6.61 – 28.24) and prescription of a loop diuretic (OR 2.11, 95% CI 1.12 – 3.98) are the strongest 
diagnostic predictors of HF in LTC facilities. (223) The use of loop diuretic as a surrogate marker 
of HF in this study population is supported by the fact that prescription of loop diuretics has 
been used to aid diagnosis in the older HF patients in clinical trials such as The Perindopril in 
Elderly People with Chronic Heart Failure (PEP-CHF) study and the Trial of Intensified versus 
standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). 
Furthermore, the present results showed the very high median dose of loop diuretics that was 
prescribed to the cohort of patients that had not a documented HF diagnosis in comparison to 
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the dose prescribed to the cohort of patients having the diagnosis documented in their charts. 
(211, 230) Other HF surrogate markers such as natriuretic peptides have been used to identify HF 
in the older LTC residents. (211) The ambiguity surrounding the diagnosis of HF may adversely 
impact guideline-led prescribing practice, medication choice and dosing offered to the HF 
population in LTC facilities. (223, 224) 
 
The impact of this uncertain diagnosis could be reflected in the utilisation rates and dosing of 
the recommended HF medications. The prescription rates of RASi (24.1%) and beta-blockers 
(22.6%) in the present study were significantly lower than those outlined in the Geriatric 
Outcomes and Longitudinal Decline in Heart Failure (GOLD-HF) study where RASi was 
prescribed to 60% of HF patients and beta-blockers to 50% of patients.  In a study of American 
Medicare/Medicaid certified nursing homes by Li et al., RASi was prescribed to 56% of 
residents and beta-blockers to 54%. (218, 219) 
 
The older age represents a considerable barrier to guideline-led prescribing and the uptitration 
of the medications in LTC facilities. (218, 224) In the current HF population, the 100% target dose 
was achieved in less than 5% of patients only. Li and colleagues justified the prescription of 
RASi and beta-blocker to fewer than 60% of otherwise eligible HFrEF patients by the fact of 
the patients older age. (218) Barywani and colleagues found that among ambulatory octogenarian 
patients, 53% achieved the guideline-recommended target doses of RASi, and just 21% 
achieved the beta-blocker target dose. (154) The older HF patients and particularly those in LTC 
represent a gap in the HF evidence as they are frequently excluded from the clinical trials. (109) 
Furthermore, as medication side effects can be more pronounced in older patients, those who 
prescribe to LTC residents may be reluctant to start, resume or uptitrate a guideline-directed 




However, the regression model estimated an opposite effect of coronary artery disease and the 
comorbidity burden on the achievement of High-GAI based management. The adjusted model 
estimated coronary artery disease (OR 1.84, 95% CI 1.01 – 3.38) as a positive associate of HF 
guideline-led prescribing. Similarly, Li et al. study in the USA showed the positive impact of 
comorbid cardiovascular conditions or risk factors on the prescription of RASi and beta-
blockers in LTC residents. (218) Both Li et al. and the current study identified a positive 
relationship between comorbidity burden and the achievement of High-GAI based 
management despite using different methods of comorbidity calculation. (218)  
 
Overall, adherence to guideline-led prescribing in the current population is moderate despite 
the adjustment for patients’ contraindications to therapies. In some instances, this suboptimal 
use of HF medications might be an appropriate strategy for the older multimorbid HF patients. 
TIME-CHF trial did not demonstrate any mortality or hospitalisation benefit related to the 
intensification of medications in these vulnerable patients, but this intensification strategy was 
associated with more serious adverse drug reactions in older patients in comparison to the 
younger HF patients. (211, 232) 
 
The current study showed that one-quarter of patients were prescribed at least one potentially 
inappropriate medicine. This is in line with international reports that potentially inappropriate 
prescribing is highly prevalent in LTC facilities, ranging from 12% in one report to 70% in 
another. (221, 233) Despite the different specificity of PIMHF compared to other explicit tools, 
the current results are confirmatory to the findings of a previous analysis of the current 
population. (221) That study applied the STOPP/START criteria to all 732 residents of the 
current LTC facilities and found a 70% prevalence of potentially inappropriate prescribing. (221) 
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There is clear evidence that the use of certain medications is harmful or contraindicated in HF 
patients as they may cause or exacerbate congestion or have a detrimental inotropic effect. (102) 
The PIMHF prescribing review tool may be of benefit in identifying opportunities to improve 
prescribing quality in HF patients residing in LTC. (112) 
 
The drug therapy problems identified in this work represent a unique opportunity for the 
inclusion of clinical pharmacists into the multidisciplinary healthcare teams of LTC facilities. 
Implementation of a clinical pharmacy service improved the transition of care and reduced 
rehospitalisation rates by up to 30% among patients of high cardiovascular risk. (204) However, 
there is a striking lack of HF-specific studies concerned about the role of clinical pharmacists 
in LTC facilities. There was an uncontrolled before-after study performed in two Belgian 
nursing homes over 100 patients and published in 2010. In these two nursing homes, an 
educational intervention led by a clinical pharmacist decreased the rate of medication errors by 




The one-point data collection limited the opportunity to study medications modifications over 
time. Also, the uncertain diagnosis of HF in 166 residents might have affected the quality of 
prescribing. Prescription rates were reported assuming these would be the same as utilisation 
rates, as the residents’ medication administration is monitored by nursing staff at the LTC 
facilities. Similar to the Canadian GOLD-HF study, the study data was collected a number of 
years before its analysis, however, given the paucity of data on prescribing to patients in LTC 





Adherence to guideline-led prescribing is moderate in these LTC facilities. Prescription rates 
of potentially inappropriate medications are high among older HF patients. However, 
optimising medications in this population is hampered by difficulties in confirming HF 
diagnosis. 
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6 Chapter 6 
Guideline-Led Prescribing to Heart Failure Patients at 
Discharge from an Egyptian Critical Care Unit: The 
Impact of a Clinical Pharmacy Service 
 
 
According to the literature review of published HF studies in Egypt (Chapter 2), the number 
of HF clinical care studies is scarce. Also, the review demonstrated that some healthcare 
settings were not included in any of the published studies. Therefore, the aim of this chapter is 
to study HF guideline-led prescribing towards recently stabilised HF patients at the discharge 
point from the critical care setting. Evidence from this study may help to identify the potential 









Discharge prescriptions for HF patients may not adhere to the recommendations of the clinical 
practice guidelines. Clinical pharmacists are uniquely positioned to optimise HF prescribing 




To assess guideline-led prescribing to HF patients at discharge from an Egyptian critical care 




A retrospective observational study of HF patients discharged from a critical care unit (CCU) 
between 2013 and 2017. The GAI-3 was used to assess guideline-led prescribing. High-GAI 
was the prescribing of ≥ 2 GAI medicines. A clinical pharmacy service was introduced to the 




The study included 284 HF patients, mean ± SD  66.7 ± 11.5 years, 53.2% male. At discharge, 
loop diuretic was the most frequently prescribed HF medication (n = 242, 85.2%); followed by 
MRA (n = 156, 54.9%); RASi (n = 146, 51.4%); and beta-blockers (n = 85, 29.9%). Population 
GAI-3 was 45.5%; however, when adjusted for prescription of ≥ 50% target dose this decreased 
to 24.3%. High-GAI was prescribed to 136 patients (47.9%). These patients were younger (62.6 
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vs 70.5 years, p-value < 0.001); less affected by kidney disease (22.1% vs 33.8%, p-value = 
0.028) and had fewer comorbidities (4.9 ± 2.3 vs 5.6 ± 2.5, p-value = 0.017) than those without 
High-GAI. Prescription of beta-blocker increased (24.1% vs 38.6%, p-value < 0.001) and 
digoxin utilisation decreased (34.7% vs 23.7%, p-value < 0.049) after the introduction of the 




Contraindications, older age and kidney function adversely affected guideline-led prescribing 
in this critically-ill population. Clinical pharmacists may have a role in optimising guideline-






6.2 Introduction  
 
Pharmacotherapy is a core component of HF management as it improves symptoms and 
prevents worsening of the disease. (1, 21, 48) Guideline-led prescribing is strongly associated with 
improved survival, prognosis, and quality of life in HF. (1, 21, 48, 76) The guidelines strongly 
recommend, and the optimal patient outcomes are achieved with the appropriate prescription 
of the target doses of HF guideline-directed medical therapies. (41, 84) In the BIOSTAT-CHF 
and QUALIFY studies, the optimisation of HF guideline-directed medical therapies and the 
prescription of ≥ 50% of target doses demonstrated short and long-term benefits in patient 
survival and rehospitalisation outcomes. (48, 76) 
 
Hospitalisation is a significant opportunity to implement guideline-directed medical therapies 
for chronic HF in a monitored setting. A meta-analysis studying the effects of EBBB 
demonstrated that discontinuation of EBBB in patients hospitalised with acute HF was 
associated with significantly increased in-hospital mortality, short-term mortality and short-
term rehospitalisation. (42) Therefore, in-hospital initiation or resumption of guideline-directed 
medical therapies is one of the significant predictors of optimal long-term use of therapies and 
consequently, better clinical outcomes. (235) However, studies evaluating prescribing at 
discharge show that discharge therapeutic plans for HF patients are often not adherent to the 
guidelines. (235, 236) In one long-term registry, discharge prescription rates of HF guideline-
directed medical therapies were lower than 75%. (236) Elsewhere, Gilstrap and colleagues 
identified some reasons for the considerable omission of HF guideline-directed medical 
therapies during hospitalisation or at discharge despite their survival benefits. (146, 237) For 
instance, reduced kidney functions and hypotension represent substantial barriers to the 




Mainly, little is known about the quality of HF prescribing at discharge from critical care units. 
The critically-ill HF population represents a challenge for prescribers as these patients are often 
older, suffering from multiple severe comorbidities, prescribed appropriate and inappropriate 
polypharmacy and more likely to experience contraindications to therapies. (21, 236, 238) 
Therefore, discharge prescribing may not be optimised in this population. (21, 236) 
 
The clinical pharmacist is uniquely positioned to address such drug therapy problems in order 
to optimise HF care and improve clinical outcomes. (239) Implementation of clinical pharmacy 
services can improve the transition of care and reduce rehospitalisation rates by up to 30%. (204) 
The inclusion of clinical pharmacists in HF care teams has been shown to optimise guideline-
led prescribing during and after hospitalisation. (206)  However, there are no reports on clinical 
pharmacist activities in HF in the MENA settings (16, 206) and little is known about guideline-
led prescribing towards recently stabilised HF patients at discharge from critical care units in 
the MENA region. (16) 
 
The Egyptian Long-Term Registry is an HF registry that represents a comprehensive dataset 
from cardiology wards and settings throughout the country. However, there is no data about 





Therefore, this study aimed to assess guideline-led prescribing to HF patients at discharge from 
a critical care setting and to assess the effect, if any, of including a clinical pharmacist in this 






This is a retrospective observational study of HF patients hospitalised in the Critical Care Unit, 
(CCU) of Cairo University Hospitals, Egypt, between January 1st, 2013 and December 31st, 
2017. The ethics approval was granted by the Research and Ethics Committee of Future 
University in Egypt, Cairo, Egypt (registration number REC-FPSPI-9/56), (Appendix 6). 
Permission to conduct the research was granted by the Management Board of Critical Care 
Medicine Department of Cairo University, Egypt. The study is reported according to STROBE 
guidelines. (187) 
 
Patients were included if they were ≥ 18 years on the date of admission, had a diagnosis of HF, 
had an electronic record of discharge medications and were discharged from the CCU during 
the study period. The diagnosis and type of HF were based on data recorded in the patient’s 
electronic medical record. Heart Failure with reduced ejection fraction was defined as an EF < 
50% while HFpEF was defined as an EF ≥ 50%. (9) Data accessed in the patient’s electronic 
medical record included age, gender, admission date, discharge date, presenting complaint; 
comorbidities, laboratory and medical investigations. The following information on discharge 
medications was also accessed in the electronic medical records: drug name, dose and 
frequency. As this population is prescribed a high number of medications, hyperpolypharmacy, 
that is the prescription of ≥10 regular daily medications, was calculated. (189)  
 
The ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 
are the guidelines referenced throughout this work as they are the guidelines that were in use in 
Egypt for most of the study timeframe. (9) Guideline-led prescribing was assessed using the 
GAI-3 (46), the adjusted GAI-3 (176) and the GAI-based target dose. (179) The GAI-3 was 
calculated as the proportion of each of the following medications prescribed for each patient: 
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RASi (ACE inhibitor or ARB), EBBB MRA. (9, 46) The adjusted GAI-3 took into account 
patient’s contraindications to these therapies (Table 6.1). (9, 147, 176) The GAI-based target dose 
considered the prescription of ≥ 50% of the recommended target dose of each of the 
pharmacological substance class as adherence to the guidelines (Table 6.1). (9, 179)  The GAI-5 
was calculated using five medication classes: the GAI medicines plus digoxin and loop 
diuretics. (9, 46)  The study population was then subdivided into those with High-GAI based 
management; that is the prescription of  ≥ 2 of the GAI medicines and those with Low-GAI 
based management; the prescription of ≤ 1 GAI medicine. (147) Potentially inappropriate 
prescribing was evaluated using the PIMHF tool, an HF-specific list that includes 11 medicines 
or medicine classes that are cautioned or contraindicated in HF patients (Appendix 1). (112) 
 
6.3.1 Clinical Pharmacy service in the Critical Care Unit 
 
Clinical pharmacy service was introduced in the CCU from January 1st, 2016 onwards. The 
clinical pharmacy team was composed of five clinical pharmacists, each with more than four 
years of clinical experience and a senior pharmacist director with greater than  10 years clinical 
experience and holds a PhD in Clinical Pharmacy. The clinical pharmacists (i) participate in the 
daily ward round to provide prescribing recommendations; (ii) perform medication review and 
medication reconciliation to identify drug-related problems; and (iii) provide a drug information 
service for prescribers.  
 
6.3.2 Statistical analysis 
 
Comparisons between (i) patients with High-GAI and Low-GAI based management and (ii) 
patients receiving care before and after the introduction of the clinical pharmacy service were 
conducted using independent Student’s t-test for continuous data and Chi-square or Fisher’s 
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exact test for categorical data. All tests were two-tailed, and a p-value of < 0.05 was regarded 
as statistically significant.  
 
Univariable logistic regression analysis was performed and a multivariable logistic regression 
model developed in order to determine the clinical factors associated with High-GAI 
achievement. The multivariable logistic regression model included the variables that were 
considered clinically relevant and variables where there was a significant difference in the 
comparison between High-GAI and Low-GAI populations. Therefore, the multivariable model 
adjusted for age and sex included the number of comorbidities, HF type, blood urea nitrogen > 
20 mg/dl, serum creatinine > 2.5 mg/dl, and prescription of ivabradine. The odds ratios (OR) 
and 95% confidence intervals (CI) of the adjusted multivariable analysis were reported. Data 





Table 6.1 Guideline-directed medical therapies, their contraindications, and target doses as described in the European Society of Cardiology Guidelines 
for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. (9) 
Medication class Contraindications 
Agents 100% Target 
Daily Dose 
Renin-angiotensin system inhibitors 
(ACE inhibitor / Angiotensin-II receptor 
blocker) 
 
 History of angioedema 
 Known bilateral renal artery stenosis 








150 mg  
20 mg  
20 mg  
10 mg  
32 mg 
150 mg 
320 mg  
Evidence-based beta-blockers 
 
 Second- or third-degree AV block 





10 mg  
50 mg 
10 mg 




50 mg  
50 mg 
Digoxin -   - 




Usual daily dose 
≤ 240 mg  
≤ 5 mg  
≤ 20 mg  
 
Agents listed are those agents from each class that were prescribed to one or more patients in the study population. Abbreviations: ACE, angiotensin-converting 





6.4.1 Baseline profile and characteristics of Heart Failure patients 
 
Data were available for 284 patients. The mean ± SD age of patients was 66.7 ± 11.5 years, 
and 53.2% were male. Ejection fraction was available for 220 patients, and the mean ± SD EF 
was 45.1% ± 16.7%. Heart Failure with reduced ejection fraction affected 138 patients (62.7%). 
Coronary artery disease was the HF aetiology in 132 patients (46.5%), and the acute coronary 
syndrome was the main presenting complaint in 81 patients (28.5%). The mean number of 
comorbidities was 5.2 ± 2.4 with hypertension (n = 140, 49.3%), diabetes (n = 130, 45.8%) and 
atrial fibrillation (n = 109, 38.4%) as the most frequently occurring comorbidities (Table 6.2).  
 
6.4.2 Prescribing to Heart Failure population 
 
At discharge, the mean number of daily medications was 9.1 ± 2.5 (Table 6.2).  Fourteen 
patients (4.9%) were not prescribed any HF medications. Prescription rates for the three GAI 
medicines were RASi (n = 146, 51.4% patients); EBBB (n = 85, 29.9% patients); and MRA (n 
= 156, 54.9% patients). Monotherapy was prescribed to 53 patients (18.7%) of whom, 45 
(15.8%) were prescribed a loop diuretic as the single HF medication. A combination of two 
GAI medicines was prescribed to 94 (33.1%) patients, and all three medicines were prescribed 
to 42 (14.8%) patients. Prescription of ≥ 50% of the guideline-recommended target doses of 
RASi, EBBB and MRA was achieved in 40 (14.1%), 21 (7.4%) and 145 (51.5%) patients, 
respectively (Figure 6.1). The most frequently prescribed HF medication was loop diuretics 
(242 patients, 85.2%), with 43 (15.2%) patients prescribed more than one loop diuretic at 




The contraindications to the guideline-directed medical therapies, as outlined in the guidelines, 
are described in Table 6.1. No patient experienced a contraindication to RASi or MRA. At least 
one contraindication to EBBB therapy was present in 70 (24.6%) patients, 23 (8.1%) having a 
second or third-degree AV-block and 47 (16.5%) having asthma. Of these patients, 49 (17.2%) 
were not prescribed an EBBB at discharge. 
 
Population mean GAI-3 was 45.5%, and adjusted GAI-3 was 51.3%. GAI-3 target dose was 
24.3%. Population mean GAI-5 was 50.3%. There were significant differences between HFrEF 
and HFpEF patients in GAI-3 (56.6% vs 26.3%, p-value < 0.001); adjusted GAI-3 (62.4% vs 
33.8%, p-value < 0.001) and GAI-5 (60.0% vs 34.4%, p-value < 0.001). PIMHF items were 
prescribed to 51 (18.1%) patients (Table 6.2).  
  
6.4.3 High-GAI and Low-GAI achievement 
 
High-GAI based management was achieved in 136 patients (47.9%). These High-GAI patients 
had lower EF (37.9% ± 13.8% vs 51.9% ± 16.4%, p-value < 0.001); were younger (62.6 ± 10.7 
vs 70.5 ± 11 years, p-value < 0.001); were more likely to be male (65.4% vs 41.9%, p-value < 
0.001); had fewer comorbidities (4.9 ± 2.3 vs 5.6 ± 2.5, p-value = 0.017); and were less likely 
to have chronic kidney disease (22.1% vs 33.8%, p-value = 0.028) than those patients with 
Low-GAI. Also, the prescription of recommended target doses of RASi, EBBB and MRA were 
significantly higher in the High-GAI cohort than the Low-GAI cohort (Figure 6.1).  
 
6.4.4 Clinical Pharmacy contribution 
 
There was no statistical difference between HF patients before (n = 170) and after (n =114) the 
introduction of clinical pharmacy service in terms of demographic characteristics or 
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comorbidities. Medications prescribed in the period before and after the introduction of the 
service are described in Table 6.3. The prescription of EBBB increased significantly from 
24.1% before the clinical pharmacy service to 38.6% post the implementation of the service 
(p-value < 0.001) while the prescription of digoxin decreased significantly during the same 
period (34.7% vs 23.7%, p-value = 0.049). Prescribing of pregabalin, a PIMHF item, increased 
after introduction of clinical pharmacy (0.6% vs 7.9%, p-value < 0.001).   
 
6.4.5 Logistic regression analysis 
 
In the multivariable logistic regression analysis, the clinical factors associated with High-GAI 
were age (OR 0.96, 95% CI 0.92 - 0.98), serum creatinine > 2.5 mg/dl (OR 0.31, 95% CI 0.09 
– 0.98) and HFrEF (OR 5.50, 95% CI 2.66 – 11.55). The model estimation correctness was 





Table 6.2 Baseline characteristics and medications profile of the total population, patients 
prescribed High-GAI and patients prescribed Low-GAI, N = 284 patients. 





(n = 284) (n = 136) (n = 148) 
 
Clinical profile  
Age (years) 66.7 ± 11.5 62.6 ± 10.7 70.5 ± 11 
<0.001 
Male 151 (53.2) 89 (65.4) 62 (41.9) 
<0.001 
MAP (mmHg) 94.9 ± 17.6 93.3 ± 19 96.3 ± 16.2 
0.436 
Heart rate (bpm) 86.2 ± 22.0 87.9 ± 21.6 84.6 ± 22.3 
0.701 
Ejection Fraction (%)† 45.1 ± 16.7 37.9 ± 13.8 51.9 ± 16.4 < 0.001 
HFrEF† 138 (62.7) 89 (83.2) 49 (43.4) 
< 0.001 
Hypertension 140 (49.3) 69 (50.7) 71 (48.0) 
0.313 
Atrial fibrillation  109 (38.4) 48 (35.3) 61 (41.2) 
0.541 
Coronary artery disease 132 (46.5) 69 (50.7) 63 (42.6) 
0.376 
Diabetes 130 (45.8) 60 (44.1) 70 (47.3) 
0.132 
Chronic kidney disease 80 (28.2) 30 (22.1) 50 (33.8) 0.028 
Asthma/COPD 64 (22.5) 34 (25.0) 30 (20.3) 
0.812 
Number of comorbidities 5.2 ± 2.4 4.9 ± 2.3 5.6 ± 2.5 
0.017 
Clinical Status at Discharge 
 
Low blood pressure (<90/60 mmHg) 9 (3.5) 8 (6.7) 1 (0.7) 0.011 
High blood pressure (>140/90 mmHg) 88 (34.6) 34 (28.6) 54 (40.0) 
0.214 
Heart rate ≤ 70 bpm 107 (37.7) 46 (33.8) 61 (41.2) 
0.333 
Heart rate ≥ 100 bpm 57 (20.1) 28 (25.5) 29 (24.0) 
0.412 
Hyperkalaemia (K+ > 5.0 mg/dl) 9 (3.2) 3 (2.2) 6 (4.1) 
0.877 
High blood urea nitrogen (> 20 mg/dl)  153 (53.9) 63 (46.3) 90 (60.8) 
< 0.01 
High serum creatinine (> 2.5 mg/dl)  31 (10.9) 7 (5.1) 24 (16.2) 
< 0.01 




Table 6.2 Baseline characteristics and medications profile of the total population, patients 






 (n = 284) (n = 136) (n = 148) 
 
Discharge Medications Profile   
RASi 146 (51.4) 125 (91.9) 21 (14.2) 
< 0.001  
EBBB  85 (29.9%) 67 (49.3) 18 (12.2%) 
< 0.001 
MRA 156 (54.9) 122 (89.7) 34 (23.0) 
< 0.001  
Digoxin 86 (30.3) 48 (35.3) 38 (25.7) 
0.501 
Loop Diuretics 242 (85.2) 120 (88.2)  122 (82.4) 0.423 
Ivabradine  31 (10.9) 21 (15.2) 10 (6.8) 
0.020 
PIMHF items prescribed 51 (18.1) 19 (14.0) 32 (21.6) 
0.312 
Regular medications 9.1 ± 2.5 9.3 ± 2.3 8.9 ± 2.6 
0.545 
Hyperpolypharmacy  121 (43.7) 59 (43.4) 62 (41.9) 
0.065 
Device-based therapy ƪ 38 (13.4) 19 (14.0) 19 (12.8) 
0.435 
Major Prescribing Patterns at Discharge 
 
Loop diuretic as monotherapy 45 (15.8) - 45 (30.4) - 
RASi + Beta blocker 56 (19.7) 56 (41.7) - - 
RASi + MRA 110 (38.7) 110 (80.9) - - 
Loop diuretic + RASi  123 (43.3) 108 (79.4) 15 (10.1) < 0.01 
Loop diuretic + MRA  146 (51.4) 114 (83.8) 32 (21.6) < 0.01 
Loop diuretic + MRA + Digoxin 54 (19.1) 43 (31.6) 11 (7.4) 0.021 
Loop diuretic + RASi + MRA 102 (35.9) 102 (75.0) - - 
 
Comparisons were made between Heart Failure patients with High-GAI and Low-GAI. Categorical 
variables are expressed as frequencies and percentages. Continuous variables are expressed as 
mean ± standard deviation. †Ejection fraction available for 220 patients. ƪ Device-based therapy: 
implantable cardiac defibrillator, cardiac resynchronisation therapy or left ventricular assistance device. 
Abbreviations: COPD, chronic obstructive pulmonary disease; EBBB, evidence-based beta-blocker; 
GAI, Guideline Adherence Index; HFrEF, heart failure with reduced ejection fraction; K+, serum 
potassium; MAP, mean arterial blood pressure; MRA, mineralocorticoid receptor antagonist; PIMHF, 
potentially inappropriate medicines in heart failure; RASi, renin-angiotensin system inhibitor (ACE 
inhibitor or angiotensin-II receptor blocker). 
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Table 6.3 Prescribing of Heart Failure medications before and after implementation of clinical 
pharmacy service, N = 284 patients. 




Clinical Pharmacy  
P-value 
(2013-2015) (2016-2017)  
(n = 170) (n = 114)  
Discharge Medications Profile  
RASi 91 (53.5) 55 (48.2) 0.345 
RASi ≥ 50% Target dose 25 (14.7) 15 (13.2) 0.456 
EBBB  41 (24.1) 44 (38.6) <0.001 
EBBB ≥ 50% Target dose 9 (5.3) 12 (10.5) 0.218 
MRA 99 (58.2) 57 (50.0) 0.546 
MRA ≥ 50% Target dose 93 (54.7) 52 (45.6) 0.617 
Digoxin  59 (34.7) 27 (23.7) 0.049 
Loop diuretic 149 (87.6) 93 (81.6) 0.341 
Dual loop diuretics  19 (11.2) 23 (20.2) 0.032 
Ivabradine  18 (10.6) 13 (11.4) 0.421 
Regular medications  9.0 ± 2.4 9.3 ± 2.6 0.784 
Hyperpolypharmacy  71 (41.8) 50 (43.9) 0.435 
Discharge Guideline Adherence Indices  
GAI-3 (%) 45.2 45.7 0.598 
Adjusted GAI-3 (%) 50 52.6 0.854 
GAI-Target dose (%) 25 23 0.349 
GAI-5 (%) 51.6 48.4 0.632 
High-GAI  81 (47.6) 55 (48.2) 0.881 
Potentially inappropriate prescribing in Heart Failure  
Any PIMHF item 29 (17.1) 22 (19.3) 0.651 
Non-dihydropyridine CCB 18 (10.6) 7 (6.1) 0.627 
Pregabalin  1 (0.6) 9 (7.9) 0.015 
Oral corticosteroid 4 (2.4) 6 (5.3) 0.845 
Medicinal formulations with 
high sodium content 
8 (4.7) 2 (1.8) 
0.746 




Comparisons were made between Heart Failure care provided before and after the implementation of 
clinical pharmacy service at the critical care unit. Categorical variables are expressed as frequencies 
and percentages. Continuous variables are expressed as mean ± standard deviation. Abbreviations: 
CCB, calcium channel blocker; EBBB, evidence-based beta-blocker; GAI, guideline adherence index; 
MRA, mineralocorticoid receptor antagonist; PIMHF, potentially inappropriate medicines in heart 





Figure 6.1 Prescription of guideline-directed medical therapies and achievement of 50% target dose for each medication class, presented as Low-GAI 
population and High-GAI population.   
The proportion of patients prescribed each medication class was compared between High-GAI and Low-GAI populations. This comparison for each of the three 
GAI medicines was statistically significant (p-value < 0.001). 
The proportion of patients prescribed ≥ 50% target dose of each medication class was compared between High-GAI and Low-GAI populations. This comparison 
for each of the three GAI medicines was statistically significant (p-value < 0.001).  





The present study represents the first application of the GAI and PIMHF prescribing review 
tools in a critical care setting. Heart Failure prescribing was sizeably deviated from the 
guideline-directed disease-modifying strategy. At discharge, the mean guideline adherence was 
45.5%, and when adjusted for target dose achievement, this reduced to 24.3%. This study 
showed that the inclusion of clinical pharmacy service in this setting slightly improved the 
adoption of guideline-led prescribing. 
 
A recent systematic review found that the GAI-3 of studies published in the period from 2005 
to 2016, ranged from 14% to 95%, with a mean GAI-3 of 63%. (147) The GAI-3 was first 
introduced in 2005 (46) and later modified to include contraindications to therapies (176) and 
target dose. (179) The GAI-3 of this population was lower than the international mean; however, 
the GAI-3 reported here is comparable to recently reported GAI-3 in Brazil (41%) and China 
(43%).  (147) The study population may also be the sickest of those reported in the literature on 
the GAI-3, as these patients were at discharge from a critical care setting where prescribers 
may not place a strong focus on the long-term HF outcomes. (147)  
 
The prescription rates and the High-GAI achievement reported in this study are significantly 
lower than those reported in QUALIFY, an international registry that included recently 
discharged Egyptian HF patients. (48) The differences reported here between patients with High-
GAI and those with Low-GAI reflect the adverse impact of age and multimorbidity on 
guideline adherence. Patients with Low-GAI had higher EF; however, they were older, had a 
higher comorbidity burden and worse kidney function than High-GAI patients. The adjusted 
GAI-3 takes into account the contraindications to therapy listed in the ESC guidelines. 
However, in the present study, adjusting for these contraindications had a small effect on 
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correcting guideline adherence levels. It is possible that prescribers take other considerations 
into account when prescribing guideline-directed medical therapies. For instance, almost 30% 
of the population experienced chronic kidney disease, and these patients were significantly less 
likely to be prescribed High-GAI than patients with normal kidney function. Therefore, this 
diagnosis is a potential explanation for the omission of RASi and MRA at discharge. (76, 196) A 
conservative prescribing pattern is seen here, which may represent physicians preferring the 
short-term cardio-renal stability over the life-saving disease-modifying strategies. (185, 240) It 
may also represent prescribers’ concerns about the risk of adverse drug reaction, medication 
costs to the patient and the burden of hyperpolypharmacy. (185, 240) 
 
In the present study, there is a high prescription rate of loop diuretics and MRAs which may 
indicate physician’s preference for the low-priced fixed-dose combinations such as 
‘furosemide/spironolactone’ containing products that are available on the Egyptian market. 
These affordable products may enhance patient’s compliance and persistence. Furthermore, a 
high incidence of diuretic resistance has been reported among Egyptian patients, and adjunct 
medications such as metolazone are not commonly included in the hospital formularies. (16, 241) 
The prescription of this fixed-dose formulation contributed to higher target dose achievement 
among patients prescribed MRA than the other guideline-directed medical therapies at 
discharge. The inaccessibility of adjunct diuretics such as metolazone may also have 
contributed to the unexpectedly high rate of prescription of two or more loop diuretics.    
 
In the present study, there was a low rate of target dose achievement. However, this low rate 
possibly reflects the critical care setting from which the recently stabilised patients are being 
discharged, the focus of prescribers on acute illness rather than long-term outcomes and an 
assumption that doses may be titrated upwards in an ambulatory setting. For instance, 53% of 
patients in the ‘BIOSTAT-CHF’ study required a 12-week stepwise approach to reach ≥ 50% 
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of the recommended target dose. (76) This implies a requirement of the ambulatory care services 
to provide long-term care plans to uptitrate HF medications as recommended. However, it is 
of note that in Egypt, outpatient follow-up and monitoring in chronic diseases are not optimal. 
(121, 125) 
 
The prescription rate of PIMHF items in the present hospital discharge population (18.1%) is 
slightly higher than that reported in an ambulatory European one (14.6%). (112) The high 
prevalence of hyperpolypharmacy and multimorbidity among this critically-ill population may 
contribute to this higher rate. This may be explained by the fact that the patients included in 
this study were recently stabilised following a critical emergency admission to the unit, 
implying disease progression and a higher number of medications compared to more stable HF 
populations. (112) A small but non-significant difference was observed in the prescription of 
PIMHF items between High-GAI and Low-GAI cohorts. Interestingly, the rate of PIMHF 
prescription marginally increased after the introduction of a clinical pharmacy service. This 
was driven by an increase in the prescription of pregabalin. The indications for pregabalin 
prescription have expanded in recent years, and its prescription rates have increased 
accordingly. The use of this medication in HF patients is cautioned as it is associated with 
increasing peripheral oedema. (238) It is possible that the indication for this medication 
outweighs any prescriber concerns. This latter point would seem at odds; however, with the 
keen focus of prescribers on HF symptoms as indicated by high rates of diuretic prescription. 
Alternatively, it may be the case that prescribers and pharmacists are not familiar with such 
cautions pointing to a need for ongoing medical education on emerging prescribing matters. 
(238)   
 
The management of HF is complex and multifaceted. As a consequence, guidelines recommend 
a multidisciplinary approach to the optimal delivery of HF care. (1, 21) Several Egyptian reports 
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before 2015 show high rates of digoxin use and underutilisation of EBBB, somewhat at odds 
with the ongoing changes in clinical practice at that time. (15, 16) In the present study, the 
implementation of a clinical pharmacy service significantly increased the EBBB prescription 
by 14.5% and significantly decreased digoxin prescription by 10%. The prescribing changes 
reported here indicate optimised adherence of routine practice to the most recent ESC 
guidelines. (1) However, the overall GAI-3 and the proportion of patients achieving High-GAI 
did not significantly increase with the introduction of clinical pharmacy. The pharmacists in 
this study could make a recommendation about patient medications but had no authority to 
make changes to inpatient or discharge prescriptions. Reports from Egypt and other MENA 
countries indicated that physicians are reluctant to alter a colleague’s prescription despite 
appropriate recommendations made by pharmacists. (242-244) This may have the effect of 
reducing the impact of the pharmacist service. Elsewhere, studies suggest that the acceptance 
rates for clinical pharmacist interventions in HF and acute coronary syndrome patients range 
from 70-81%. (204, 239) Unfortunately, the prescribing interventions recommended by 
pharmacists in this study were not recorded on the unit electronic medical records; therefore, 
we cannot assess the uptake percentage of these interventions. Moreover, without knowing 
what the clinical pharmacists’ recommended interventions, it is not possible to ascertain if the 
focus of their interventions was on guideline-led prescribing and disease-modifying therapies. 
It is possible that pharmacists focussed their efforts on inpatient issues such as therapeutic drug 
monitoring, renal dose adjustment and intravenous to oral switching or that in some patients, 
morbidities other than HF were the focus of the pharmacist and prescriber.  
 
6.6 Limitations  
 
Some limitations must be acknowledged in this study. The present study is retrospective, 
single-centred and includes only the discharge medications of critically-ill patients with HF. 
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However, the setting is the largest CCU in Egypt. This work was conducted in 2013 – 2017, 
before the widespread adoption of sacubitril-valsartan in HF care. However, cost implications 
may limit the use of this drug in Egypt in the short term. Therefore, the authors believe that the 
focus on prescription and dose of RASi in the present study is warranted. Unfortunately, the 
rationale for initiating, maintaining, or discontinuing therapy during hospitalisation or at 
discharge was not recorded on the electronic medical records, and such information may have 




Our study is the first to comprehensively consider HF guideline adherence, potentially 
inappropriate prescribing and the role of the clinical pharmacist in a low-middle budget 
healthcare setting. It highlights some inconsistencies between the recommended HF care and 
the current routine practice. Although clinical pharmacy services in Egypt are in their infancy, 
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7  Chapter 7 
Factors Influencing Guideline-Led Prescribing to Heart 
Failure Patients: A Novel Questionnaire in an Egyptian 
Critical Care Setting 
 
 
In the previous chapter, the results showed the moderate adoption of HF guideline-led 
prescribing at discharge. There are many causative factors that may lead to this. Therefore, 
the current chapter aims to explore the perspective of the Egyptian prescribers of the same 
clinical setting in order to describe the full picture of guideline-led prescribing from a second 
angle: the perspective of prescribers. Evidence from this chapter helps to identify the barriers 









Heart Failure represents a crucial issue for the healthcare systems in the MENA region due to 
its considerable human and economic burden. Guideline-led prescribing improves HF patient 
outcomes, however little is known about the factors influencing guideline-led prescribing to 




To assess the behaviours and perspective of prescribers in the Critical Care Medicine 




A descriptive survey was disseminated to all medical staff (n = 62) in the department. The 11-




The response rate was 54.8% (n= 34). The international HF guidelines were the primary source 
of prescribing information for 84.2% of respondents. Staff were more familiar with the latest 
ESC guidelines’ recommendations than Associate Staff (86.7% vs 36.8%, p-value = 0.012) 
and considered patient’s perspectives more often (86.7% vs 26.3%, p-value = 0.036). Renal 
functions were the clinical factor most frequently influencing the prescribing of loop diuretics 
or RAASi. Pulmonary functions influenced beta-blockers prescription. Patient gender did not 
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affect the prescription of loop diuretics or RAASi but did influence the prescription of beta-
blockers. The most frequently cited barrier to guideline-led prescribing was the absence of 
locally-drafted guidelines. A majority of prescribers agreed that implementation of clinical 
pharmacy services, physician education and electronic reminders might improve the 




Although experienced physicians are familiar with and use international guidelines, all 
physicians would welcome local guidance on HF prescribing and more significant clinical 





Heart Failure clinical practice guidelines are a robust evidence-based tool for prescribers to 
manage medication decisions for patients with this complex disease. (1) Application of the 
guidelines improves the quality of prescribers’ clinical decisions and promotes consistent and 
standardised care. (1, 48) Heart Failure guideline-led prescribing leads to beneficial clinical 
outcomes in terms of patient’s mortality, morbidity and quality of life. (48, 76) Therefore, 
optimisation of HF guideline-directed medical therapies is strongly recommended during and 
after acute decompensation of the disease. (1) However, international reports suggest that 
prescribers do not optimally adhere to the recommended HF guideline-led prescribing at 
discharge from certain clinical settings. (48, 147) In one study, more than one-third of eligible HF 
patients have not been prescribed the full list of the recommended HF guideline-directed 
medical therapies at discharge (48) and elsewhere, only 50% of patients achieved the 
recommended target doses of the HF guideline-directed medical therapies. (76) 
 
Many physicians report poor awareness of the latest guidelines’ recommendations. (245, 246) A 
national survey in the UK showed that 73% of cardiologists use the HF guidelines in managing 
the disease. (202) The SHAPE survey indicated that guidelines have only a modest influence on 
physicians’ prescribing decisions; for instance, just 34% of the European cardiologists reported 
the use of HF guidelines in their daily prescriptions. (155)   
 
Guideline-led prescribing in HF may be challenging due to patients’ age (183), gender (143), low 
BP (146), renal dysfunction (146), presence of pulmonary disorders (184) and the complexity of 
medication regimens (185). Women and the elderly are generally under-represented in clinical 
trials, which may lead to physician uncertainty as to the applicability and safety of guideline-
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led prescribing to these patients. (203, 247) The high risk of medication-related adverse events and 
contraindications to medications also represent major barriers to guideline-led prescribing. (155, 
203) Furthermore, the lack of resources and the geographical location impede the affordability 
and applicability of prescribing the full list of HF indicated medications. (246, 248, 249) For 
instance, the prescription rates of guideline-directed medical therapies range from 30% in 
Egypt (16) to 50% in Brazil, (171) and up to 85% in Germany (164). 
 
There is a lack of data quantifying prescribers’ preferences regarding potential facilitators for 
improving guideline-led prescribing in HF. (203, 245, 246) Pharmacists are uniquely positioned to 
address medication-related problems in order to optimise guideline-led prescribing during and 
after hospitalisation. (204, 239) Implementation of clinical pharmacy services has been shown to 
reduce HF rehospitalisation rates by up to 20%. (239) Electronic clinical reminders have also 
demonstrated a positive impact on prescribing quality and the reduction of medication errors 
in HF patients. (250) 
 
In the MENA countries and particularly Egypt, no survey or qualitative research has been 
conducted in the field of HF prescribing practice. (155, 251) Also, the effect on HF prescribing 
practice of language, culture, healthcare system and the acceptance of clinical pharmacy in the 




This study aimed to assess the behaviours and perspective of critical care physicians towards 
prescribing to HF patients and to investigate the potential barriers and solutions to HF 





7.3.1 Ethical consideration 
 
The Research and Ethics Committee of Future University in Egypt granted the ethics approval 
for the study (Serial number REC – FPSPI – 11/76), (Appendix 7). The management board of 
the Critical Care Medicine Department, Cairo University Hospitals granted permission for the 
work to proceed in the department. Written information about the study was provided prior to 
participation, and all participants provided informed consent prior to survey completion.  
 
7.3.2 Study design and measurements 
 
In absence of relevant surveys, a new survey was designed to be customised to Egyptian 
prescribing practice, cultural, hierarchical and social systems that might be different from 
Western European countries. The survey was developed with a focus on HF guideline-directed 
medical therapies and was informed by the results of Chapter 6 of this thesis. (155, 243, 251-254) 
This descriptive survey was designed in line with the Academy of Critical Care: Development, 
Evaluation and Methodology recommendations. (255)  The development of the survey items was 
informed by (i) the class I recommendations of the ESC Guidelines for the Diagnosis and 
Treatment of Acute and Chronic Heart Failure 2016 (1) and (ii) the current literature on 
guideline-led prescribing. (147, 184, 246, 256) After the first draft of the questionnaire was developed, 
face validity was tested using a convenience sample of three Critical Care Medicine 
Department medical staff members who were independent of the study team. Further iterations 
of the questionnaire were then developed until a final agreement was reached by all authors. 
The study was written in the English language, as this is the language used professionally in 
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the department and the language used in medical education in Egypt. A native English speaker 
(MB) reviewed the questionnaire to ensure its clarity.  
 
The final version consisted of an 11-item questionnaire with 10 choice-questions and one open-
ended question (Appendix 8). Seven choice-questions used a 5-point Likert scale that allowed 
the choice of one single answer only. For six questions, the Likert scale was anchored by 
‘Never’ and ‘Always’ and for one question, it was anchored by ‘Completely Unfamiliar’ and 
‘Very Familiar’. The open-ended question was optional.   
 
7.3.3 Data collection 
 
All 62 physicians working in the Critical Care Medicine Department were invited to complete 
the questionnaire. There are different grades of the medical staff in the department: (i) 
Associate Staff who are junior residents and senior residents; and (ii) Staff who are specialists 
(Master’s degree) and consultants (Doctor of Medicine degree). Dissemination of the 
questionnaire was via hardcopy or electronically. The hardcopy of the questionnaire was 
distributed to Staff at the monthly departmental clinical meeting and was distributed to 
Associate Staff during their scheduled morning shifts in July and August 2018. An identical 
electronic version of the questionnaire was hosted on the Survey Monkey website 
(www.surveymonkey.com), and a link to this was distributed via the institutional email 
addresses and the LinkedIn profiles (where available) of the 62 physicians. The electronic 
questionnaire was open to receiving responses from July - November 2018. One reminder 
message was sent via the institutional email system. All responses were recorded anonymously. 




7.3.4 Statistical analysis 
 
The study population was subdivided based on the physician’s position as Staff or Associate 
Staff. Data were analysed using SPSS® version 22.0 for Microsoft Windows 10. Categorical 
data were compared using the Chi-square test or Fischer’s Exact test.  All statistical tests were 
exact two-tailed tests, and a p-value < 0.05 was regarded as statistically significant. The 
percentage of respondents who only chose ‘Often’ or ‘Always’ answers to the Likert scale 




7.4 Results  
 
7.4.1 Completion and response rates 
 
The survey was returned by 34 of the 62 physicians giving a response rate of 54.8%. All the 
medical grades were represented among the respondents with 15 Staff (44.2%) and 19 
Associate Staff (55.8%) completing the survey. The breakdown of the respondents was as 
follows: junior residents, n = 8; senior residents, n = 11; specialists, n = 4; and consultants, n = 
11. Thirteen responses were collected via the electronic questionnaire; the remainder of 
responses were collected via the hardcopy. All respondents completed the questionnaire in full. 
 
7.4.2 Information sources for prescribing Heart Failure medicines 
 
Responses to the sources of information that guide the respondents are provided in Figure 7.1. 
International clinical practice guidelines were the most frequently used sources of information 
with 84.2% of respondents reported using these; however, Staff were more likely to use the 
international clinical guidelines than Associate Staff (100.0% vs 68.0%, p-value = 0.027). Half 
of the respondents stated that they rely on their own clinical knowledge. A minority (2.9%) of 
the respondents reported that they used informal information sources such as Facebook medical 
groups; however, no respondent reported accessing information in the Egyptian National 
Formulary or the informal local medical books. Two or more sources of prescribing 
information were chosen by 64.7% of respondents. 
 




7.4.3 Familiarity with and adherence to guidelines  
 
Respondents were asked to rate their familiarity with the most recent European HF guidelines 
(Figure 7.2). A majority of respondents (55.9%) described themselves as ‘Familiar’ or ‘Very 
Familiar’ with these guidelines. Staff were more likely to be familiar with these guidelines 
than Associate Staff (86.7% vs 36.8%, p-value = 0.012). Notably, 12.5% of Associate Staff 
reported that they are ‘Completely Unfamiliar’ with the latest ESC guidelines. While 76.5% of 
respondents stated that they ‘Always’ or ‘Often’ comply with the guidelines’ recommendations 
when prescribing to their HF patients, 10.5% of Associate Staff reported that they ‘Rarely’ or 
‘Never’ comply with the guidelines whereas no Staff reported this.   
 
7.4.4 Patient’s clinical factors influencing the prescribing choices of Heart 
Failure medicines 
 
A majority of respondents selected renal functions (88.2%) and serum potassium (85.3%) as 
the patient factors that influence them when prescribing a loop diuretic (Table 7.1). Associate 
Staff were more likely to be influenced by the patient’s pulmonary functions when prescribing 
a loop diuretic than Staff (73.7% vs 33.3%, p-value = 0.036). When prescribing a RAASi, the 
majority of respondents reported that they are influenced by serum potassium level (88.2%), 
renal functions (85.3%) and BP (79.4%). When prescribing a beta-blocker, HR (88.2%), BP 
(82.4%) and pulmonary functions (76.5%) were the patient factors most likely to influence 
prescribers. Just 5.9% stated that HR is not a factor that influences their prescribing of beta-
blockers. In prescribing loop diuretics and RAASi, few prescribers reported being influenced 
by patient gender. However, gender was reported as a consideration when prescribing a beta-
blocker by 29.4% of respondents. 
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7.4.5 Discussion of medication choice with patients 
 
Respondents were asked if they discuss medication choice with their patients, and 44.1% of 
respondents stated that they ‘Always’ or ‘Often’ do so. Staff were more likely to discuss 
medication choice with patients than Associate Staff (86.7% vs 26.3%, p-value = 0.036). 
Conversely, 17.6% of respondents reported that they never discuss medication choice with their 
patients.  
 
7.4.6 Barriers to prescribing the guideline-directed medical therapies  
 
Respondents were asked to what extent they considered specific issues to be a barrier to 
prescribing the guideline-directed medical therapies to their HF patients (Figure 7.3). The most 
frequently chosen options were the lack of hospital guidelines (79.4% Always/Often); 
medication cost (76.5% Always/Often); and lack of national guidelines (67.6% Always/Often). 
The most frequently cited barriers for Staff were the lack of national guidelines and the lack of 
hospital guidelines (80.0% Always/Often for both) while Associate Staff most frequently cited 
medication cost as a barrier to guideline-led prescribing (84.2% Always/Often). The workload 
was deemed a barrier by Associate Staff more than by Staff (52.3% vs 13.3%, p-value = 0.026).  
 
7.4.7 Potential actions to improve Heart Failure prescribing outcomes 
 
Respondents were asked what potential solutions they believed could be implemented in order 
to optimise guideline-led prescribing (Figure 7.4). The greater involvement of clinical 
pharmacists in HF patient care was identified as a potential solution by 67.6% of respondents 
while regular email bulletins about HF medicines was chosen by 64.7% of respondents. 
Differences emerged between Staff and Associate Staff preferences. Staff were supportive of 
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clinical pharmacist involvement in patient care (73.3% chose this option) but were least 
supportive of receiving education from clinical pharmacists (53.3% chose this option). 
Associate Staff were most supportive of receiving regular emails about HF medicines (68.4% 
chose this option) and least supportive of using the hospital information technology (IT) system 
to receive prescribing recommendations for individual patients (42.1% chose this option). More 





Table 7.1 Patient clinical factors influencing the prescribing choices of heart failure guideline-
directed medicines, N = 34 respondents. 
 
% of respondents who only 
chose ‘Often’ or ‘Always’ 
Total 
(n = 34) 
Associate Staff  
(n = 19) 
Staff  
(n = 15) 
N (%)  N (%)   N (%)   
Loop diuretic    
Age 10 (29.4) 5 (26.3) 5 (33.3) 
Blood pressure  22 (64.7) 10 (52.6) 12 (80.0) 
Gender 2 (5.9) 2 (10.5) 0 (0.0) 
Heart rate 12 (35.3) 8 (42.1) 4 (26.7) 
Liver functions 7 (20.6) 5 (26.3) 2 (13.3) 
Pulmonary functions* 19 (55.9) 14 (73.7) 5 (33.3) 
Renal functions  30 (88.2) 16 (84.2) 14 (93.3) 
Serum potassium  29 (85.3) 15 (78.9) 14 (93.3) 
Renin-angiotensin aldosterone system inhibitor  
Age 12 (35.3) 7 (36.8) 5 (33.3) 
Blood pressure  27 (79.4) 13 (68.4) 14 (93.3) 
Gender 3 (8.8) 3 (15.8) 0 (0.0) 
Heart rate 9 (26.5) 7 (36.8) 2 (13.3) 
Liver functions 7 (20.6) 2 (10.5) 5 (33.3) 
Pulmonary functions 11 (32.4) 8 (42.1) 3 (20.0) 
Renal functions  29 (85.3) 15 (78.9) 14 (93.3) 
Serum potassium  30 (88.2) 16 (84.2) 14 (93.3) 
Beta-blocker    
Age 13 (38.2) 9 (47.4) 4 (26.7) 
Blood pressure  28 (82.4) 17 (89.5) 11 (73.3) 
Gender 10 (29.4) 5 (26.3) 5 (33.3) 
Heart rate 30 (88.2) 18 (94.7) 12 (80.0) 
Liver functions 5 (14.7) 4 (21.1) 1 (6.7) 
Pulmonary functions 26 (76.5) 15 (78.9) 11 (73.3) 
Renal functions  5 (14.7) 4 (21.1) 1 (6.7) 
Serum potassium  10 (29.4) 7 (36.8) 3 (20.0) 
 
Survey question: When prescribing (i) a loop diuretic, (ii) renin-angiotensin-aldosterone system 
inhibitor, or (iii) beta-blocker to a heart failure patient, to what extent do the following patient factors 
influence your prescribing choices? Please use the scale from ‘Never’ up to ‘Always’.  
 
Data are presented for the total population, Associate Staff and Staff and the * indicates p-value < 0.05 
for the comparison between Associate Staff and Staff. The proportion of respondents who indicated 





Figure 7.1 Information sources for prescribing Heart Failure guideline-directed medical 
therapies.  
Survey question: What information sources guide you for prescribing Heart Failure medicines? You 
may choose more than one option.  
 
Data are presented as Staff (specialists and consultants), and Associate Staff (junior and senior 
residents) and the * indicates p-value < 0.05 for the comparison between the two groups.   
 
† Informal Egyptian medical books refer to empiric books that are written by undergraduate medical 
students or medical residents, citing their clinical experience without referencing the written 
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Figure 7.2 Familiarity of respondents with the European Society of Cardiology Guidelines on the 
Management of Acute and Chronic Heart Failure. (1) 
 
Survey question: The European Society of Cardiology published a new guideline on Acute and Chronic 
Heart Failure in 2016. Please rate your familiarity with this guideline using the scale from ‘Completely 
Unfamiliar’ up to ‘Very Familiar’. 
 
Data are presented as Staff members (specialists and consultants) versus Associate Staff (junior and 
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Figure 7.3 Barriers to prescribing the guideline-directed medical therapies from the perspective 
of respondents.  
 
Survey question: To what extent do you agree or disagree that each of the following is a barrier / 
obstacle to prescribing guideline-directed therapies in your patients? Please use the scale from ‘Never’ 
up to ‘Always’.  
 
Data are presented for the total population. The proportion of respondents who indicated ‘Often’ or 
‘Always’ in response to the question is drawn in red bars (right bars) while the proportion of respondents 
who indicated ‘Never’, ‘Rarely’ or ‘Neutral’ is drawn in black bars (left bars). Abbreviations: CPD, 







Figure 7.4 Potential actions to improve Heart Failure prescribing outcomes from the perspective 
of respondents. 
 
Survey question: To what extent do you agree that each of the following actions would help you to 
improve Heart Failure prescribing outcomes? You may choose more than one option.  
 
Data presented for the total population, Associate Staff and Staff. The proportion of respondents who 
















































































This survey is a novel analysis in the HF literature quantifying the perspectives and behaviours 
of prescribers in a critical care setting regarding the evidence-practice mismatch for prescribing 
in HF. The majority of respondents use the international guidelines, and over half are familiar 
with the most recent guidelines. However, over three-quarters of respondents identified the 
lack of locally-drafted guidelines and the cost of medications to the patient as limiting their 
adherence to guideline-led prescribing practice. Furthermore, the respondents identified vital 
solutions to improve guideline-led prescribing, including enhancement of clinical pharmacist 
role and electronic interventions.  
 
Clinical practice guidelines serve as a framework for clinicians managing HF patients. (1) The 
current international guidelines were identified as the most frequently used sources of HF 
prescribing information in the present setting, particularly amongst Staff. This suggests that 
greater postgraduate clinical experience changes prescribers practice and that more junior 
clinicians may continue to rely on knowledge gained in medical school where guideline-
directed care may not be strongly emphasised. (257) This evidence-based knowledge of the Staff 
members was positively translated into two prescribing practices demonstrated in their 
responses. First, the Staff members placed higher importance on discussing medications with 
their patients, which is strictly in line with the latest ESC guidelines’ recommendations. (1) 
Secondly, Staff broadly supported the greater implementation of clinical pharmacy services 
and electronic updates. This support reflects an understanding of the important role of the 




Low prescribing rates of beta-blockers have been reported among Egyptian HF patients. (16, 143) 
The Long-Term Registry of Egypt demonstrated a considerable underutilisation of beta-
blockers regardless of gender or HF severity. (16, 143) In the present survey, 77% of respondents 
identified pulmonary functions as a factor to consider prior to prescribing a beta-blocker. In 
the SHAPE survey, poor pulmonary functions were identified by 68% of respondents as a 
reason for beta-blocker omission or discontinuation. (155) In a UK-based study, poor pulmonary 
functions were reported as the major reason for omitting beta-blocker prescription in up to 11% 
of eligible ambulatory HF patients. (184) According to the ESC guidelines (1), chronic obstructive 
lung disease or dyspnoea are not contraindications to beta-blocker therapy; however, it appears 
that there is ongoing clinician concern regarding the risk of beta-blocker-induced 
bronchospasm despite evidence of patient tolerance and confirmed safety of beta-blockers in 
pulmonary diseases. (259, 260)  
 
Clinicians reported that gender influenced the prescribing of beta-blockers but not the 
prescribing of RAASi or loop diuretics. The Egyptian HF Long-Term Registry found that 
compared to males, female HF patients were less likely to receive guideline-recommended loop 
diuretics and RAASi due to their different comorbidity and cardiovascular risk factors 
profiles.(143) However, the same registry found a considerable underutilisation of beta-blockers 
regardless of gender. The discrepancy between the registry findings and the current survey 
results might reflect concerns related to the adverse drug reaction profile of beta-blockers. (184)  
The onset of HF occurs a decade younger in the Egypt population than in European or North 
American populations, and adverse events may exert a greater effect on the quality of life of 




The survey inquired about the barriers to implementation of HF guidelines at the level of the 
patient, physician and healthcare setting. The lack of locally- or nationally developed 
guidelines was cited as a substantial barrier to guideline-led HF care by over 75% of 
respondents. The barriers identified in the current survey are similar to previous reports from 
Europe and the USA,  (202, 203, 256) where this has been reported as a barrier in primary care 
settings. (202, 256) Several reasons may explain this barrier in a hospital-based setting. First, the 
HF clinical trials are often highly selective and may not include patients whom physicians 
consider to be similar to the real-world patients. (202, 247) This disparity may lead to physician 
uncertainty about guidelines’ applicability, particularly in an HF population who might be 
older, multimorbid or acutely-ill. (155, 202)  
 
The evidence-practice mismatch is of particular importance in low-middle income countries. 
(122, 246, 248, 249) International evidence illustrates the adverse effects of limited patient literacy 
and socio-economic status on HF clinical outcomes and management in terms of prescription 
of medications, use of device-based therapy, patient adherence and even mortality. (248, 249) This 
may be why 50% of the survey respondents stated that they base their clinical decisions on 
their clinical experience rather than on guidelines. The setting of the survey in a middle-income 
country may also explain why respondents consider medication cost as an important barrier to 
guideline-led prescribing. In this setting, costs to the patient or the healthcare provider may 
constrain the prescriber in the provision of some of the recommended long-term therapeutic 
strategies. (122, 246, 248, 249) In a European HF population, the prescription rates of the guideline-
recommended therapies exceeded 85% of patients (164) while the cost implications of some 
medications and the lack of standardised outpatient records may limit the prescription of the 




Respondents supported the greater implementation of clinical pharmacy services as a means to 
improve guideline-led prescribing. This solution was supported more strongly by Staff than by 
Associate Staff. The inclusion of clinical pharmacy services in the HF multidisciplinary team 
is endorsed by several guideline authorities. (1, 258, 261) Clinical pharmacists in hospitals are 
uniquely positioned to manage prescribing problems encountered by prescribers in caring for 
complex and often multimorbid HF patients. (204, 239) In Canada, the inclusion of a clinical 
pharmacist in an HF multidisciplinary team brought about a significant reduction in patient 
mortality over a four-year follow-up period. (258) Elsewhere, the inclusion of clinical pharmacy 
services in HF care reduced rehospitalisation rates by 20%. (204, 239) The acceptability of clinical 
pharmacy in the present study would seem at odds with previous reports from Egypt and other 
MENA countries that showed prescribers’ reluctance to alter a colleague’s prescription despite 
the appropriate course of action recommended by the pharmacist. (242, 243) Staff were also in 
favour of electronic notifications about prescribing in individual HF patients while Associate 
Staff preferred email updates about HF prescribing. While such interventions may be effective 
(250), it has been shown that multiple and repetitive electronic interventions can lead to a risk of 
alert fatigue and the prescriber may be less likely to accept the suggested interventions due to 
desensitisation or cognitive overload. (262)  
 
7.6 Limitations  
 
The majority of eligible prescribers completed the survey in full, and there is a balance of 
Associate Staff and Staff responses. However, it is possible that survey non-responders may 
have expressed different perspectives to those expressed by respondents. To maximise 
response rates and minimise this risk of bias, we used a systematic method for following-up 
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with the non-responders and made the study questionnaire available in both paper and online 




Experienced physicians are familiar with and use international guidelines in their prescribing 
practice; however, a majority of prescribers in this setting would welcome local HF prescribing 
guidelines and more significant input from clinical pharmacy services. The work presented 
here has implications for future studies designing locally-drafted guidance to make the 
international HF guidelines actionable and applicable in a middle-income setting and taking 




The authors would like to thank Ms Dina Mahmoud, Clinical Pharmacist in the Critical Care 
Medicine Department for her assistance in data collection.   
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8 Chapter 8 
 
Overall Discussion and Conclusions 
 
 
This chapter summarises the key findings from this programme of research and discusses the 
contribution of the thesis to the current literature. The clinical implications of the research are 
highlighted, and the strengths and limitations of the work are discussed, alongside providing 





The overarching aims of this PhD thesis were:  
firstly, to assess the level of adherence to the guideline-led prescribing and to identify the 
potential barriers to its adoption in the routine clinical practice in Ireland as a European country 
of high income and Egypt as a MENA country of medium-income; and secondly, to determine 
the prevalence of potentially inappropriate prescribing in HF context in the same clinical 
settings.   
 
The series of research presented in this thesis is the first to combine the assessment of HF 
prescribing from the two angles of medical prescribing practice: appropriate and potentially 
inappropriate in order to comprehensively explore the potential opportunities for improvement 
and the relationship between the two types of medical prescribing practice in HF. The initial 
five chapters addressed the general aims and objectives of this thesis, while this final chapter 
aims to review and interpret the results from this programme of research and to discuss their 
contribution to the current literature. The key prescribing patterns in the three clinical settings 
discussed in Chapters 4 to 6 are presented below (Table 8.1). The clinical implications of the 
research are highlighted. The strengths and limitations of this work are discussed, and proposals 
for future work are presented. 
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Table 8.1 Summary of Heart Failure profile and prescription rates of guideline-directed medical 
therapies in the Irish and Egyptian clinical settings reported in the thesis. 
 
Study Chapter  Chapter 4 Chapter 5 Chapter 6 
Clinical Setting Profile  
Study centre MUH 14 LTCs CCU 
Prescriber's speciality Cardiologists Geriatricians/GPs 
Critical Care 
Physicians 
Geographical location Cork City Cork County Cairo 
N population 127 265 284 
Type of patients Ambulatory Ambulatory 
hospitalised 
critically-ill 
Type of clinical setting 2ry Care 1ry care 3ry Care 
University teaching setting Yes No Yes 
Reference ESC Guidelines 2012/2016 2005 2012 
Clinical Profile of Patients 
Mean ± SD age (years) 71.7 ± 13.1 84.8    ± 7.4 66.7 ± 11.5 
Patients ≥ 80 years  30.70% 71.30% 12.30% 
Mean number of comorbidities 7.4 ± 2.7 11.6 ± 3.5 5.2 ± 2.4 
Hypertension 62.2% 49.4% 49.3% 
Coronary artery disease 30.7% 32.5% 46.5% 
Target HR ≤ 70 bpm 31.5% 42.3% 37.7% 
Medications Profile of Patients 
RASi 67.7% 24.2% 51.4% 
RASi ≥ 50% Target Dose  52.7% 10.6% 14.8% 
EBBB 77.2% 22.6% 29.9% 
EBBB ≥ 50% Target Dose 47.2% 6.0% 7.4% 
MRA 26.0% 4.9% 54.9% 
MRA ≥ 50% Target Dose 18.9% 4.5% 51.5% 
Dual loop diuretics 4.7% 0.0% 15.2% 
No HF-related therapy prescribed 6.3% 8.3% 4.9% 
High-GAI achievement  63.0% 54.7%* 47.9% 
Mean number of regular medications 8.2 ± 3.1 9.2 ± 3.2 9.1 ± 2.5 
Hyperpolypharmacy 30.7% 32.8% 43.7% 
Multivariable analysis  
Positive clinical factors associated 
with High-GAI 
1) HFrEF 1)  Coronary artery 
disease 




2) Absence of 
CKD 
3) Younger age 
PIMHF prescription prevalence 19.7% 24.2% 18.1% 
NDP-CCB in HFrEF patients 5.5% - 0.0% 
NDP-CCB + EBBB 9.4% 0.0% 0.0% 
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*High-GAI considered the prescription of renin-angiotensin system inhibitor, beta-blocker, and loop 
diuretic. Abbreviations: CCU, Critical Care Unit of Cairo University Hospitals, Cairo, Egypt; CKD, 
chronic kidney disease; EBBB, evidence-based beta-blocker; ESC, European society of cardiology; 
GAI, guideline adherence index; GP, general practitioners; HF, heart failure; HFrEF, heart failure with 
reduced ejection fraction; HR, heart rate; LTCs, long-term care facilities; MRA, mineralocorticoid 
receptor antagonist; MUH, Mercy University Hospital, Cork, Ireland; NDP-CCB, non-dihydropyridine 
calcium channel blocker; NSAIDs, non-steroidal anti-inflammatory drugs; PIMHF, potentially 
inappropriate medicines in heart failure; RASi, renin-angiotensin system inhibitor. 
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8.2 Overview of the key findings and contribution to existing 
knowledge 
 
Assessment based on prescription rates alone is not sufficient to evaluate the prescribing quality 
in routine clinical practice as they do not consider many important factors such as patient's (i) 
eligibility for; (ii) contraindication to therapy; or (iii) achievement of the guideline-
recommended target dose. Hence, the systematic review (Chapter 3) evaluated studies of the 
available numerical prescribing review tools for assessing the quality of HF prescribing in 
clinical practice. (147) Sixteen studies met the inclusion criteria, and thirteen studies were 
eligible for inclusion in a meta-analysis. The review identified four different measurement 
tools. The most frequently cited tool was the Guideline Adherence Index (GAI). The 
international mean of GAI-3 is 63%. High-GAI based management showed a significant 
survival benefit. It was associated with a reduced risk of mortality (Hazard Ratio 0.29, 95% CI, 
0.06−0.51) and reduced rehospitalisation (Hazard Ratio 0.64, 95% CI, 0.41−1.00). However, 
increasing patient age and comorbidity burden are the most frequently cited barriers to 
initiation or resumption of the guideline-directed medical therapies. This is conceivable as the 
more comorbidities the patient has, the less freedom the physician has to prescribe the full list 
of the recommended medications. (263) 
 
In an update of this systematic review conducted in April 2019, four additional studies were 
identified. The results of which were consistent with the previously included studies, and thus 
did not change the conclusion of the published review. All four additional studies were using 
the new QUALIFY score and were based on data from the QUALIFY global registry. (47, 48, 93, 
182) The newly included studies emphasised the survival benefit of the high implementation of 




Chapter 4 identified the gaps in medication use and dosing that persist in an Irish contemporary 
outpatient practice in the absence of an HF-specific DMP. The international registries and 
reports revealed the survival benefits of guideline-directed medical therapies. (47, 76, 86, 87) It is 
therefore evident that unjustified omission, underuse or under-dosing of the recommended 
medications is not good medical practice. This implies the importance of the optimisation of 
medications for the ambulatory HF outpatients. (47, 86, 87) The utilisation rates of guideline-
directed medical therapies in the study setting were RASi (67.7%), EBBB (77.2%) and MRA 
(26.0%). These rates add to the fact that managing MRA therapy is more challenging than 
managing RASi and EBBB therapies. (113, 196) This can be partly interpreted by the fact that 
MRA therapy is often associated with worsening renal functions and hyperkalaemia. (113, 196, 197)  
 
Additionally, the absence of clinical barriers between HF patients having a High and Low-GAI 
based management among the study population draws attention to the so-called ‘clinical 
inertia’ in routine outpatient practice. (198, 199) The results showed that no patient achieved the 
100% target dose of all three guideline-directed medicine classes. This finding is strictly in line 
with the longitudinal follow-up study of CHAMP-HF patients. (198, 200) In CHAMP-HF, no 
outpatient received a medication titration within 12 months post-discharge despite eligibility 
and absence of contraindications. (198, 200) Also, only 1% of CHAMP-HF outpatients have been 
prescribed the target dose of all three guideline-directed medicines. (86)   
 
Despite the ESC guidelines’ recommendation, the most frequently used PIMHF in the study 
was the non-dihydropyridine CCB (n = 15, 11.8%). Of which, twelve patients were prescribed 
a concurrent EBBB (9.4%). Therefore, this study emphasises the need for clinical pharmacy 
services to overcome clinical inertia in terms of optimisation and uptitration of the guideline-
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directed therapies and management of the potentially inappropriate prescribing in outpatient 
practice. (207, 235) 
  
According to the literature review in Chapter 2, LTC facilities were not included in the HF-
specific published literature in Ireland. The international literature on HF found that the 
omission of the lifesaving guideline-directed medical therapies is usually common in patients 
who were ≥ 80 years. (109, 264) Long-Term Care residents with HF are often older and suffer 
from significant physical limitations, cognitive impairment and a high degree of comorbidity 
as well as complicated drug regimens and problematic polypharmacy. (219) These patients differ 
substantially from the typical HF patients enrolled in randomised clinical trials, and that might 
explain the divergence from treatment guidelines. (109, 219, 224)  Thus, the aim of Chapter 5 was 
then to measure the level of guideline-led prescribing and potentially inappropriate prescribing 
in the Irish LTC facilities as well as identifying the clinical factors associated with High-GAI 
based management in this vulnerable HF population.  
 
This multi-centre study showed the high reliance of geriatricians and general practitioners 
(GPs) on loop diuretics prescription as the primary medication in these older HF patients rather 
than the guideline-directed medical therapies. For instance, loop diuretics were prescribed to 
140 patients (52.8%) as HF single therapy. The study found 8.3% of HF patients that were not 
prescribed any HF-related medications. The study reported the negative impact of reduced 
renal functions and contraindications on guideline-led prescribing. As prescribed to 10% of 
patients, NSAIDs were the most frequently prescribed potentially inappropriate medications. 
Considering that the Cork region contains approximately 15% of the population of Ireland, the 
results are likely representative of LTC centres nationwide. As the majority of HF literature in 
LTC facilities focus on the undetected diagnosis or the clinical outcomes, so this study 
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represents a prescribing review report for the quality and patterns of HF management in LTC 
facilities. (215, 219, 223, 224) Also, this study confirms previous research findings that the older HF 
patients who need LTC after discharge from the hospital face higher risks of poor outcomes 
and poorer quality of management. (212, 215) 
 
The literature on HF prescribing practice in Egypt is very scarce. Chapter 2 showed that the 
critical care units were not covered by the published Egyptian research regarding HF care. 
Therefore, the 5-year analysis in Egypt (Chapter 6) aimed to describe the guideline adherence 
in HF at discharge and to study the potential role for clinical pharmacists to optimise 
prescribing outcomes in a middle-income healthcare setting of critically- and acutely-ill 
hospitalised HF patients. Evidence suggests that pre-discharge initiation of the guideline-
directed medical therapies not only increases the likelihood of therapy continuation and 
persistence but also translates into improved clinical outcomes. (1, 265-267) Pre-discharge can be 
an ideal time to start or resume medications as patients with HF can have appropriate discharge 
therapeutic plans in a controlled setting, and therefore, the ability to monitor and possibly 
uptitrate therapy. (1, 265-267) 
 
The study (Chapter 6) in Egypt reflected the deviation of the discharge therapeutic plans from 
the lifesaving guideline-directed disease-modifying approach. Over the study period, the 
overall guideline adherence was moderate in comparison to the international numbers. 
Prescription of the guideline-recommended target dose was also deemed problematic at the 
discharge point. Among all discharges, 7.4% of patients only were prescribed ≥ 50% of the 
target dose of EBBB. However, this might be conceivable based on the type of patients in this 
clinical setting. It is essential to mind that the ESC guidelines were developed in stable HF 
patients from high-income or Western countries; thus, the recently stabilised patients of 
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different living conditions and different socioeconomic levels may lack some evidence for a 
directed physician’s practice and clinical outcomes. (249)  
 
Overall, the findings of this study corroborate prior and recent research showing the moderate 
adoption of guideline-led prescribing in chronic worsening HF patients in Europe and the USA. 
(235, 236, 268, 269) In a nationwide study in Denmark, Gislason et al. found that patients who have 
not initiated their guideline-indicated medications within 90 days of discharge have a very low 
probability of later initiation. (225) That is why the current study (Chapter 6) is important to the 
Egyptian medical practice because it has been reported that outpatient follow-up and 
monitoring in chronic diseases are not optimal in Egypt. (121, 125) Keeping in mind the lack of 
standardised outpatient records in the Egyptian hospitals, it is imperative to ensure the 
appropriate prescription and uptitration of HF medications at the discharge point to ensure the 
delivery of optimal care. (197) Furthermore, a post-hoc analysis of the Registry Focused on Very 
Early Presentation and Treatment in the Emergency Department of Acute Heart Failure 
(REALITY-AHF) data examined 1,682 patients hospitalised with acute HF in Japan. (266) This 
analysis found that the presence of prescriptions for the three guideline-directed therapies 
(RASi, EBBB and MRA) at discharge was associated with a significant reduction of 70% in 
one-year mortality. (266)  
 
Then, a question about the benefits of clinical pharmacy service implementation as 
multidisciplinary care might be raised in this medium-income clinical setting. The service 
slightly optimised the quality of HF prescribing practice as they significantly improved the 
beta-blockers prescription rate and reduced digoxin use in line with the latest recommendations 
of the clinical practice guidelines and international reports. (1, 41, 47) It is of note that beta-
blockers underutilisation and digoxin overutilisation are the most important HF prescribing 
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anomalies in Egypt from 2002 to 2018. (15, 16, 143) Thus, this study represents an effort to improve 
and assess the uptake of guideline-led prescribing towards HF patients at discharge by the 
implementation of clinical pharmacy services. (207, 235, 239) 
 
The results of this study led us to conduct a questionnaire in the same unit (Chapter 7). The 
questionnaire aimed to identify the potential barriers to guideline-led prescribing by elucidating 
individual reasoning beyond clinical decision-making. The questionnaire provided a new 
understanding of the reasons behind the suboptimal adherence to the clinical practice 
guidelines from the perspective of low-middle income countries and particularly, Egypt. The 
majority of respondents agreed on the limiting effect of kidney functions prior to prescribing 
the inhibitors of the RAAS. The questionnaire also identified the needs and difficulties faced 
by prescribers in their routine practice. The most frequently cited barrier to guideline-led 
prescribing was the absence of locally-drafted guidelines. This barrier may reflect prescribers’ 
uncertainty of the effect of the international guidelines in the Egyptian population. It is of note 
that HF patients from the Middle-East region were presented only in the EMPHASIS clinical 
trial, which implies the striking absence of this segment of patients in the landmark clinical 
trials. (71) Elsewhere, Blum and colleagues found that HF patients with higher socioeconomic 
levels are less likely to be rehospitalised within the first 30 days of discharge. (270) This implies 
a mismatch between the HF population of the evidence-based clinical trials and the real-world 
of HF patients in Egypt. (249) That is why the prescribers might make their decisions based on 
their personal clinical experience even when the guidelines might recommend a different 
course of action. In order to improve prescribing quality, a majority of prescribers agreed on 
the importance of clinical pharmacy services implementation. This finding represents a 
disparity between the theoretical acceptance of clinical pharmacy presence (Chapter 7) and the 




Overall, this survey represents an important extension to the European HF surveys SHAPE 
2008 and ADDress 2008 but from an Egyptian point of view. (155, 251)  Importantly, our survey 
added the perspective of prescribers regarding the potential facilitators for optimisation of HF 
prescribing, which is not addressed in any of the aforementioned surveys. Considering that the 
CCU of Cairo University Hospitals is the largest one in Egypt, so the results are likely to be 
representative of the other four critical care settings in Egypt. Also, the survey response rate 
and results demonstrated its feasibility for use in a larger, multi-centre study of HF care as seen 
in its high completion and response rates as well as its short completion time.  
 
8.3 Comparison of Heart Failure management in Ireland and 
Egypt 
 
8.3.1 Cardiologists versus non-Cardiologists 
 
One of the important benefits of guideline-led prescribing is to decrease the variation in HF 
prescribing practice. (1, 78, 82) The prescribing quality of cardiologists in the MUH is more likely 
to be better compared to the non-cardiologists in the LTC, Ireland or CCU, Egypt in terms of 
RASi, EBBB, target dose achievement and High-GAI achievement (Table 8.1). (164, 201) This 
finding is in line with the finding of the systematic review (Chapter 3). (147) 
 
8.3.2 Guideline-directed medical therapies  
 
Neither the cardiologists nor the non-cardiologists in the two countries prescribed RASi to all 
HF patients. The presence of HFrEF was estimated to be a positive associate of adherence to 
guideline-led prescribing in the university teaching hospitals (MUH and CCU). This reflects 
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the critical impact of EF on prescribing practice regardless of the type of clinical setting due to 
the strong guidelines’ recommendation and the wide availability of clinical trials in HFrEF. (4)  
 
In the two university teaching hospitals, there was an Irish reliance for the use of EBBB as 
single HF therapy while in Egypt, the reliance was for loop diuretics. This may reflect the 
different perspective of the two prescribers as well as the different clinical status of the studies’ 
populations. In Ireland, it was clear that the guideline-directed disease-modifying approach and 
mortality reductions were the predominant perspective towards the ambulatory HF patients. In 
Egypt, HF management is appeared to be guided by the fluid status to prevent fluid congestion 
and consequently, reduce the rate of healthcare resources utilisation either in terms of 
rehospitalisation or outpatient clinics visits. (271) Furthermore, it is important to consider that 
loop diuretics are the cheapest HF medications within all the medication classes. This cost 
implication is cited as one of the top barriers to guideline-led prescribing in the survey (Chapter 
7). Therefore, this might represent a significant motive for the higher use of loop diuretics.   
 
Both university teaching hospitals in Ireland (MUH) and in Egypt (CCU) prescribed a dual 
loop diuretic therapy to their HF patients ranging from 5% in Ireland up to 15% in Egypt. 
Recently, Yao and colleagues did not find any survival benefit for the use of dual-loop diuretics 
over the use of a single loop diuretic. (69) The Efficacy of Vasopressin Antagonism in Heart 
Failure: Outcome Study With Tolvaptan (EVEREST) clinical trial showed that intensive 
diuretic therapy in-hospital or post-discharge was not associated with any rehospitalisation or 
mortality benefit, in comparison to the low dose of loop diuretic therapy. (67) The ESC 




The series of studies in this thesis found a disparity in the utilisation of MRA and MRA ≥ 50% 
target dose in Egypt and Ireland. This medication class had the highest prescription among all 
three guideline-directed medical therapies and greatest achievement of the recommended ≥ 50 
% target dose in the CCU study of Egypt while its utilisation was low in both Irish studies 
(MUH and LTC studies). In Egypt, this high rate might be referred to the wide availability and 
affordable price of the combined furosemide-spironolactone product ‘Lasilactone®’ in the 
Egyptian market. Also, its high utilisation is based on the additive diuretic effect of MRA and 
to decrease the number of daily tablets for enhanced patient’s compliance and persistence. In 
Ireland, this underutilisation still represents a gap in knowledge similar to the European results 
as this underutilisation is seen in almost all European and American registries from 2011 till 
2019. (86, 113, 196, 236) Savarese et al. enumerated some reasons for this underutilisation. The old 
age and chronic kidney disease might be the main reasons for the low utilisation despite the 
fact that MRA are not contraindicated in stable chronic kidney disease. Another potential 
reason was the omission of other HF medications such as RASi or EBBB that may lead to 
MRA omission. (113)  
 
8.3.3 Potentially inappropriate prescribing in Heart Failure 
 
In Ireland, the concurrent EBBB and non-dihydropyridine CCB combination is deemed high 
in the MUH data reflecting a need for questioning the prescribers about their perspective. In 
LTC facilities, there is room for preventing PIMHF items prescription and particularly 
NSAIDs. In Egypt, pregabalin was the driving PIMHF items even, after the introduction of 
clinical pharmacy services. The high PIMHF utilisation in all settings points to the need for a 
continued professional education intervention to increase prescriber’s awareness about the 




8.3.4 Impact on the existing Heart Failure literature of Ireland and Egypt 
 
Overall, the last four thesis studies covered many gaps in knowledge that were identified in the 
narrative literature review of the thesis (Chapter 2). Chapter 4 represents the first assessment 
of HF prescribing practice in routine clinical practice in the absence of HF disease management 
programmes. Chapter 5 represents the first specific analysis of HF management in Irish LTC 
facilities.  Chapter 6 represents the first comprehensive assessment of HF management in terms 
of patient’s eligibility, consideration of contraindications and target dose achievement in Egypt. 
This is the first study of potentially inappropriate prescribing in Egypt regardless of the disease 
specificity. This study represents the first document for assessment of multidisciplinary care in 
Egypt and its feasibility for application in other low-medium income countries. Chapter 7 is 
the first document to address the barriers to guideline-led prescribing in Egypt and Middle-
East. 
 
8.4 Implications for policy, clinical practice and future research 
 
8.4.1 Implications for policy 
 
Clinical practice guidelines are important documents for guiding HF management and 
establishing benchmarks for quality of care. Optimal implementation of HF guidelines reduces 
healthcare costs associated with hospitalisation, prescription medicines, surgery, and other 
procedures. The economic benefit behind clinical guidelines can be the principal reason for 
promoting its implementation in healthcare settings. Also, the implementation of guidelines 
can prompt government or private payers to provide coverage or to reimburse doctors for 
evidence-based services. Clinicians may turn to clinical practice guidelines for medico-legal 
protection or reinforce their position in dealing with administrators who disagree with their 
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practice policies. A potential framework that may help in increasing the awareness and 
implementation of HF guideline-led prescribing is outlined in Table 8.2. (81, 272-275) 
 
Secondly, this series of studies highlighted the adverse effect of multimorbidity and 
contraindications to therapies on HF prescribing quality despite the different income in each 
setting. This finding can represent a potential subject for leaders in HF research to address this 
gap in practice to increase the applicability and practicality of the clinical guidelines. Secondly, 
there is a vital need for better continued professional education for increasing awareness of the 
potentially inappropriate prescribing in HF. 
 
The analysis of HF prescribing quality presented in Chapter 4 -6 is essential at the national 
level and could inform policy decisions. Another factor that could optimise the uptake of this 
research into policy is the publication of the systematic review (Chapter 3). This source of 
evidence has been suggested as a useful tool in policy development. (276) 
 
8.4.2 Implication for practice 
 
As a pharmacist, I am very much interested in empowering the role of pharmacists and 
particularly, clinical pharmacists in improving and optimising guideline-led prescribing and 
drug utilisation review. A meta-analysis of 12 randomised trials evaluating the effects of 
pharmacist’s care on patient’s outcomes in HF found that healthcare teams incorporating 
pharmacists reduced HF hospitalisations by 30% compared with usual routine care. (277) 
Chapter 4 was conducted in a setting with no pharmacist input and showed the phenomenon of 
clinical inertia as no patient achieved the 100% target dose of all three guideline-directed 
medical therapies. This implies a unique opportunity for the pharmacist to establish and run 
titration clinics. (207)  
223 
 
The current series of studies highlighted the use of some potentially inappropriate medications 
that impede or contradict the effect of guideline-directed medical therapies. These prescribing 
anomalies represent a potential room for clinical pharmacists to optimise HF prescribing 
practice. The ongoing PHARM-CHF (PHARMacy-based interdisciplinary program for 
patients with Chronic Heart Failure) randomised trial testing if team-based care with a 
pharmacist can improve medication management and adherence, provides more data on this 
promising intervention. (278) 
 
Despite the high evidence to support the inclusion of clinical pharmacists in the 
multidisciplinary healthcare teams to reduce medications errors and improve the transition of 
care, it is evident that from our research that in both Ireland and Egypt, pharmacists still play a 
limited role in this regard. (84, 206, 207, 239, 261, 279-281) This can also be seen by the minor 
contribution of the clinical pharmacists in the Egyptian setting. In Egypt, the physician’s fear 
of professional encroachment and the limited healthcare budget may represent barriers to more 
significant clinical pharmacy implementation. In Ireland, this limited role can be partly 
explained by the off-site location of community pharmacists, with limited opportunity to 
interact with LTC staff, outpatients clinics or primary care providers.  
 
However, pharmacists first need to be up-skilled via further professional education in 
conducting academic detailing and the practicality of HF guideline-directed management. This 
was illustrated by one of the survey respondents as the need for well-trained and qualified 






8.4.3 Implications for future research      
 
In Ireland, studies about the benefit and contraindications of MRA prescribing is an important 
step. Also, an update of Chapter 4 regarding LTC prescribing quality is essential to compare 
the progression from 2010 to 2019.  
 
In Egypt, qualitative research is needed to confirm some findings of the CCU survey (Chapter 
7) and to explore barriers and misconceptions about EBBB prescription. Also, the 
dissemination of the current survey to a multi-centre study, including cardiology and primary 
care units, can provide a higher level of responses generalisability and policymaking. Next, a 
prospective study is necessary in the CCU setting in order to evaluate the acceptance rate and 
economic effectiveness of clinical pharmacists’ interventions. 
 
8.5 Strengths and limitations 
 
One of the key strengths of the programme of research presented in this thesis is the "real-
world" cohort study design. Randomised clinical trials (RCTs) are always highly selective and 
controlled studies. (71, 109) This may lead to a mismatch between the study populations of RCTs 
and the real-world patient population. (71, 256) Also, disease-management programmes are not 
affordable and applicable to all HF care settings in Ireland. Secondly, HF patients over 75 years 
or critically-ill patients are not represented in almost all RCTs; we conducted two studies 
specific to these vulnerable populations. (109) Thirdly, the comparative approach of this thesis 
demonstrated some differences in the prescribing perspectives between a developed country 




Some limitations must be acknowledged. First, the observational design of the studies has a 
lower evidence class than interventional studies in terms of causality relationship. However, 
this design aided us to review a larger number of patients charts and to study different 
healthcare settings in the two countries. Also, this design was helpful to perform a 5-year 
analysis in Egypt and a multicentre analysis in Ireland. Second, the single – centred design of 
Egypt based studies may present a limitation. However, this design was needed to study the 
details of HF prescribing practice in focused view and to elucidate the clinical reasoning of the 
prescribers in the same setting beyond prescribing practice. Thus, this design was helpful to 
have a full picture of HF prescribing practice in a leading clinical setting in Egypt. Also, it is 
important to consider the suboptimal availability and quality of patient charts data in the 




Table 8.2 List of ideas to increase guideline adherence and implementation. (81, 272-275) 
 




Short versions of Heart Failure guidelines for clinicians in print or electronic format including pocket cards, 
summaries, key messages or electronic reminders 
Algorithm Flowcharts or clinical pathways that provide step-by-step guidance for patient management 
To-Do checklist 





Resources to support educational meetings or self-directed learning, such as PowerPoint presentations, 
educational modules, webinars or educational games. 
Resources 
Human, infrastructure or funding resources, or instructions or processes needed for guideline 
implementation, e.g.: 
 Titration clinics: a patient-centric and comprehensive approach under the supervision of a clinical 
pharmacist to improve medication rational use and uptitration reduce the risk of adverse events, 
potentially inappropriate prescribing and improve medication adherence. 
 Coaching care teams on ways to identify high-risk patients lacking evidence-based services. 
 Linking Heart Failure care practices to regional health and drug information centres. 
Evaluation support 
Audit tools 
Guidelines or manuals to evaluate and audit guideline-directed practice before and after guideline 
implementation. 
Measures 
 Quality indicators or performance care measures by which to assess compliance with the 
guidelines’ recommendations 
 Developing dashboards so clinicians can use data to manage patient care more effectively. 
Dashboards often provide at-a-glance views of key performance indicators relevant to a particular 
objective or business process. 
 Sending messages of commitment to excellence and quality. 





Given the challenges of a growing older population with multiple comorbidities and who are 
frequently prescribed multiple drugs, healthcare professionals require effective, safe, and 
sustainable approaches to improve prescribing to HF patients. This thesis presents a 
comprehensive and detailed body of research on the contemporary prescribing practice to HF 
patients in the Irish and Egyptian routine clinical practice. At the end of this series of studies, 
one would expect a higher output of clinical pharmacy by greater empowerment of clinical 
pharmacy services in Ireland and broader implementation of services in Egypt in order to 
improve patient health outcomes and prevent adverse events. The thesis identified the need for 
locally-drafted guidance to make the international guidelines actionable and applicable for 
implementation in the Egyptian context; the need to introduce clinical pharmacy services in 
outpatient HF and LTC facilities in Ireland and the vital role of clinical pharmacists in acute 
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Appendix 1: St. Vincent’s Potentially Inappropriate 
Medicines in Heart Failure (PIMHF) tool 
 
1. Non-Steroidal Anti-Inflammatory Drugs 
2. Cox-2 Inhibitors 
3. Oral Corticosteroids 
4. Decongestants 
5. Non-Dihydropyridine Calcium Channel Blockers 
6. Thiazolidinediones (-Glitazones)  
7. Pregabalin 
8. Metformin in Patients With Poor Renal Functions * 
9. Oral Beta-2 Agonists 
10. Itraconazole 
11. Medicinal Formulations of High Sodium Content ** 
 
* Poor renal functions were defined as creatinine clearance lower than 50 millilitres per 
minute.(112) 
** The medicinal formulations were defined based on the list of George et al. (282)
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PubMed 25 4 7 0 0 10 19 4 51 1 5 4 116 246 
SCOPUS 13 4 8 0 0 13 32 7 0 0 4 11 0 92 
WOK all 
databases 
10 5 8 0 0 16 27 11 0 2 13 9 92 193 
EmBase 54 5 12 0 0 18 38 15 0 4 7 21 155 329 
Science Direct 252 1 2 0 1 108 195 28 0 25 49 105 762 
152
8 
greylit.org 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
opengrey.e
u 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Academic 
Search 
Complete.         
CINAHL                     
Psyinfo 
12 2 4 0 0 9 12 6 0 1 5 2 2 55 
Cochrane 
Library 




0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 367 22 42 0 1 175 325 73 51 35 84 152 1127 
245
4 
Abbreviations: WOK, Web of Knowledge
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Appendix 3: The breakdown of the output of the updated systematic review search strategy (May 


















































PubMed 12 21 6 2 5 48 112 112 22 21 109 22 0 492 




6 25 7 0 0 54 107 108 0 52 1 0 0 360 
EmBase 25 4 3 0 0 8 8 1 0 0 0 5 3 57 
greylit.o
rg 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
opengrey
.eu 




e.         
CINAH
L                     
Psyinfo* 









0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 49 76 40 8 7 434 228 361 22 78 346 49 3 1697 
*The research did not have access to the database due to its cost restriction. Abbreviations: WOK, Web of Knowledge
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Appendix 4: Letter from the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals in respect of the 
study Guideline-led prescribing to ambulatory Heart Failure 






Appendix 5: Data Collection sheet used in the study Guideline-led prescribing to ambulatory Heart 
Failure patients in a cardiology outpatient service (Chapter 4). 
 
Compilation Date:          /      /2016. R. ID                           M / F 
Patient Name:                                               DOB             /           /    
Conditions: 
 
1.   
2.   
3.   
4.   
5.   
6.   
7.   
8.   
9.   
10.   
c.   
HF Dx site: 
Hospitalized? 
Current Medications: Loop - ACEI/ARBS – BBs – MRAs – Digoxin – Ivabradine- NH – 
ICD/CRT 
Name / Dose /Frequency                                                  Prescriber      
 
      Date 
 
 
Lab Investigations              Smoker:    Yes  /  No 
Ht=                               Wt= 
 
HR =                            BP=                               BGL= 
 
BNP=      CHA2DS2-VASC= 
 
SOB – NYHA class=                 INR=               SCr= 
 
Echo      /20       EF= 
Echo     /20      EF= 
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Appendix 6: Letter from the Research Ethics Committee, 
Faculty of Pharmacy and Pharmaceutical Sciences, Future 
University in Egypt in respect of the study Guideline-led 
prescribing to heart failure patients at discharge from a critical 






Appendix 7: Letter from the Research Ethics Committee, 
Faculty of Pharmacy and Pharmaceutical Sciences, Future 
University in Egypt in respect of the study Factors Influencing 
Prescribing of Guideline-led Prescribing to Heart Failure 








Appendix 8: Questionnaire used in Chapter 7: Factors 
influencing guideline-led prescribing to heart failure patients: 
a novel questionnaire in a critical care setting. 
 


























Appendix 9: List of Postgraduate Training Modules and 
Academic Workshops 
 
List of Postgraduate Training Modules 
 
Definition of a postgraduate module  
At UCC, a module represents a self-contained unit of a student's workload for the year and 












2016 PG 6021 
English for Postgraduate 
Studies 
5 
To equip students whose first language is not English to successfully begin their postgraduate 
studies in English. 
2016 ST 6013 
Statistics and Data Analysis 
for Postgraduate Research 
Students 
10 
To provide an introduction to the statistical methods relevant to data analysis and practical 
applications of these methods. 
2016 PG 7021 
An Introduction to Ethics 
of Health Research 
5 
To examine the ethical issues which arise in the context of conducting clinical research 
involving human and animal participants 




To facilitate postgraduate students to critically engage in philosophical and methodological 
debates around qualitative inquiry and to develop their knowledge and skills in the application 
of qualitative research methods. 
2017 PG 6015 
An Introduction to 
Research Integrity, Ethics 
and Open Science 
5 
To introduce students to the principles of responsible conduct in research and research data 
management and to the ethical considerations applying in specific disciplines. 
2017 PG 7016 
Systematic Reviews for the 
Health Sciences 
5 
To give postgraduate students an introduction to the principles and practice of systematic 
reviewing, as applied to their own PhD research To develop knowledge and understanding of 
systematic reviewing methods, applied to the quantitative and qualitative health research 
literature. 
2019 PG 7038 Almost PhinisheD 5 
To support students in the final write-up and submission stages and to develop the advanced 
doctoral student's professional profile. To develop personal effectiveness and career 
management skills as outlined in the UCC PhD Graduate Skills Statement. 
2019 PG 6003 
Teaching and Learning 
Module for Graduate 
Studies 
5 
To introduce graduates to the principles and practices of teaching and learning at the third level 
through engagement with teaching scenarios enacted through experiential learning and research 
informed teaching. 
Total Credit hours 45  
 
Abbreviations: ECTS, European Credit Transfer System; PG, Postgraduate training module.   
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List of Academic Workshops 
 
Workshop Facilitator/Organiser 
A clinical seminar about Pharmaco-
epidemiology 
Ass. Prof. Kathleen Bennett, Royal College 
of Surgeons in Ireland  
Articulate Storyline & Video-scribe training 
workshop 
Dr Eileen O’Leary, UCC 
Dr Suzanne McCarthy, UCC  
Patrick Kiely, UCC 
Clinical Research Basic Skills workshop Ronan Madden Assistant Librarian, UCC 
Endnote reference manager workshop  Richard Bradfield, Liaison Librarian, UCC 
How to Plan your PhD?  
Prof. Hugh Kearns, Flinders University – 
Adelaide, Australia. 
Information Literacy workshop UCC medical library staff 
Introduction of Drug Development & Good 
Clinical Practice for Investigation Medicinal 
Products training 
UCC, Science Foundation Ireland and 
Royal College of Surgeons in Ireland 
Master Poster design and presentation 
workshop 
Dr Colman Casey, UCC 
Dr Teresa Barbosa, UCC 
Prof. Josephine Hegarty, UCC 
One Day Writing for Publication Workshop  
www.grammatology.co.uk 
Daniel Soule, UCC 
Smoking Cessation workshop – Jigsaw 
educational technique  
Dr Margaret Bermingham, UCC 
Ms Lisa Buckley, UCC 
The seven secrets of Highly Successful 
Research Students 
Prof. Hugh Kearns, Flinders University - 
Adelaide, Australia. 
Turbocharge your Writing workshop  
Prof. Hugh Kearns, Flinders University - 
Adelaide, Australia. 
Two-Day Short Course Introductory to 
Intermediate SPSS 
Dr Kathleen O'Sullivan, UCC  
Writing a Good research paper workshop  Prof. Ivan Perry, UCC 




Appendix 10: UCC Travel Bursaries 
  
The Graduate School in the College of Medicine and Health at UCC awards 10 Travel 
Bursaries of €1,000 each for students currently registered for a doctoral degree in the College 
of Medicine and Health. 
The purpose of these awards is twofold: 
 To facilitate students who wish to present their work at an international conference. 
 To facilitate the training of students who wish to acquire skills that are essential for 












UCC Travel Bursary for attending ESC Heart Failure Congress, 
Athens 2019 
 
 
